



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## **Pax6 limits the competence of developing cerebral cortical cells to respond to inductive intercellular signals**

### **Citation for published version:**

Manuel, M, Tan, KB, Kozic, Z, Molinek, M, Marcos, T, Abd Razak, F, Dobolyi, D, Dobie, R, Henderson, B, Henderson, NC, Chan, WK, Daw, M, Mason, J & Price, D 2022, 'Pax6 limits the competence of developing cerebral cortical cells to respond to inductive intercellular signals', *PLoS Biology*, vol. 20, no. 9, e3001563. <https://doi.org/10.1371/journal.pbio.3001563>

### **Digital Object Identifier (DOI):**

[10.1371/journal.pbio.3001563](https://doi.org/10.1371/journal.pbio.3001563)

### **Link:**

[Link to publication record in Edinburgh Research Explorer](#)

### **Document Version:**

Peer reviewed version

### **Published In:**

PLoS Biology

### **General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# PAX6 LIMITS THE COMPETENCE OF DEVELOPING CEREBRAL CORTICAL CELLS TO RESPOND TO INDUCTIVE INTERCELLULAR SIGNALS

Martine Manuel<sup>1,2</sup>, Kai Boon Tan<sup>1,2</sup>, Zrinko Kozic<sup>1</sup>, Michael Molinek<sup>1</sup>, Tiago Sena Marcos<sup>1</sup>, Maizatul Fazilah Abd Razak<sup>1</sup>, Dániel Dobolyi<sup>1,2</sup>, Ross Dobie<sup>2,3</sup>, Beth E. P. Henderson<sup>2,3</sup>, Neil C. Henderson<sup>2,3</sup>, Wai Kit Chan<sup>1</sup>, Michael I. Daw<sup>1,3,4</sup>, John O. Mason<sup>1</sup>, David J. Price<sup>1,5</sup>

<sup>1</sup>Simons Initiative for the Developing Brain, Patrick Wild Centre, University of Edinburgh, ~~Hugh Robson Building, George Square~~, Edinburgh ~~EH8 9XD~~, UK.

<sup>1,2</sup>These authors contributed equally.

<sup>2</sup>Current address: Wolfson Institute for Biomedical Research and Department of Neuroscience, Physiology and Pharmacology, University College London, London ~~WC1E 6BT, UK~~~~United, Kingdom~~.

<sup>2,3</sup>Centre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, Edinburgh ~~EH16 4TJ, UK, United Kingdom~~

<sup>3,4</sup>Co-affiliation: Zhejiang University-University of Edinburgh Institute, Zhejiang University, ~~719 East Haizhou Rd., Haining, Zhejiang, 314400, People's Republic of China~~~~P.R. China~~

<sup>5</sup>Author for correspondence: ~~David.Price@ed.ac.uk~~

## ABSTRACT

The development of stable specialized cell types in multicellular organisms relies on mechanisms controlling inductive intercellular signals and the competence of cells to respond to such signals. In developing cerebral cortex, progenitors generate only glutamatergic excitatory neurons despite being exposed to signals with the potential to initiate the production of other neuronal types, suggesting that their competence is limited. Here we tested the hypothesis that this limitation is due to their expression of transcription factor Pax6. We used bulk and single cell RNAseq to show that conditional cortex-specific Pax6 deletion from the onset of cortical neurogenesis allowed some progenitors to generate abnormal lineages resembling those normally found outside the cortex. Analysis of selected gene expression showed that the changes occurred in specific spatiotemporal patterns. We then compared the responses of control and Pax6-deleted cortical cells to in vivo and in vitro manipulations of extracellular signals. We found that Pax6 loss increased cortical progenitors' competence to generate inappropriate lineages in response to extracellular factors normally present in developing cortex, including the morphogens Shh and Bmp4. Regional variation in the levels of these factors could explain spatiotemporal patterns of fate change following Pax6 deletion in vivo. We propose that Pax6's main role in developing cortical cells is to minimize the risk of their development being derailed by the potential side-effects of morphogens engaged contemporaneously in other essential functions.

## ACKNOWLEDGEMENTS

We thank Ugo Borello, Matt Colligan, Petrina Georgala, Anisha Kubasik Thayil, Da Mi, Soham Mitra, Elena Puryte, Thomas Theil, Dafni Triantafyllou and staff in Bioresearch and Veterinary Services and Edinburgh Genomics for their contributions. This research was funded by grants from the Medical Research Council UK (Mr/J003662/1, D.J.P. and J.O.M.; Mr/N012291/1, D.J.P.), the Biotechnology and Biological Sciences Research Council UK (Bb/N006542/1, D.J.P. and J.O.M.), the Muir Maxwell Epilepsy Centre (<http://www.muirmaxwellcentre.com/>; M.I.D.) and Simons Initiative for the Developing Brain (<https://sidb.org.uk/>; grant number 529085, J.O.M. and D.J.P.), and Principal's Career Development and Edinburgh Global Research Scholarships from the University of Edinburgh (<https://www.ed.ac.uk/institute-academic-development/postgraduate/doctoral/career-management/principals-scholarships>; K.B.T.) and a Scholarship from the Ministry of Higher Education, Malaysia (<https://www.mohe.gov.my/en>; M.F.A.R.). The

Formatted: Superscript

Formatted: Superscript

Formatted: Left

Formatted: Superscript

Formatted: Superscript

46 funders had no role in study design, data collection and analysis, decision to publish, or preparation of the  
47 manuscript.

48

49 **COMPETING INTERESTS**

50 None.

51 **INTRODUCTION**

52 Gene regulatory networks (GRNs) modulated by intercellular signals control the generation of the  
53 specialized cell types that compose multicellular organisms [1,2](Britten and Davidson, 1969; Davidson,  
54 2010). These control mechanisms affect the developmental trajectories of cells in a variety of ways to guide  
55 the production of particular cell types and prevent the emergence of alternatives. Transcription factors  
56 whose levels vary among developing cells in precise, reproducible spatiotemporal patterns are essential  
57 components of GRNs. In some cases, their regional activation in response to inductive signals drives the  
58 production of region-specific cell types, but there are many other ways in which they can operate. For  
59 example, they can determine whether, and if so how, cells respond when confronted by inductive signals,  
60 i.e. their competence [3,4](Waddington, 1932 & 1934). Restricting the competence of cells as they develop  
61 is likely to maximize the probability of them following reproducibly their stereotypical developmental  
62 trajectories, e.g. by mitigating the effects of biochemical noise in the signals they encounter or in the  
63 intracellular pathways processing those signals (Perkins and Swain, 2009)[5] and by preventing them  
64 responding in inappropriate ways to signalling molecules surrounding them.

65 The cerebral cortex is a complex amalgamation of two major neuronal cell classes generated by  
66 developmental cell lineages expressing different sets of transcription factors (Anderson et al., 1997, 2001 &  
67 2002; Lim et al., 2018)[6-9]. One cell class uses the excitatory neurotransmitter glutamate to propagate  
68 neuronal activity through cortical circuits and is produced by progenitors located in the developing cerebral  
69 cortex itself. It develops from cell lineages that express transcription factors including Pax6, Neurog2 and  
70 Eomes. The other cell type uses the inhibitory neurotransmitter gamma aminobutyric acid (GABA) to refine  
71 and elaborate patterns of cortical neuronal activity and is produced by progenitors located subcortically. It  
72 develops from cell lineages that express substantially different sets of transcription factors. Pax6 is one of  
73 the first transcription factors to be expressed differentially between the progenitors of excitatory and  
74 inhibitory cortical neurons (Stoykova and Gruss, 1994; Mastick et al., 1997; Caric et al., 1997)[10-12],  
75 making it a good candidate to be involved in regulating the likelihood of cortical progenitors adopting an  
76 excitatory neuronal fate.

77 The *Pax6* gene emerged 500-700 million years ago and has been conserved through all triploblastic animal  
78 lineages, where it is involved in many neural and non-neural processes (Callaerts et al., 1997; Simpson and  
79 Price, 2002)[13,14]. Its expression in the developing brain of extant vertebrates and invertebrates indicates  
80 that it acquired important functions very early in this organ's evolution. In mammalian embryos, it is  
81 activated prior to neural tube closure in the anterior neuroectoderm where brain forms (Shimamura and  
82 Rubenstein, 1997)[15]. Its importance for the production of cortical excitatory neurons is demonstrated by  
83 the phenotypes of constitutively mutant mouse embryos unable to make functional Pax6. These embryos  
84 show reduced cortical expression of genes involved in excitatory neuron production and increased cortical  
85 expression of genes involved in the development of subcortically-derived cell types including inhibitory  
86 interneurons [16-24](Toresson et al., 2000; Yun et al., 2001; Heins et al., 2002; Scardigli et al., 2003;  
87 Schuurmans et al., 2004; Kroll and O'Leary, 2005; Holm et al., 2007; Quinn et al., 2009; Guo et al., 2019).  
88 We set out to discover what *Pax6* does in cortical progenitors to help govern their normal production of  
89 excitatory neurons.

90 We began by examining the effects of inducing cortex-specific *Pax6* loss-of-function in cortical progenitors  
91 using population and single cell transcriptomics followed by expression analysis of selected genes in tissue  
92 sections. The response was dichotomous: many *Pax6*-null progenitors continued to generate excitatory  
93 neurons that made cortical layers relatively normally, while others adopted abnormal developmental  
94 trajectories, the nature of which varied with age and cortical location. Subsequent in vivo and in vitro  
95 experiments revealed that Pax6 blocks the deviant trajectories by reducing the ability of cortical cells to  
96 react abnormally to substances normally present - and carrying out other essential functions - around  
97 them. We propose that the main function of Pax6 in cortical development is to imbue the process with  
98 stability and reproducibility by protecting it from potentially destabilizing signals in the cortical  
99 environment.

100

101 **RESULTS**

## 102 Removal of Pax6 from the progenitors of cortical neurons

103 Most cortical excitatory neurons are generated between embryonic day 12.5 (E12.5) and E16.5 in mice [25-  
104 29](Angevine and Sidman, 1961; Smart and Smart, 1982; Caviness, 1982; del Rio and Soriano, 1989; Gillies  
105 and Price, 1993). They are derived from cortical radial glial progenitors (RGPs), some directly and others  
106 indirectly via the initial production of transit-amplifying intermediate progenitors (IPs) [30-32](Noctor et al.,  
107 2004; Vasistha et al., 2015; Villalba et al., 2021). All RGPs express Pax6 [11](Caric et al., 1997). We used the  
108 *Emx1-Cre<sup>ERT2</sup>* allele [33](Kessaric et al., 2006) to make tamoxifen-induced cortex-specific homozygous *Pax6*  
109 conditional knock outs (*Pax6* cKOs) (Fig. S1A-S1A Fig). Heterozygous littermates with deletion in just one  
110 *Pax6* allele served as controls; previous work on heterozygotes detected no abnormalities in cortical levels  
111 and patterns of Pax6 protein expression or cortical morphogenesis, almost certainly because known  
112 feedback mechanisms caused compensatory increases in Pax6 production from the normal allele [34-  
113 36](Manuel et al., 2007; Mi et al., 2013; Quintana et al., 2018). When we gave tamoxifen at E9.5  
114 (tamoxifen<sup>E9.5</sup>), levels of normal *Pax6* mRNA in *Pax6* cKOs fell to <50% of control by E11.5, to ~10% of  
115 control by E12.5 and to almost zero by E13.5 (Fig. S1B-S1B Fig) and levels of Pax6 protein fell to ~5% of  
116 control by E12.5 (Fig. S1C, S1C and S1D Fig). By E12.5, Pax6 was undetectable by immunohistochemistry in  
117 almost all RGPs (except those in a narrow ventral pallial domain where *Emx1* is not expressed) (Fig.  
118 S1E, S1E and S1F Fig) while a Cre reporter, *RCE<sup>EGFP</sup>* (Fig. S1A-S1A Fig; Miyoshi et al., 2010[37]), was active in  
119 most cortical cells (Fig. S1E-S1E Fig). Thus, tamoxifen<sup>E9.5</sup> ensured that the vast majority of cortical neurons  
120 was generated, directly or indirectly, from RGPs that had lost Pax6 protein.

## 121 Pax6 loss caused ectopic gene expression in cortical cells

122 We first used bulk RNAseq to study the effects of tamoxifen<sup>E9.5</sup>-induced *Pax6* cKO in rostral and caudal  
123 cortex at E12.5 and E13.5 (Fig. S2A-S2A Fig). Raw data are available at the European Nucleotide Archive  
124 accession numbers PRJEB5857 and PRJEB6774. We used 4 biological replicates for each location, age and  
125 genotype; principal component analysis (PCA) on all datasets taken together showed high-level clustering  
126 by age and location (Fig. S1G-S1G Fig).

127 The number of genes with significantly altered expression levels (adjusted  $p < 0.05$ ) in *Pax6* cKO cortex  
128 increased ~3-fold between E12.5 and E13.5 (Fig. S2B; Table S1-S2B Fig and S1 Table). At each age, the  
129 numbers of upregulated and downregulated genes were similar. We identified regulated genes with nearby  
130 Pax6 binding sites using published chromatin immunoprecipitation-sequencing data from E12.5 forebrain  
131 obtained by Sun et al. [38], 2015. We followed their assignment of peaks to the gene with the nearest  
132 transcription start site (TSS), provided the peak lay within the genomic interval between 50kb upstream of  
133 the TSS and 50kb downstream of the transcription end site. The proportion of regulated genes with a  
134 nearby binding site was higher at E12.5 than E13.5 (Fig. S2C-S2C Fig), suggesting an accumulation of indirect  
135 gene expression changes with age.

136 We then examined which genes altered their expression levels in *Pax6* cKO cortex (Fig. S2D, S2D and S2E  
137 Fig). We found that a major effect was the ectopic activation of genes normally expressed only extra-  
138 cortically, either by surrounding non-cortical telencephalic cells or by cells normally located outside the  
139 telencephalon (Fig. S2D, S2D and S2E Fig). Many of these genes encoded transcription factors known to be  
140 involved in cell specification ([16,17,24,39,40-55]Corbin et al., 2000; Fode et al., 2000; Toresson et al., 2000;  
141 Yun et al., 2001 & 2002; Castro et al., 2006 & 2011; Petryniak et al., 2007; Long et al., 2009; Pinto et al.,  
142 2009; Waclaw et al., 2009; Nishida et al., 2010; Seibt et al., 2012; Kikkawa et al., 2013; Kovach et al., 2013;  
143 Wang et al., 2013; Le et al., 2017; Sessa et al., 2017; Pla et al., 2017; Guo et al., 2019). Note that our study  
144 did not aim to provide new evidence on whether genes with altered cortical expression were normally  
145 directly regulated by Pax6 binding to their enhancers or promoters (for previous data on this, in addition to  
146 those used above from Sun et al. 2015 in [38] used above, see Scardigli et al. 2003 [19,56,57] Sansom et al.  
147 2009 and Xie et al. 2013).

148 In summary, these findings indicated that acute conditional cortex-specific Pax6 removal rapidly affected  
149 the specification of at least some embryonic cortical cells.

## 150 Pax6 loss caused cortical cell lineage progressions to diversify

151 We used single cell RNAseq (scRNAseq) to explore the lineage progression of cortical cells following Pax6  
152 removal. We used the alleles described above (Fig. S1A-S1A Fig) and separated green fluorescent protein  
153 (GFP)-expressing cells by fluorescence-activated cell sorting (FACS) from single cell suspensions of E13.5  
154 and E14.5 Pax6 cKO (tamoxifen<sup>E9.5</sup>) and control rostral cortex before carrying out scRNAseq (Fig. 1A). We  
155 focused on rostral cortex, since it contained ~85% of changes detected by bulk RNAseq at E13.5 (Fig.  
156 S2B-S2B Fig). This gave four datasets of: 6,266 cells from E13.5 Pax6 cKO; 3,744 cells from E13.5 control;  
157 4,259 cells from E14.5 Pax6 cKO; 4,137 cells from E14.5 control. Raw data are available at the European  
158 Nucleotide Archive accession numbers PRJEB27937 and PRJEB32740. Differential expression analysis (DEA)  
159 using scRNAseq data to calculate Pax6-loss-induced log<sub>2</sub> fold changes (LFCs) in average gene expression at  
160 E13.5 correlated well with LFCs detected by bulk RNAseq in rostral E13.5 cortex (Fig. S1H-S1H Fig), cross-  
161 validating data obtained from the two approaches.

162 At E13.5, comparison of Pax6 cKO and control samples using Uniform Manifold Approximation and  
163 Projection (UMAP) dimensionality reduction indicated a high degree of similarity in their transcriptomic  
164 landscapes (Fig. 1B). Graph-based clustering combined with analysis of the expression of cell type-selective  
165 marker genes (such as *Nes*, *Sox9*, *Hes5*, *Neurog2*, *Eomes*, *Fezf2*, *Sox5*, *Tbr1* and *Calb2*; [51,52,58-65]Lendahl  
166 et al., 1990; Weisenhorn et al., 1994; Bulfone et al., 1995; Hevner et al., 2001; Englund et al., 2005; Lai et al.,  
167 2008; Leone et al., 2008; Kovach et al., 2013; Wang et al., 2013; Kaplan et al., 2017) separated cells of both  
168 genotypes into recognized major classes: RGPs, IPs, deep layer neurons (DLNs) and Cajal-Retzius cells  
169 (CRCs) (Fig. 1B; Fig. S3A; Fig. S4Figs 1B, and S3A, and S4). It also split the RGPs into two clusters, one of  
170 which contained very few cells in controls but many in Pax6 cKOs (Fig. 1B; Fig. S3B; Fig. S4Figs 1B, and S3B,  
171 and S4). We called these cells atypical RGPs (aRGPs) and explored their distinguishing features further.

172 The genes whose expression levels were shown by DEA to be the most different between RGPs and aRGPs  
173 are listed in Table S4S4 Table. Most gene ontology (GO) terms obtained by passing this list through the  
174 Database for Annotation, Visualization and Integrated Discovery v6.8 (DAVID v6.8; Huang et al.,  
175 2009a,b[66,67]) described processes involved in mitosis (Table S4S4 Table). For some genes, differences in  
176 their expression levels between RGPs and aRGPs might have been explained by the fact that a relatively  
177 higher proportion of aRGPs than RGPs were in S phase (Fig. S3C, S3C and S3D Fig). However, this was not  
178 the case for others, including some associated with GO terms describing cellular responses to extracellular  
179 factors, such as *Fos* (upregulated) and *Hes5* (downregulated) (Fig. S3A,E; Table S4S3A and S3F Fig and S4  
180 Table). UMAP plots showed a tendency for aRGPs to have high *Fos* expression (Fig. S3F-S3F Fig) and  
181 immunohistochemistry revealed elevated *Fos* expression in E13.5 Pax6 cKO cortex (Fig. S3G-S3G Fig).  
182 Changes in the expression of immediate early genes encoding AP-1 transcription factors of the Jun and Fos  
183 families, whose expression levels are known to be induced by a range of extracellular signals [68-73](Sheng  
184 and Greenberg, 1990; Radler-Pohl et al., 1993; Karin et al., 1997; Herdegen and Leah, 1998; Raivich and  
185 Behrens, 2006; Tuvikene et al., 2016), suggested that the loss of Pax6 might have altered cellular responses  
186 to extracellular signals, an idea explored further below.

187 At E13.5, some RGPs, aRGPs and IPs in Pax6 cKOs showing ectopic activation of genes such as *Gsx2*, *Dlx1*  
188 and *Dlx2* (selected as examples of genes normally expressed outside the cortex but within the  
189 telencephalon: "Tel" in Fig. S2E-S2E Fig) and *Prdm13* (an example of a gene normally expressed outside the  
190 telencephalon: "Extra-tel" in Fig. S2E-S2E Fig) (Fig. 1C). This suggested that diversification of gene expression  
191 was occurring as cells progressed from the RGP to the IP identity. This was even clearer a day later.

192 At E14.5, UMAP dimensionality reduction followed by graph-based clustering combined with analysis of the  
193 expression of cell type-selective marker genes (including those used at E13.5 with the addition of layer  
194 markers such as *Cux2*, *Satb2* and *Tle4*; Yao et al., 1998; Zimmer et al., 2004; Britanova et al., 2008; Alcamo  
195 et al., 2008[74-77]) separated cells of both genotypes into recognized major classes: RGPs, IPs, superficial  
196 layer 2/3 neurons (SLN-L2/3) and layer 4 neurons (SLN-L4), deep layer 5 neurons (DLN-L5) and layer 6  
197 neurons (DLN-L6), and Cajal-Retzius cells (CRCs) (Fig. 1D; Fig. S5A; Fig. S6Figs 1D, and S5A, and S6). The  
198 proportions of IPs and SLN-L2/3s were reduced in Pax6 cKOs (Fig. S5B-S5B Fig), in line with previous reports  
199 ([20,23,78,79]Schuurmans et al., 2004; Quinn et al., 2007; Tuoc et al., 2009; Georgala et al., 2011).

200 Five additional clusters populated entirely, or very largely, by Pax6 cKO cells had emerged. Two of them  
201 mapped between IPs and SLNs (Fig. 1D and Fig. S6Figs 1D and S6) and their cells expressed high levels of

202 genes such as *Crabp1*, *Lhx9* and *Nrp2* (Fig. 1E), characteristic of cortical cells located relatively  
203 dorsomedially [80-82] (Bulchand et al., 2003; Le et al., 2007; Lin et al., 2017). We designated cells in these  
204 two clusters dorsomedial (DM); the cells in one (DM-IPs) showed greater similarity to IPs than to SLNs (e.g.  
205 in terms of *Eomes* and *Neurog2* expression: Fig. S5A and Fig. S6S5A and S6 Figs) while cells in the other  
206 (DM-SLNs) were more similar to SLNs than to IPs (e.g. in terms of *Cux2* and *Satb2* expression: Fig. S5A and  
207 Fig. S6S5A and S6 Figs). Many DM cells expressed relatively high levels of *Prdm13* (Fig. 1E; Fig. S6Figs 1E and  
208 S6). Another two clusters contained cells expressing genes such as *Gsx2*, *Dlx* and *Gad* family members,  
209 which are normally associated with the development of GABAergic interneurons (Fig. 1E; Fig. S5A; Fig.  
210 S6Figs 1E, and S5A, and S6) [45,83-85] (Flames et al., 2007; Long et al., 2009; Pan, 2012; Wei et al., 2019).  
211 We found that these cells mapped with GABAergic interneurons and the ganglionic eminence (GE)  
212 progenitors that generated them when we integrated our E14.5 *Pax6* cKO scRNAseq dataset with data from  
213 normal E13.5 and E14.5 ventral telencephalon [86] (Mayer et al., 2018; Fig. S7S7 Fig). We called them  
214 ectopic GABAergic cells (eGCs).

215 A major difference between the two eGC clusters was that one (which we named eGC-P) showed strong  
216 expression of markers of proliferating cells (e.g. *Mki67*) while cells in the other (which we named eGC-N)  
217 did not (Fig. 1E and Fig. S6Figs 1E and S6). The fifth cluster contained proliferating cells (e.g. *Mki67*-  
218 expressing) that we called atypical progenitors (aPs). They were much more common in *Pax6* cKOs than in  
219 controls (Fig. S5B S5B Fig). Their gene expression profiles suggested that they were intermediate between  
220 other types of cell in both controls and *Pax6* cKOs (Fig. 1E; Fig. S5A; Fig. S6Figs 1E, and S5A, and S6). For  
221 example, they were RGP-like in expressing *Nes* and *Sox9* (albeit at lower levels in both genotypes) and IP-  
222 like in expressing *Eomes* (at lower levels in *Pax6* cKO cells). In *Pax6* cKOs, they were eGC-like in expressing  
223 *Gsx2*, *Dlx* and *Gad* family members. Co-expression analysis revealed that small proportions of aPs in *Pax6*  
224 cKOs co-expressed a marker of cells undergoing normal cortical neurogenesis (*Neurog2* and *Eomes*) and a  
225 marker of eGCs (e.g. *Gsx2* and *Dlx1*) (Fig. S5C S5C Fig).

226 Cells in all clusters expressed the telencephalic marker, *Foxg1* (Fig. S6S6 Fig). This indicated that cells  
227 undergoing ectopic activation of genes normally expressed in non-telencephalic tissue (e.g. *Prdm13*) did  
228 not lose entirely their telencephalic identity.

229 We next used RNA Velocity [87,88] (La Manno et al., 2018; Bergen et al., 2020) to explore the direction and  
230 speed of movement of individual *Pax6* cKO cortical cells along their predicted developmental trajectories,  
231 with particular focus on aPs (Fig. 2). For all control aPs and some *Pax6* cKO aPs, velocities were directed  
232 towards IPs (Fig. 2A, B Fig 2A and 2B). Whereas some of these cells in *Pax6* cKO cortex expressed markers of  
233 normal cortical neurogenesis (e.g. *Neurog2* and *Eomes*), others expressed markers of GE-derived cells (e.g.  
234 *Gsx2* and *Dlx1*) (Fig. 2C) and some were those shown previously to co-express both (Fig. S5C S5C Fig). This  
235 suggested that cells in the aP state were labile, with some transiently activating elements of the eGC  
236 expression profile before reverting to a more normal trajectory (further evidence for this is presented  
237 below). Other *Pax6* cKO aPs had velocities directed towards eGCs, either eGC-Ps or eGC-Ns (Fig. 2B, C Fig 2B  
238 and 2C). These cells showed little or no expression of *Neurog2* and *Eomes* but strong expression of *Gsx2*  
239 and *Dlx1*, suggesting that they had become more highly committed to their aberrant fates.

240 In summary, *Pax6* removal appeared to have two major effects. First, it expanded (i) the proportion of  
241 progenitor cells in a labile state between other more highly specified progenitor states (aPs) and (ii) the  
242 proportion of cells with a relatively dorsomedial cortical identity (DMs). Second, it diversified the set of cell  
243 lineage progressions open to cortex-born cells: while some lineages remained similar to those adopted by  
244 normal cortex-born cells, others resembled those normally followed by cells outside the cortex.

#### 245 Spatiotemporal variation in the effects of *Pax6* loss on selected gene expression

246 We next examined the effects of tamoxifen<sup>E9.5</sup>-induced *Pax6* deletion on spatial and temporal patterns of  
247 expression of key *Pax6*-regulated genes in cortical sections using in situ hybridization and  
248 immunohistochemistry. Comprehensive visualizations of the expression patterns of selected genes were  
249 obtained by combining data from serial sections such as those in Fig. S8A S8A Fig to generate surface-view  
250 reconstructions on representations of flattened cortical sheets (Fig. 3 Fig 3; for reconstruction method, see  
251 Fig. S8B S8B Fig).



252 *Ascl1* upregulation began in lateral-most cortex and spread across its entirety between E13.5 and E14.5,  
253 while *Neurog2* was downregulated in lateral cortex (except in the narrow ventral pallial domain where  
254 *Emx1<sup>Cre</sup>* is not expressed) (Fig. 3A-C). Measurements of the proportions of cells expressing *Neurog2* or *Ascl1*  
255 with depth through the VZ and SVZ of lateral cortex showed that the distributions of *Neurog2*+ cells were  
256 replaced by similar distributions of *Ascl1*+ cells (Fig. S8C-S8C Fig). Medial cortex, on the other hand,  
257 maintained levels of *Neurog2* expression that were similar to control (Fig. S8A; Fig. 3C-Figs S8A and 3C) and  
258 contained a relatively high incidence of *Ascl1* and *Neurog2* co-expressing cells (Fig. S8A-S8A Fig). Eomes  
259 downregulation was greater in lateral than in medial cortex (again, except in the narrow ventral pallial  
260 domain) (Fig. 3D, Fig. 3D and 3E).

261 Tamoxifen<sup>E9.5</sup>-induced *Pax6* deletion induced ectopic activation of *Prdm13* in a different pattern (Fig.  
262 3F, Fig. 3F and 3G). *Prdm13*+ cells were located in the medial two thirds of the cortex, compatible with our  
263 scRNAseq analysis showing activation of *Prdm13* in DM cells (Fig. 1E-1E Fig. 1E). They were mainly in the SVZ,  
264 where they intermingled with Eomes+ cells, some of which co-expressed both genes (Fig. 3F Fig. 3F). By  
265 E16.5, *Prdm13* expression remained detectable only in the most medial part of the cortex (Fig. S8D-S8D Fig).

266 These results indicated that *Pax6* loss had distinct effects on the expression of different genes and that the  
267 effects varied with cortical region and age.

#### 268 **Pax6 loss induced eGC production in a distinct spatiotemporal pattern**

269 We next examined cells that deviated to the eGC fate by probing for expression of *Gsx2*, *Dlx1* and *Gad1*  
270 (Fig. S9A-D Fig). In normal cortical development, *Gsx2* becomes active only in small numbers of late-stage  
271 (E16.5 or older) cortical SVZ cells that generate cell types other than cortical neurons [89](Zhang et al.,  
272 2020) (these cells are seen in Fig. S9A-S9A Fig: “Control E16.5”). Following tamoxifen<sup>E9.5</sup>, a wave of ectopic  
273 *Gsx2* activation was advancing rapidly across the cortex by E12.5. It began laterally and swept progressively  
274 further medially to occupy all parts of lateral cortex by E14.5, but did not extend all the way through medial  
275 cortex (Fig. 3H; Fig. S9A-Figs 3H and S9A). We examined the extent to which this change depended on  
276 when tamoxifen was administered (evidence in Fig. S10A, S10A and S10B Fig confirmed that tamoxifen  
277 administration at ages other than E9.5 also caused *Pax6* removal from most RGP within 3 days). We found  
278 similar distributions of *Gsx2*+ cells at E13.5 no matter whether tamoxifen was administered on E8.5, E9.5 or  
279 E10.5 (Fig. 3H; Fig. S9A-Figs 3H and S9A) and even in E13.5 constitutive *Pax6*<sup>-/-</sup> mutants that had never  
280 expressed functional *Pax6* (Fig. S9A-S9A Fig). When we administered tamoxifen later, on E13.5, *Gsx2*+ cells  
281 were distributed throughout the entire lateral cortex 3 days later. This resembled the distributions at  
282 similarly late ages (E14.5-16.5) following early tamoxifen administration (E8.5-E10.5) and not the  
283 distributions 3 days after early tamoxifen administration (Fig. S9A-S9A Fig).

284 We concluded that the spatial distribution of *Gsx2*+ cells depended mainly on cortical age rather than time  
285 elapsed since *Pax6* removal, suggesting that cortical factors that change with age have important influences  
286 on the outcome of *Pax6* removal.

287 Tamoxifen<sup>E9.5</sup> induced a wave of ectopic *Dlx1* expression similar to that of *Gsx2* expression, i.e. it was  
288 underway by E12.5 (Fig. S9B-S9B Fig) and had spread through lateral cortex but only encroached to a limited  
289 extent into medial cortex by E14.5 (Fig. 3H). Tamoxifen<sup>E9.5</sup> also led to the generation of a large population of  
290 *Gad1*+ cells in the lateral cortex (Fig. S9C, S9C and S9D Fig). Most of these cells were cortically-derived (i.e.  
291 they were GFP+ *Emx1*-lineage) but they were intermingled throughout their domain with other *Gad1*+ cells  
292 that were GFP-negative subcortically-generated immigrants (arrows in Fig. S9D-S9D Fig).

293 In the VZ and SVZ of *Pax6*-deleted lateral cortex, *Gsx2*, *Dlx1* and *Gad1* were activated by partially  
294 overlapping bands of cells centred progressively further basal to the ventricular surface (Fig. S9E-S9E Fig).  
295 The *Gsx2*+ and *Dlx1*+ bands overlapped the basal side of the *Ascl1*+ band and the *Dlx1*+ band extended  
296 further basally than the *Gsx2*+ band. This was followed by the *Gad1*+ band, which showed considerable  
297 overlap with the *Dlx1*+ band but less overlap with the *Ascl1*+ and *Gsx2*+ bands (summarized in Fig. S9F-S9F  
298 Fig). Where domains of expression overlapped, co-expressing cells were frequent. Small proportions of  
299 *Gsx2*+ or *Dlx1*+ cells co-expressed Eomes (arrows in Fig. S9G-S9G Fig), in agreement with findings in our  
300 scRNAseq data (Fig. 2C; Fig. S5C-Figs 2C and S5C).



301 We concluded that the production of eGCs unfolded in a distinct spatiotemporal pattern in mainly lateral  
302 cortex.

### 303 **Pax6 loss induced ectopic Olig2 expression largely independently of eGC production**

304 We then examined the pattern of ectopic cortical activation of *Olig2*, which is expressed in progenitors that  
305 generate cortical interneurons and oligodendrocytes, is normally restricted to the embryonic subpallium at  
306 around E13.5 (Fig. S9HS9H Fig: “Control E13.5”) and later spreads as Olig2+ cells migrate into the cortex  
307 (Fig. S9HS9H Fig: “Control E16.5”) [33,90](Kessaris et al., 2006; Miyoshi et al., 2007). Our scRNA-seq data  
308 indicated that *Olig2* was not specifically marking eGCs, but was expressed by many additional cell types  
309 including RGP, aPs, IPs and differentiating cells in *Pax6* cKOs (Figs. S6; Fig. S10CS6 and S10C Figs). Its  
310 ectopic spatiotemporal activation pattern differed from that of *Gsx2*, *Dlx1* and *Gad1* to the extent that it  
311 appeared throughout the entire lateral cortex earlier, by E13.5, but was similar in showing relatively little  
312 activation in medial cortex, even at later ages (Fig. S9HS9H Fig). The domain of Olig2 activation was similar  
313 in E13.5-E16.5 embryos regardless of whether tamoxifen was given at E9.5, E10.5 or E13.5. In lateral cortex,  
314 many progenitors co-expressed *Olig2* and *Ascl1* (Fig. S9HS9H Fig); this was supported by scRNAseq data  
315 showing that 51.8% and 67.3% of *Olig2*+ cells expressed *Ascl1* at E13.5 and E14.5 respectively.  
316 Nevertheless, our *Pax6* cKO E14.5 scRNAseq data detected *Olig2* co-expression in only a small proportion  
317 (9.6%) of cells expressing eGC markers *Gsx2*, *Dlx1*, and *Gad1* (Fig. S10CS10 Fig).

318 These findings suggested that the *Pax6*-loss-induced activation of *Olig2* and of eGC-expressed genes such as  
319 *Gsx2*, *Dlx1* and *Gad1* occurred largely independently. They provided further evidence of spatiotemporal  
320 variation in the effects of *Pax6* loss on the ectopic activation of different genes.

### 321 **The eGCs were highly proliferative**

322 Our scRNAseq data indicated the existence of a substantial population of proliferating eGCs in E14.5 *Pax6*  
323 cKO cortex. This was demonstrated, for example, by the rising levels of the mitotic marker *Mki67* along the  
324 inferred pseudotime trajectory of the lineage leading to eGC-P generation (Fig. 4A; trajectories were  
325 obtained using Slingshot and tradeSeq: [91-93]Street et al., 2018; Tritschler et al., 2019; Van den Berge et  
326 al., 2020). To test this conclusion further, we used the *Emx1-Cre<sup>ERT2</sup>* allele with tamoxifen<sup>E9.5</sup> to delete *Pax6*  
327 and then labelled proliferating cells by administering the S phase marker 5-ethynyl-2'-deoxyuridine (EdU) at  
328 E13.5, 30 minutes before death (Fig. 4B). We reacted sections for EdU and *Gsx2*, a marker of early eGCs  
329 (and also for GFP from a *Btg2*-GFP transgene that was incorporated into the mice for reasons given below)  
330 (Fig. 4C). Most *Gsx2*+ cells were in S phase (mean = 59.0% ± 3.4 sd; counts were from 20 equally-spaced  
331 coronal sections through the cortex for each embryo; n = 5 embryos from separate litters; Sheet A in  
332 counts were from 20 equally-spaced coronal sections through the cortex for each embryo; Source Data  
333 Table 32AS3A Data), confirming their high level of proliferation.

334 We then studied the types of division that *Pax6* cKO cortical progenitors made. Previous work has shown  
335 that RGP (Sox9+) and IP (Eomes+) produce either post-mitotic neurons or new progenitors  
336 [30,31,94,95](Noctor et al., 2004; Gao et al., 2014; Vasistha et al., 2015; Mihalas and Hevner, 2018).  
337 Progenitors of the latter type, often described as proliferative progenitors, do not express the anti-  
338 proliferative gene *Btg2*; others, often described as neurogenic, do express *Btg2* [96,97](Iacopetti et al.,  
339 1999; Haubensak et al., 2004). We used the *Btg2*-GFP transgene [97](Haubensak et al., 2004) with  
340 immunohistochemistry to identify neurogenic progenitors (Fig. 4D, Fig 4D and 4E). Many *Gsx2*+ cells  
341 expressed *Btg2* at E13.5 and E14.5, but a sizeable minority did not. Quantification in E13.5 tissue sections  
342 showed that 68.1% ± 6.5 (sd) of *Gsx2* protein-expressing cells were also *Btg2*-expressing (n=5 embryos from  
343 separate litters; counts were made in from 20 equally-spaced coronal sections through the cortex for each  
344 embryo; n = 5 embryos from separate litters; Sheet A in S3 Data Source Data Table 32AS3A Data). This was  
345 similar to scRNAseq data, which showed *Btg2* expression in 76.2% and 74.0% of *Gsx2*+ cells at E13.5 and  
346 E14.5 respectively. These data indicated that, overall, about a quarter of the cortical cells that activated  
347 *Gsx2* were proliferative (i.e. *Btg2*-non-expressing; their daughters would divide at least once more). The  
348 emergence in *Pax6* cKO cortex of substantial numbers of repeatedly and rapidly dividing progenitors caused  
349 a large expansion of the eGC population, described in the next section.

### 350 **Transient subcortical masses of eGCs formed beneath lateral cortex**

351 Abnormal collections of *Gad1*+ cells coalesced beneath the cortical plate (CP) and superficial to the reduced  
352 population of Eomes+ cells in *Pax6* cKO lateral cortex between E14.5 and E16.5 (Fig. 4F; Fig. S11A; Figs 4F  
353 and S11A). We refer to them here as sub-CP masses. Their expression of GFP, which indicated they were  
354 *Emx1*-lineage (Fig. S9C,D; Fig. 4G; Figs S9C and S9D, and 4G), combined with their *Gad1* positivity identified  
355 these cells as eGCs (Fig. 1D; Fig. 1D and 1E). Based on findings described above, it was likely that many of  
356 them had gone through an early transient phase of *Gsx2* expression (Fig. S9F; Fig. S9F). To confirm this, we  
357 lineage-traced cells using *Gsx2-Cre* [33] (Kessaris et al., 2006) and the GFP Cre-reporter allele [37] (Miyoshi  
358 et al., 2010).

359 Since we could not use *Gsx2-Cre* in combination with *Emx1-Cre<sup>ERT2</sup>*, these experiments were done in  
360 *Pax6<sup>Sev/Sev</sup>* (*Pax6*<sup>-/-</sup>) constitutive mutants (Fig. S11B-D Fig), whose pattern of *Gsx2* expression was similar to  
361 that in *Pax6* cKO cortex (Fig. S9A; Fig. S9A). We confirmed that *Gsx2*-lineage cells lost their *Gsx2* protein as  
362 they moved away from the ventricular surface, activating the *Gsx2-Cre*-activated GFP reporter but no  
363 longer *Gsx2* protein (Fig. S11B; Fig. S11B). In E14.5 control cortex, *Gsx2*-lineage cells were scattered and had  
364 the elongated appearance associated with migration from the *Gsx2*+ subpallium (Fig. S11B; Fig. S11B). In line  
365 with our prediction, most cells in the E16.5 sub-CP masses were *Gsx2*-lineage and most of their cells were  
366 *Gad1*+ (Fig. S11C; Fig. S11C). In these experiments, we also observed a population of GFP+ *Gad1*-negative  
367 neurons scattered through the CP of E16.5 *Pax6*<sup>-/-</sup> but not control lateral cortex: many of these neurons had  
368 the shape and apical dendrite associated with young cortical excitatory neurons (Fig. S11D; Fig. S11D). This  
369 result agreed with a prediction from our scRNAseq analysis that some cells that first expressed markers of  
370 eGCs later reverted to a cortical excitatory neuronal fate (Fig. 2C), reinforcing the suggestion of instability in  
371 the identities of *Pax6* cKO cells exiting the RGP state.

372 We returned to using *Pax6* cKOs (tamoxifen<sup>E9.5</sup>) to gain further information on the development of eGCs  
373 and sub-CP masses. Only extremely rarely did we find examples of *Emx1*-lineage (i.e. GFP+) *Gad1*+ cells in  
374 the CP of *Pax6* cKOs (an example is shown in Fig. S11E; Fig. S11E), indicating that the vast majority of eGCs  
375 were unable to contribute to the CP. We estimated the total numbers of subcortically-derived *Gad1*+  
376 interneurons (i.e. non-*Emx1*-lineage, GFP-negative), the total numbers of cells contained in the sub-CP  
377 masses and the total numbers of all GFP+ cells in the lateral CP of control and *Pax6* cKO cortex at E18.5 (Fig.  
378 4G; Fig. 4G and 4H; methodology in Fig. S11F; Fig. S11F). In *Pax6* cKOs, the numbers of *Gad1*+ GFP-negative  
379 cells in the lateral CP remained unchanged, indicating that immigration of subcortical *Gad1*+ cells into the  
380 lateral CP had proceeded normally. The numbers of GFP+ cells in the lateral CP were significantly reduced  
381 (Fig. 4H;  $p < 0.02$ ; Student's paired t-test). Adding the numbers of cells in the sub-CP masses to the numbers  
382 in the lateral CP revealed that, overall, significantly more cells in total were generated in *Pax6*-deleted than  
383 in control lateral cortex (Fig. 4H;  $p < 0.05$ ; Student's paired t-test). This was explicable by the switch of a  
384 significant proportion of cortical progenitors to the generation of highly proliferative eGCs that populated  
385 the sub-CP masses.

386 The sub-CP masses were no longer visible by postnatal day 34 (P34) (Fig. S11G; Fig. S11G). This was most  
387 likely due to the death of their cells. The proportion of cells expressing the apoptosis marker caspase-3 was  
388 much higher in the sub-CP masses than in overlying CP (Fig. S11H; Fig. S11H). It rose from 1.0% ( $\pm 0.85$  sd) at  
389 E14.5-16.5 to 7.1% ( $\pm 4.6$  sd) at P10, whereas it remained consistently very low in control cortex (mean =  
390 0.29%  $\pm 0.21$  sd, all ages combined) (Sheet B in Source Data Table S3; Data). We concluded that the  
391 very high level of proliferation among *Gsx2*-lineage cells in the lateral *Pax6* cKO cortex generated large sub-  
392 CP masses of eGCs that were eventually removed through cell death.

### 393 Sub-CP mass cells showed immature electrophysiological properties

394 We tested whether sub-CP mass cells developed electrophysiological properties resembling those of  
395 interneurons by making whole-cell current-clamp recordings at P5-P10 (Fig. 4I) [98-100] (Connors and  
396 Gutnick, 1990; Markram et al., 2004; Scala et al., 2021). These ages encompassed those by which normal  
397 cortical neurons have acquired the ability to generate individual or trains of action potentials (APs) in  
398 response to depolarizing stimuli [101-103] (Luhmann et al., 2000; Daw et al., 2007; Yang et al., 2018). The  
399 sub-CP masses were easily identified in slices at all ages by their intense GFP expression (Fig. 4J).

400 The properties of the sub-CP mass cells were similar across the range of ages studied here. None of them  
401 generated mature APs. A third (22/66) produced either spikelets (spikelet peak < 10mV; spikelet amplitude

Formatted: Font: Not Bold

402 = 5-25mV; little or no afterhyperpolarization, AHP; Fig. 4K) or, in two cases, underdeveloped APs (peak  
403 amplitude > 30mV and AHP > 15mV). Most (44/66) produced neither (Fig. 4L). Spikelet amplitudes were  
404 reduced by ~90% following the addition of 300nM tetrodotoxin (TTX), which blocks the voltage gated Na<sup>+</sup>  
405 channels responsible for the rising phase of the AP [104,105](Elliott and Elliott, 1993; Bean, 2007) (Fig. 4M),  
406 suggesting that spikelets were immature APs. One possibility was that the cells that produced spikelets  
407 were eGC-Ns, whereas those that did not were eGC-Ps.

408 The sub-CP mass cells had much lower capacitances and higher input resistances ( $R_{in,s}$ ) and resting  
409 membrane potentials (RMPs) than P5-P7 cortical neurons recorded in layer 5 of primary somatosensory  
410 cortex (Figs. 4N-P, Fig. and S14D-F and S5; Table S5). Their relatively low capacitances were a sign that  
411 they had relatively small somas (Fig. 4N). When we split them into those that produced spikelets and those  
412 that did not we found that the former had higher capacitances, indicating that they were slightly larger (Fig.  
413 4N). The relatively high  $R_{in,s}$  and RMPs of the sub-CP mass cells, neither of which differed significantly  
414 between cells that did or did not generate spikelets, were likely attributable to immaturity in the numbers  
415 of ion channels in their cell membranes [103,106-108](LoTurco et al., 1991; Destexhe et al., 2003; Tyzio et  
416 al., 2003; Yang et al., 2018).

417 We concluded that although the transcriptomes of these cells showed progress towards a GABAergic  
418 interneuron fate, they were unable to develop corresponding cellular properties. Whether this was because  
419 they had a cell autonomous inability to mature and/ or a problem with the environment in which they  
420 found themselves was not tested here.

#### 421 **The production of eGCs did not depend on *Gsx2* activation**

422 We next questioned whether early activation of *Gsx2* by eGCs contributed to their activation of genes such  
423 as *Dlx1* and *Gad1* and their repression of *Neurog2* and *Eomes*, as it does in the GEs [16,17,39,47](Toresson  
424 et al., 2000; Corbin et al., 2000; Yun et al., 2001; Waclaw et al., 2009). We carried out tamoxifen<sup>EG.5</sup>-induced  
425 *Pax6* and *Gsx2* cortex-specific co-deletion (double conditional KO, or dCKO; Fig. 5A; Fig. S12A, Figs 5A and  
426 S12A). Co-deletion of *Gsx2* did not prevent the production of *Dlx1*+ and *Gad1*+ cells in similar numbers as in  
427 *Pax6* single cKOs (Fig. 5B, Fig 5B and 5C). It had no detectable effect on activation of *Ascl1* expression and  
428 did not reverse the *Pax6*-loss-induced loss of *Neurog2* from the bulk of the lateral cortex (Fig. S12B, S12B  
429 and S12C Fig). While *Gsx2* protein was not detected in dCKOs (Fig. 5B), mRNA from *Gsx2* exon 1 was (the  
430 deletion removed the homeodomain-encoding exon 2; Fig. S12A, S12A Fig; Waclaw et al., 2009[47]),  
431 allowing us to use in situ hybridization to recognize cortical cells that had activated the *Gsx2* gene even in  
432 dCKOs. Using this approach, we found no evidence that loss of *Gsx2* protein from *Gsx2*+ cells caused them  
433 to upregulate *Eomes* expression (Fig. 5D). Nor did it cause cortical activation of *Gsx1*, which occurs in the  
434 dorsal LGE (dLGE) following *Gsx2* removal (Fig. S12D, S12D Fig [17,52,109](Yun et al., 2001; Toresson and  
435 Campbell, 2001; Wang et al., 2013).

436 We obtained further evidence that *Gsx2* loss had a very limited effect on the development of eGCs using  
437 RNAseq to compare gene expression levels in dCKOs versus *Pax6* single cKO cortex at E13.5. Raw data are  
438 available at the European Nucleotide Archive accession number PRJEB21105. This analysis found only two  
439 genes were significantly upregulated following deletion of *Pax6* alone and significantly downregulated by  
440 co-deletion of *Gsx2* (adjusted  $p < 0.05$ ; Fig. S12E, S12E and S12F Fig), namely *Gsx2* itself and *Robo3*. Fifteen  
441 other genes showed small, significant differences in expression levels in dCKO compared to *Pax6* single cKO  
442 cortex: all were increased in dCKOs and only one of them, *Zic4*, was significantly affected (slightly increased)  
443 in *Pax6* single cKOs (Fig. S12F, S12F Fig).

444 We examined the effect of *Pax6* and *Gsx2* co-deletion on *Robo3* expression more closely. In controls  
445 expressing both *Pax6* and *Gsx2*, there was a declining medial-to-lateral gradient of *Robo3* expression across  
446 the cortex, similar to that described previously for *Robo3* protein (Fig. 5E) [110](Barber et al., 2009). In  
447 *Pax6*-deleted cortex, there was additional *Robo3* expression in cells partly intermingled with, and partly  
448 basal to, the *Gsx2*+ cells in lateral cortex (Fig. 5E). Few cells appeared to be double-labelled, agreeing with  
449 detection by scRNAseq of *Gsx2* in only 0.2% of *Robo3*+ cells at E13.5 and 6.2% at E14.5. These *Robo3*+ cells  
450 were cortex-born (i.e. they were GFP+) (Fig. 5E). This additional *Robo3* expression in lateral cortex was  
451 reduced in *Pax6-Gsx2* dCKO cortex (Fig. 5E).

452 We then examined how *Robo3* expression was affected by *Gsx2* in its normal domain of expression in the  
453 GEs by using a *CAGG-Cre<sup>ERTM</sup>* allele with tamoxifen<sup>E9.5</sup> to delete *Gsx2* throughout the entire embryo (Fig- 5F).  
454 This increased *Robo3* expression in the LGE, where *Gsx2* is normally strongly expressed. This effect was  
455 opposite to that caused by *Gsx2* deletion in eGCs (Fig- 5G).

456 We concluded that although *Gsx2* was one of the earliest genes expressed in eGCs, the expression of other  
457 eGC marker genes did not require its expression, suggesting that *Pax6* deletion has parallel effects on  
458 multiple eGC marker genes. Moreover, the transcriptional responses of eGCs to *Gsx2* loss were unlike those  
459 of normal *Gsx2*-expressing GE cells, which might reflect an intrinsic difference in the nature of the two cell  
460 types and/ or a difference in their extracellular environments.

#### 461 **Pax6 was not required in RGP for their production of cortical excitatory neurons**

462 As described above (Fig- S1B-F Fig), almost all *Pax6* protein was lost across all *Emx1*-expressing cortex by  
463 E12.5 in *Pax6* cKOs generated by tamoxifen<sup>E9.5</sup>. This near-universal loss had a near-universal effect on the  
464 expression of some genes. For example, some genes with strong expression across control E13.5 cortex  
465 became undetectable in most *Pax6* cKO cortical regions by E13.5 (Fig- S13S13 Fig), indicating that most cKO  
466 cells altered their gene expression at least to some extent. Nevertheless, *Pax6* loss from RGP did not stop  
467 them from generating large numbers of cells that were competent to migrate into the CP (in agreement  
468 with previous studies: [11,78]Carie et al., 1997; Tuoc et al., 2009) (Fig- S14A, BS14A and S14B Fig), where  
469 they differentiated into deep and superficial layer neurons (our scRNAseq data; Fig- 1D). Moreover, *Pax6*  
470 cKO CP contained *Slc17a7* (*Vglut1*), a specific marker of glutamatergic neurons and synapses, distributed in  
471 a similar pattern to that in controls (Fig- S14CS14C Fig).

472 Further evidence that *Pax6* removal from RGP did not prevent their generation of apparently normal  
473 cortical neurons came from whole-cell current-clamp recordings from GFP+ cells in layers 2/3 and 5 in  
474 primary somatosensory cortex (S1) (Fig- S14D-H Fig). We detected no effects of genotype on the individual  
475 intrinsic functional properties of recorded cells (Table S5S5 Table), nor were cells separated by genotype  
476 using unsupervised hierarchical agglomerative clustering based on the cells' property profiles (Fig-  
477 S14G, HS14H and S14G Fig; [111,112]Andjelic et al., 2009; Soldado-Magraner et al., 2019). Of the 73 GFP+  
478 cells recorded in *Pax6*cKO cortex, one (in layer 2/3) showed properties compatible with those of fast spiking  
479 interneurons (Fig- S14I Fig; [102,113]Daw et al., 2007; Butt et al., 2008). It is possible that this represented a  
480 rare example of an eGC contributing to the cortical layers (see above; Fig- S11E Fig-). No such cells were  
481 found in controls (n=70 cells).

#### 482 **Why Pax6 deletion altered the fates of only some cortical cells: a hypothesis**

483 We then turned to the question of why some cortical cells switched fate while others did not after *Pax6*  
484 deletion from cortical progenitors. A parsimonious explanation was that *Pax6* loss increased the *potential*  
485 for all RGP to generate inappropriate cell lineages, but *triggering* this required additional, extracellular  
486 factors. Systematic cross-cortical variations in the types and levels of these factors might have been  
487 responsible for generating the spatiotemporal patterns of normal and abnormal specification seen after  
488 *Pax6* deletion. We set out to test this idea.

#### 489 **Immigrating cortical interneurons enhanced the misspecification of Pax6 cKO cortical cells**

490 The striking similarity between the spatiotemporal characteristics of the wave of eGC production and the  
491 wave of subcortically-generated interneuron immigration (Fig- S15A Fig-), which was not disrupted by *Pax6*  
492 removal (see above), suggested that the immigrating interneurons might have been one source of  
493 extracellular factors triggering abnormal specification among *Pax6* cKO cortical cells. To test this possibility,  
494 we removed subcortical tissue from one side of cultured coronal slices of E13.5 *Pax6* cKO (tamoxifen<sup>E9.5</sup>)  
495 telencephalon to prevent further interneuron influx and compared the production of *Gsx2*+ cells on the  
496 two sides after 48h in culture, using the GFP reporter to mark cells of cortical origin (Fig- 6A, B Fig 6A and  
497 6B). The numbers of subcortically-generated interneurons (i.e. GFP-negative *Gad1*+ cells) were ~4 times  
498 higher on the intact side (Fig- 6C, D Fig 6C and 6D), as anticipated from previous work using this approach  
499 [6](Anderson et al., 1997). Proportions of GFP+ *Gsx2*+ cells were several times higher on the intact side,  
500 with significant differences in the more lateral parts of cortex (Fig- 6E, F Fig 6E and 6F).

501 This outcome suggested that the proportions of *Pax6* cKO cortical cells that deviated to develop as eGCs  
502 was influenced by extracellular factors.

#### 503 **Misspecification of *Pax6* cKO cortical cells depended on their ability to respond to Shh**

504 We then hypothesized that the signalling molecule, Shh, might be one factor contributing to the  
505 reprogramming of *Pax6*-deleted RGP and their daughters. The embryonic cortex contains Shh from a  
506 variety of sources, including immigrating interneurons [114-116](Winkler et al., 2018; Komada et al., 2008;  
507 Baudoin et al., 2012) and cerebrospinal fluid (CSF) [117](Chau et al., 2015). Immunohistochemistry showed  
508 that Shh levels varied considerably with cortical location and that its distribution patterns were similar in  
509 control and *Pax6* cKO embryonic cortex of equivalent ages (Fig. S6G and S15C; evidence for antibody  
510 specificity is in Fig. S15B Fig). Shh levels were higher laterally at E13.5 and increased across the cortex over  
511 the following two days (Fig. 6G).

512 To test the importance of endogenous Shh, we injected either an antagonist of the Shh receptor *Smo*  
513 (vismodegib; [118]Morinello et al., 2015) into the lateral ventricle or electroporated a plasmid expressing  
514 both an shRNA against *Smo* and GFP into the cortex of *Emx1-Cre* induced *Pax6* cKO embryos and measured  
515 the effects on cortical *Gsx2* expression (Fig. 6H-M). (We used *Emx1-Cre* rather than *Emx1-Cre<sup>ERT2</sup>* because  
516 we found it gave better survival rates following in utero surgery, while inducing a similar pattern of *Gsx2*  
517 expression.) Vismodegib intraventricular injection significantly lowered by ~40% the proportions of  
518 proliferative zone cells expressing *Gsx2* compared to vehicle-only injection (Fig. 6H-J). Cells expressing *Smo*  
519 shRNA (GFP+) were on average significantly less immunoreactive for *Gsx2* than a randomly selected sample  
520 of interspersed non-expressing (GFP-) cells, a difference that was lost when a control scrambled shRNA  
521 (GFP+) was used (Fig. 6K-M; for quantification method see Fig. S15D Fig).

522 Further evidence came from adding the Shh pathway blocker cyclopamine, either in beads or in solution, to  
523 cultured *Pax6* cKO slices (Fig. 6N, O Fig 6N and 6O). This reduced their ectopic cortical expression of *Gsx2*.  
524 Interestingly, it had little if any effect on normal *Gsx2* expression in the GEs, suggesting that their state of  
525 commitment was higher than that of the more labile eGC population.

526 Previous work had shown that the ability of embryonic telencephalic cells to express GE marker genes in  
527 response to the ventralizing morphogen Shh requires the transcription factor *Foxg1*, which we found was  
528 expressed by cortical RGP and their daughters in both control and *Pax6* cKO cortex (Fig. S6 Fig)  
529 [119,120](Danesin et al., 2009; Manuel et al., 2010). We postulated that *Pax6* and *Foxg1* have opposing  
530 actions (which might be direct, indirect or both) on specific aspects of cortical cells' competence to respond  
531 to Shh, including their ability to activate ventral telencephalic marker genes, but not others (Fig. 7A). This  
532 idea was based on the following evidence from our RNAseq data and previous studies. First, we found that  
533 *Pax6* removal caused little or no change in canonical readouts of Shh activity, namely *Ptch1* and *Gli1* mRNA  
534 expression levels [121-126](Goodrich et al., 1996; Marigo and Tabin, 1996; Lee et al., 1997; Wijgerde et al.,  
535 2002; Bai et al., 2002; Bai et al., 2004); only *Gli1* was significantly upregulated to a small extent (LFC=0.56) in  
536 caudal cortex at E13.5 (Table S4S1 Table). Second, in *Pax6* cKO cortex, there were no abnormalities in the  
537 expression of mRNAs for Shh itself, the Shh receptor *Smo* or modulators of the Shh intracellular signal  
538 transduction pathways such as *Kif7* and *Sufu* [127-129](Svard et al., 2006; Endoh-Yamagami et al., 2009;  
539 Liem et al., 2009) (Table S4S1 Table). Third, previous work in *Foxg1<sup>-/-</sup>* telencephalon found that while cells  
540 failed to activate GE marker genes in response to Shh, they did activate *Ptch1* and *Gli1* normally  
541 [120](Manuel et al., 2010).

542 To test the prediction that the upregulation of GE markers in *Pax6* cKOs would be reversed by *Foxg1*  
543 removal, we used tamoxifen<sup>E9.5</sup>-induced *Emx1-Cre<sup>ERT2</sup>* to delete both copies of *Pax6* together with both, one  
544 or neither copies of *Foxg1* from embryonic cortical cells (Fig. 7B; Fig. S16A Figs 7B and S16A). Deletion of  
545 both copies of *Foxg1* resulted in the loss of *Foxg1* mRNA from almost all cortical cells by E13.5 (Fig.  
546 S16B, C S16B and S16C Figs); the few remaining undeleted cells formed small clones expressing both *Foxg1*  
547 and *Pax6* (arrows in Fig. S16C Fig). Deletion of one copy of *Foxg1* appeared to lower its cortical mRNA and  
548 protein levels (Fig. S16C Fig).

549 Deletion of both copies of *Pax6* together with one copy of *Foxg1* reduced the numbers of cortical cells  
550 expressing *Gsx2*, *Dlx1* and *Gad1* at E14.5 (Fig. 7C, D Fig 7C and 7D). Deletion of both copies of both *Pax6* and



551 *Foxg1* abolished cortical expression of *Gsx2* and *Dlx1* (Fig 7C and 7D Fig. 7C,D) and left only *Gad1*+ cells that  
552 were GFP-negative and presumably had originated subcortically (arrows in Fig. 7E). Deletion of one or both  
553 copies of *Foxg1* also reduced *Ascl1* expression in *Pax6* cKOs, with a greater effect in lateral than in medial  
554 cortex (Fig. S16D S16D Fig). The reduction of the proportions of progenitor layer cells that were *Eomes*+ in  
555 E16.5 *Pax6* cKO cortex was reversed by co-deletion of one or both copies of *Foxg1* (Fig. S16E, S16E and  
556 S16F Fig).

557 To confirm that these actions of *Foxg1* were cell autonomous, we electroporated *Pax6*<sup>-/-</sup>; *Foxg1*<sup>-/-</sup> double  
558 conditional knock-out cortex with a plasmid construct that resulted in the expression of mCherry and the  
559 re-expression of *Foxg1* by small groups of cells (Fig. 7F, Fig 7G and 7F). Two days after electroporation, an  
560 average of 33.2% (±7.4 s.d.; n=3 embryos) of electroporated cells re-expressed *Gsx2* (Sheet E in Source Data  
561 Table S6E S7E Data) and many were re-expressing *Dlx1* and *Olig2* (Fig. 7G). Electroporated cells were much  
562 less likely than their non-electroporated neighbours to express *Eomes* (Fig. S16G Fig), in line with their re-  
563 direction to an eGC-like fate.

564 In summary, these findings all suggested that *Pax6* limits the competence of cortical cells to respond to *Shh*  
565 in their local environment by preventing them from adopting *Foxg1*-dependent developmental trajectories  
566 towards GE-like fates.

#### 567 ***Pax6* deletion increases cortical cells' sensitivity to *Shh* pathway activation**

568 We then compared the sensitivity of control and *Pax6* cKO cortical cells, in terms of their ability to express  
569 GE/ eGC marker genes in response to *Shh* pathway activation. We dissociated E13.5 control or *Pax6* cKO  
570 cortex (tamoxifen<sup>E9.5</sup>) carrying the GFP Cre-reporter, cultured the cells for 48h in the presence of *Shh*  
571 signalling agonist (SAG; Chen et al., 2002 [130]) or vehicle alone (Fig. 8A) and quantified numbers of GFP+  
572 cells expressing *Gsx2*, *Olig2* or *Dlx1* (Fig. 8B; quantification method in Fig. S17 Fig). In common with  
573 previous studies, we used SAG concentrations in the nM range [130,131] (Heine et al., 2011; Chen et al.,  
574 2002), which existing evidence suggested would likely have covered the levels of pathway activation  
575 experienced by telencephalic cells in vivo ([117,132] Radonjic et al., 2016; Chau et al., 2015).

576 We found that no cells cultured with the lowest doses of SAG expressed *Gsx2*, *Dlx1* or *Olig2*, despite the  
577 fact that all three genes would have been expressed by significant numbers of cells in E13.5 *Pax6* cKO  
578 cortex. The likely explanation for this, in line with suggestions made above, was that they were in a labile  
579 state requiring continual activation of their *Shh* signalling pathways to maintain their aberrant identity, and  
580 the signals they were receiving in vivo would have been dissipated by dissociation.

581 We found that control cells responded in a concentration-dependent manner to addition of SAG, in  
582 agreement with previous work showing that non-physiological elevation of *Shh* signalling in normal  
583 embryonic cortex can activate the expression of ventral telencephalic marker genes [39,133-137] (Gaiano et  
584 al., 1999; Corbin et al., 2000; Rallu et al., 2002; Quinn et al., 2009; Shikata et al., 2011; Yabut et al., 2015).  
585 However, *Pax6* cKO cells were significantly more sensitive to SAG than control cells (Fig. 8C). The  
586 concentration-response functions for *Gsx2* and *Dlx1* were relatively similar, reflecting the close association  
587 between their expression patterns in vivo, but differed from those for *Olig2*, which showed a different  
588 pattern of activation in vivo (Fig. S9H Fig). EC<sub>50</sub>s for *Olig2* were ~2-3 times higher, with cells less likely to  
589 express *Olig2* than *Gsx2* or *Dlx1* in response to low/ intermediate levels of SAG (Fig. 8C). Since our in vivo  
590 findings had shown that early *Olig2* activation was more widespread than early *Gsx2* and *Dlx1* activation in  
591 *Pax6* cKO cortex (Fig. S9A,B, S9A, and S9B, and S9H Fig), this suggested that factors additional to *Shh*  
592 activation were required to explain the difference between the in vivo patterns of activation (see the next  
593 section).

594 The concentration-response functions for *Gsx2* and *Dlx1* appeared to plateau with ~85% of GFP+ cells  
595 expressing the markers, suggesting that ~15% of E13.5 cortical cells were not competent to respond to *Shh*  
596 activation. Since this was similar to the percentage of differentiating glutamatergic neurons in E13.5 control  
597 or *Pax6* cKO cortex (Fig. S3B Fig), we tested whether the incompetent cells were those that were most  
598 highly differentiated. In one set of experiments, we identified differentiating neurons by their expression of  
599 *Tubb3* (Fig 8D and 8E Fig. 8D,E). We found that 9.9-11.5% of control and *Pax6* cKO GFP+ cells expressed  
600 *Tubb3* whether SAG was added or not and that all GFP+ *Gsx2*-negative cells in SAG-treated cultures were

601 Tubb3+, with only 2.0-2.3% of GFP+ cells expressing both Gsx2 and Tubb3. In another set of experiments,  
602 we identified cells that had divided in culture by adding the thymidine analogue EdU to the culture medium  
603 (Fig. 8A,F,G Fig 8A and, 8F, and 8G). We found that EdU was incorporated by most of the GFP+ cells that  
604 had activated Gsx2 in response to SAG, but by none of those that remained Gsx2-negative. We concluded  
605 that the cells that were the most highly differentiated were the least susceptible to the effects of SAG.

#### 606 **Bmps contributed to regional differences in ectopic gene activation**

607 We next considered whether Pax6 is also involved in regulating the responses of developing cortical cells to  
608 other morphogens. Previous research has shown that the embryonic dorsal telencephalic midline is a rich  
609 source of Bmps, including Bmps 4-7 [138](Furuta et al., 1997), and that Bmps can inhibit the expression of  
610 genes involved in the specification of GABAergic neurons [139](Gulacsi and Lillien, 2003). Our evidence  
611 indicated that many aspects of cortical Bmp signalling remained close to normal in Pax6 cKO cortex. Our  
612 RNAseq data showed that Pax6 removal had no detectable effects on the expression of mRNAs for any of  
613 the Bmps and identified only two canonical Bmp signalling pathway genes with significantly altered  
614 expression levels in Pax6-deleted cortex (both only at E13.5: *Bmpr1b* LFC=-0.76 rostrally and -0.64 caudally;  
615 *Smad3* LFC=-0.35 rostrally and -0.28 caudally) (Table S4S1 Table). Second, phospho-Smad1/5/9  
616 immunoreactivity, whose levels correlate positively with Bmp activity and, therefore, tend to be higher in  
617 medial than in lateral embryonic cortex [140-143](Cheng et al., 2006; Hu et al., 2008; Doan et al., 2012;  
618 Lehtinen et al., 2011), showed a similar pattern in control and Pax6 cKO embryos (Fig-S18A Fig).

619 We tested the effects of Bmp4 on the expression of *Gsx2* and *Prdm13*, whose spatial expression patterns  
620 were altered in different ways by Pax6 deletion. We added increasing doses of Bmp4 to cultured E13.5  
621 control and Pax6 cKO cortical slices and measured gene expression levels with qRT-PCR and visualised  
622 expression patterns in sections (Fig. 9A). We found that addition of Bmp4 to Pax6 cKO cortex lowered  
623 overall *Gsx2* mRNA levels and caused loss of *Gsx2*-expressing cells in sections (Fig. 9B,C Fig 9B and 9C).

624 The effects of Bmp4 on *Prdm13* expression were more complex (Fig. 9D,E Fig 9D and 9E). Whereas addition  
625 of Bmp4 at concentrations  $<1\mu\text{g mL}^{-1}$  had no detectable effect on overall levels of *Prdm13* measured with  
626 qRT-PCR, and higher concentrations suppressed overall expression (Fig. 9D), in situ hybridizations in  
627 sections revealed that addition of Bmp4 actually increased *Prdm13* expression in lateral cortex (Fig. 9E,  
628 green arrows). A possible reason why this was not reflected in the overall levels of *Prdm13* mRNA was that  
629 it appeared to be offset by decreased expression in medial cortex (Fig. 9E, asterisk). It seemed possible that  
630 *Prdm13* responded biphasically to Bmp activation in Pax6 cKO cortex, such that: i) *Prdm13* was activated in  
631 the range of Bmp activation levels that existed endogenously in medial cortex or were achieved in lateral  
632 cortex after exogenous application of Bmp4; ii) *Prdm13* expression was suppressed at the relatively higher  
633 Bmp activation levels that were achieved medially when endogenous Bmp activation was supplemented by  
634 exogenous Bmp4. Our findings indicated that cells in both medial and lateral Pax6 cKO cortex were  
635 competent to express *Prdm13* and whether they did so depended on them receiving the requisite signals.

636 Figure 9F outlines how Shh and Bmp4 might combine to generate the spatial expression patterns of *Gsx2*  
637 and *Prdm13* in Pax6 cKOs (Fig. 3). In this model, *Gsx2* activation in cells exposed to supra-threshold levels of  
638 Shh is counteracted in medial cortex by relatively high levels of Bmp signalling, preventing *Gsx2* expression  
639 in this region. *Prdm13* is activated by intermediate levels of Bmp signalling but suppressed by the highest  
640 levels, which might explain the lowering of *Prdm13* expression very close to the dorsal midline (Fig. 3F,G Fig  
641 3F and 3G).

642 We found that Bmp4 did not suppress the expression of *Olig2* in Pax6 cKO cortex (Fig-S18B Fig). The  
643 selective effect of Bmps on *Gsx2* expression with no effect on *Olig2* expression suggested one possible  
644 reason why, in vivo, *Gsx2*-expressing cells were initially less widespread than *Olig2*-expressing cells  
645 following Pax6 deletion (Fig. S9A,B,H,S9A and, S9B, and S9H Fig).

#### 646 **Conclusion**

647 Figure 9G illustrates our main findings using Waddington's epigenetic landscape in which the  
648 developmental trajectory of a cell is represented as a ball rolling downhill through valleys created by the  
649 actions of that cell's genes [144-146](Waddington, C.H. 1957; Ferrell, 2012; Moris et al., 2016). Pax6's  
650 actions ensure that, under physiological conditions, cortex-born cells progress unerringly towards their



651 excitatory neuronal fate. If Pax6 is deleted, alternative trajectories become available (at what are known as  
652 pitchfork bifurcations: [146,147]Huang et al., 2007; Moris et al., 2016). Morphogens such as Shh and Bmps,  
653 whose concentrations vary dynamically and regionally, have the effect of tilting each cell's landscape to a  
654 variable degree, thereby influencing which alternative is likely to be adopted [145](Ferrell, 2012). Pitchfork  
655 bifurcations are associated with unstable and reversible transition states in which the cell shows a mixed  
656 identity between the original and the destination states (Moris et al., 2016)[146]. We envisage that the aPs  
657 we identified by scRNAseq in Pax6 cKO cortex are examples of cells in this state.

658

## 659 DISCUSSION

### 660 Pax6 affects the competence of cortical cells to respond to signalling molecules

661 Regionally expressed transcription factors such as Pax6 can contribute to the development of cellular  
662 diversity in several ways: (i) by regulating cells' competence to respond to signalling molecules around  
663 them; (ii) by controlling their production of intercellular signalling molecules; (iii) by acting internally to  
664 influence cellular development without affecting intercellular signalling. Our present study has highlighted  
665 the overriding importance of Pax6 in the first of these mechanisms during cortical neurogenesis, although it  
666 is probably involved to some extent in all three.

667 Pax6 is expressed in many cell types in structures including the eye, brain, spinal cord and pancreas  
668 [148,149](Walther and Gruss, 1991; Turque et al., 1994). Its regulation of cellular competence during  
669 cerebral cortical neurogenesis is mirrored by some of its actions in other tissues. For example: Pax6 is  
670 involved in establishing the competence of different sets of murine thalamic cells to produce either  
671 glutamatergic or GABAergic neurons [150](Robertshaw et al., 2013); PAX6 restricts the competence of  
672 neuroepithelium derived from human embryonic stem cells to express markers of GABAergic progenitors in  
673 response to SHH application [151](Chi et al., 2017); Pax6 regulates the competence of cells to respond to  
674 inductive signals during vertebrate and invertebrate eye development [152,153](Collinson et al., 2000; Luan  
675 et al., 2014). It is important to stress, however, that the nature of Pax6's effects vary considerably in  
676 different contexts: for example, whereas it limits cells' competence to express genes such as *Gsx2* during  
677 cerebral corticogenesis, it has an opposite effect on *Gsx2* expression in diencephalic cells [36,154](Caballero  
678 et al., 2014; Quintana Urzainqui et al., 2018). This and other context-dependent differences likely arise at  
679 least in part from differences in its combinatorial expression with other transcription factors, such as *Foxg1*  
680 in the telencephalon [36](Quintana Urzainqui et al., 2018) or *Irx3* in the diencephalon [150](Robertshaw et  
681 al., 2013).

682 Regarding the second possibility listed above - that Pax6 regulates the production of intercellular signalling  
683 molecules that affect how other cells develop - our RNAseq data identified very few changes in the  
684 expression of genes encoding signalling molecules. These did, however, include a change in *Fgf15*  
685 expression, which was upregulated in rostral cortex following Pax6 deletion. This is potentially interesting  
686 because experimentally-induced upregulation of *Fgf15* in embryonic cortex can facilitate the activation of  
687 ventral telencephalic genes [155](Yabut et al., 2020). Although previous work on the embryonic cortex of  
688 mouse chimeras containing mixtures of wild-type and Pax6-null cells found no evidence that wild-type cells  
689 were affected by abnormal signalling from Pax6-null cells [23](Quinn et al., 2007), it remains possible that  
690 altered signal production by Pax6-deleted cells affects other Pax6-deleted cells, due to their altered  
691 competence.

692 Regarding the third possibility listed above, Pax6's regulation of genes not directly involved in intercellular  
693 signalling almost certainly contributes to some of its cellular actions. For example, we have argued  
694 previously that Pax6 limits cortical progenitor cell cycle rates through mechanisms that include direct  
695 repression of *Cdk6* [35](Mi et al., 2013). Nevertheless, such explanations are probably incomplete. For  
696 example, Shh is a mitogen [156-158](Kalyani et al., 1998; Wechsler-Reya and Scott, 1999; Groves et al.,  
697 2020) and the highly proliferative nature of many eGCs identified in the present study might be caused in  
698 part by cortical cells' having enhanced responses to Shh that include effects on their proliferation.

699 Our overall conclusion is that, while Pax6's dominant role during cortical neurogenesis is to limit the  
700 developmental potential of cortical cells to respond to signalling molecules that are carrying out other  
701 functions around them, it is very likely to act in other ways too.

#### 702 **Pax6 raises cortical cellular thresholds for responses to morphogens such as Shh**

703 In developing multicellular organisms, the reproducible production of distinct specialized cell types in  
704 specific locations involves cells acquiring information about their relative positions through interactions  
705 with their extracellular environment. For example, one iconic model proposes that cells in a contiguous  
706 population, or field, acquire positional information from their levels of exposure to substances distributed  
707 in concentration gradients across the field [159](Wolpert, 1969). It is thought that such mechanisms specify  
708 the two major domains of the rostral neural plate, a ventral domain producing the basal ganglia and a  
709 dorsal domain producing the cerebral cortex. The morphogen Shh is one example of a substance whose  
710 concentration varies dorsoventrally as these two domains emerge, with its high ventral levels contributing  
711 to the specification of ventral fates [160,161](Marti et al., 1995; Matisse and Wang, 2011). As the rostral  
712 neural tube expands and complexifies, however, so do the distributions of morphogens that affect its  
713 subsequent development. For example, the closure of the neural tube to create the nervous system's  
714 ventricular system gives numerous morphogens, including Shh, widespread access to developing  
715 telencephalic cells via the cerebrospinal fluid [117](Chau et al., 2015) and interneurons migrating into the  
716 cortex produce numerous morphogens, including Shh [114-116,162](Komada et al., 2008; Baudoin et al.,  
717 2012; Voronova et al., 2017; Winkler et al., 2018). Previous work has suggested that Shh levels in  
718 embryonic cortex are high enough that they could, potentially, induce the ectopic expression of ventral  
719 marker genes [155](Yabut et al., 2020). These observations bring into sharp focus the importance of  
720 mechanisms regulating not only the distributions of morphogenetic substances but also the responses of  
721 cells to them.

722 A classic proposition is that cells have intrinsic thresholds determining how aspects of their development  
723 are influenced by surrounding morphogens [159](Wolpert, 1969). Our work suggests that Pax6 raises some  
724 of these intrinsic thresholds in embryonic cortical cells, preventing them from activating erroneous  
725 programs of gene expression in response to physiological levels of Shh, Bmps and possibly other  
726 morphogens around them [89,114-116,155,163-167](Dahmane et al., 2001; Viti et al., 2003; Komada et al.,  
727 2008; Xu et al., 2010; Baudoin et al., 2012; Winkler et al., 2018; Yabut and Pleasure, 2018; Yabut et al., 2020;  
728 Zhang et al., 2020; Delmotte et al., 2020). The reasons for thinking in terms of threshold adjustment is that  
729 Pax6 does not produce an absolute block under all circumstances to the possibility of morphogen-induced  
730 ectopic gene expression. Previous work has shown that non-physiological elevation of Shh signalling in  
731 Pax6-expressing embryonic cortex can activate the ectopic expression of ventral telencephalic marker  
732 genes [39,133-137](Gaiano et al., 1999; Corbin et al., 2000; Rallu et al., 2002; Quinn et al., 2009; Shikata et  
733 al., 2011; Yabut et al., 2015). Our in vitro data showed that Shh can induce Pax6-expressing cortical cells to  
734 express ventral telencephalic markers in a concentration-dependent manner, but Pax6 cKO cells respond  
735 with much greater sensitivity.

736 Pax6 acts selectively on the various cellular process affected by morphogen signalling. It does not prevent  
737 morphogens such as Shh and Bmps having important physiological functions in processes including cortical  
738 cell proliferation, migration and neuronal morphogenesis [114,115,166,168,169](Komada et al., 2008;  
739 Baudoin et al., 2012; Saxena et al., 2018; Yabut and Pleasure, 2018; Hou et al., 2021). This selectivity might  
740 be a consequence of Pax6 acting around the point where the intracellular signal transduction pathways  
741 target the genome; for example, it might reduce the ability of molecules acting late in these pathways, such  
742 as Gli and Smad transcription factors [158,161,166,170](Matisse and Wang, 2011; Hegarty et al., 2013;  
743 Yabut and Pleasure, 2018; Groves et al., 2020), to bind some of their potential genomic target sites. At least  
744 some such effects might involve indirect actions, via effects of Pax6 on the expression of other transcription  
745 factors. For example, Ascl1 is a possible intermediate. We found that its upregulation in Pax6 cKO cortex is  
746 widespread and is associated with multiple lineages. Previous work has shown (i) that forced expression of  
747 Ascl1 in embryonic cortex activates the ectopic expression of ventral markers such as *Dlx1* and *Gad1* in  
748 some cortical cells [40](Fode et al., 2000), (ii) that Ascl1 promotes chromatin accessibility during  
749 neurogenesis and (iii) that *Olig2* is one of Ascl1's direct targets (Raposo et al., 2015)[171].

750 A remarkable feature of the mechanisms that regulate the development of multicellular organisms is the  
751 extent to which the same morphogens are reused in multiple diverse mechanisms as the embryo grows. It  
752 seems highly likely that adjustments to how cells at different locations and ages respond to the same  
753 morphogens would have been instrumental in allowing the diversification of morphogen function during  
754 evolution. The evolution of mechanisms limiting cellular competence, such as those described here, would  
755 have allowed a morphogen to acquire new functions by minimizing the risk of the beneficial consequences  
756 being offset by its pre-existing potential to induce changes that would be undesirable in the new context.

#### 757 **Pax6's effects on Shh signalling might control the timing of cortical excitatory neuron specification**

758 Previous studies have shown that Shh can repress *Pax6* expression in diverse tissues including the  
759 telencephalon [134,150,155,172,173,174](Macdonald et al., 1995; Ericson et al., 1997; Rallu et al., 2002;  
760 Danjo et al., 2011; Robertshaw et al., 2013; Yabut et al., 2020). The fact that Shh levels are highest in  
761 ventral telencephalon from the earliest stages of its development is likely to be a major factor establishing  
762 the ventral-low versus dorsal-high difference in *Pax6*'s expression levels [175-178](Echelard et al., 1993;  
763 Shimamura et al., 1995; Gunhaga et al., 2000; Rallu et al., 2002b). Our findings indicate that, as dorsal  
764 telencephalic development progresses, its high levels of *Pax6* repress the potential actions of morphogens  
765 including Shh itself, thereby opening a time-window for the unhindered production of a normal  
766 complement of cortical excitatory neurons.

767 When this time-window opens, *Pax6* is normally expressed by a large proportion of cortical cells, with  
768 highest levels in RGP cells [11,62,179](Caric et al., 1997; Englund et al., 2005; Wong et al., 2015). For example,  
769 our scRNAseq data showed that more than 70% of cells express *Pax6* at E13.5. As the cortex ages, a  
770 progressively smaller proportion of cells express *Pax6* (~50% at E14.5 in our scRNAseq data) as non-RGP  
771 populations, including non-RGP progenitors such as IPs, expand. This decline coincides with the normal  
772 cortical activation from ~E16.5 onwards of *Gsx2* and *Olig2* in a small proportion of SVZ cells [89](Zhang et  
773 al., 2020). These cells are thought to be tri-potential IPs that generate interneurons for the olfactory bulb,  
774 cortical oligodendrocytes and astrocytes. Their generation requires Shh and they and their daughters  
775 express many of the same genes as those activated earlier in *Pax6*-deleted cortex. It seems plausible that,  
776 in normal corticogenesis, the waning influence of *Pax6* in late progenitor populations allows the time-  
777 window for the focussed production of cortical excitatory neurons to close.

#### 778 **Pax6 loss generates cortical cells with varying degrees of similarity to normal cell types**

779 Previous studies have shown that even if cortical progenitors lose the ability to produce functional *Pax6*,  
780 whether due to constitutive or conditional mutation, they can still generate many cells that migrate into  
781 the CP to form layers containing neurons with excitatory morphologies and connections resembling those  
782 in normal cortex [11,78](Caric et al., 1997; Tuoc et al., 2009). In the present study we confirmed and  
783 extended these previous conclusions: the transcriptional profiles of *Pax6*-deleted cells that were  
784 differentiating into excitatory neurons and the electrophysiological properties of *Pax6*-deleted CP neurons  
785 were indistinguishable from those of control cells. Overall, we found no evidence that *Pax6* is required to  
786 instruct the specification of cortical excitatory neurons from cortical progenitors.

787 Our analyses indicated that some populations of cells that are present in normal cortex expanded following  
788 *Pax6* loss. This applied to cells in the dorsomedial part of the embryonic cortex. The expansion of these  
789 populations might have been due, at least in part, to an increased sensitivity to Bmps, which are present at  
790 higher levels dorsomedially and are involved in the specification of dorsomedial cell identities during  
791 normal development [138,139,140,142,180](Furuta et al., 1997; Gulacsi and Lillien, 2003; Cheng et al.,  
792 2006; Caronia et al., 2010; Doan et al., 2012).

793 Previous reports have suggested that *Pax6*-deleted cortical progenitors generate cells with a dorsal LGE  
794 (dLGE) identity that go on to produce immature olfactory bulb interneurons, as do dLGE cells in normal  
795 telencephalon [21,24,181](Stenman et al., 2003; Kroll and O'Leary, 2005; Guo et al., 2019). While some  
796 evidence supports this interpretation, we suggest that it should be treated with caution. Most tellingly, we  
797 found that many of these cells do not respond to *Gsx2* loss in the same way as normal dLGE cells. This  
798 difference might reflect intrinsic differences with normal dLGE cells and/ or differences in their extracellular  
799 environments. Similarly, intrinsic and/ or environmental factors might contribute to the accumulation of

800 abnormal cell types beneath the CP and their subsequent death. Overall, it seems unwise at present to  
801 assume that these abnormal cell types are necessarily representative of cell types present in normal  
802 telencephalon.  
803

## 804 METHODS

### 805 Animals

806 All experimental procedures involving mice were regulated by the University of Edinburgh Animal Welfare  
807 and Ethical Review Body in accordance with the UK Animals (Scientific Procedures) Act 1986 ([licencing  
808 number P53864D41](#)). All the alleles used and their genotyping have been described before: *Btg2-GFP*  
809 [\[97\]](#)([Haubensak et al., 2004](#)); *CAGG-Cre<sup>ERTM</sup>* [\[182\]](#)([Hayashi and McMahon, 2002](#)); *Emx1-Cre* [\[183\]](#)([Gorski et  
810 al., 2002](#)), *Emx1-Cre<sup>ERT2</sup>* [\[33\]](#)([Kessaris et al., 2006](#)), *Foxg1<sup>loxP</sup>* [\[184\]](#)([Miyoshi and Fishell, 2012](#)), *Gsx2-Cre*  
811 [\[33\]](#)([Kessaris et al., 2006](#)), *Pax6<sup>loxP</sup>* [\[185\]](#)([Simpson et al., 2009](#)), *Pax6<sup>Sev</sup>* [\[186\]](#)([Hill et al., 1991](#)), *Gsx2<sup>loxP</sup>*  
812 [\[47\]](#)([Waclaw et al., 2009](#)); *RCE:loxP* (*R26R CAG-boosted enhanced green fluorescence protein (EGFP) Cre*  
813 reporter) [\[37\]](#)([Miyoshi et al., 2010](#)); *Shh* [\[187\]](#)([Chiang et al., 1996](#)). Activation of CreERT2 or CreERTM was  
814 achieved by giving pregnant females 10mg of tamoxifen by oral gavage.

### 815 Quantitative real-time polymerase chain reaction (qRT-PCR)

816 Total RNA was extracted using either the RNeasy Plus Mini kit (Qiagen) for samples taken directly from  
817 cortex or the RNeasy Micro kit (Qiagen) for cultured cortical slices and cDNA was synthesized with a  
818 Superscript reverse transcriptase reaction (Thermo Fisher Scientific).

819 *Pax6*: qRT-PCR was performed using a DNA Engine Opticon Continuous Fluorescence Detector (MJ  
820 Research) and a Quantitect SYBR Green PCR kit (Qiagen). We used the following primer pairs. *Pax6*: 5'-  
821 TATTACGAGACTGGCTCCAT-3' and 5'-TTGATGACACACTGGGTATG-3'; *Gapdh*: 5'-  
822 GGGTGTGAACACGAGAAAT-3' and 5'-CCTCCACAATGCCAAAGTT-3'. We calculated the relative  
823 abundances of *Pax6* and *Gapdh* transcripts for each sample. For each biological replicate, we ran three  
824 technical replicates.

825 *Crabp1*, *Gsx2*, *Olig2*, *Prdm13*: qRT-PCR was performed using the Applied Biosystems StepOnePlus RT-PCR  
826 machine (Thermo Fisher Scientific) and a TaqMan Gene Expression Assay (Thermo Fisher Scientific)  
827 containing a TaqMan probe with a fluorescein amidite dye label on the 5' end and a minor groove binder  
828 and non-fluorescent quencher on the 3' end. TaqMan probes used in this experiment, designed and  
829 supplied by Thermo Fisher Scientific, were as follows. *Crabp1*: Mm00442775\_g1; *Gsx2*: Mm00446650\_m1;  
830 *Olig2*: Mm01210556\_m1; *Prdm13*: Mm01220811\_m1. For each sample, we ran three technical replicates  
831 with no-template control. Target gene expression was calculated as fold change relative to gene expression  
832 in the vehicle alone condition.

### 833 Western blots

834 Proteins extracted from homogenized and lysed cortical tissue were resolved on denaturing gels. Primary  
835 antibodies against Pax6 (1:500; rabbit; Covance) and  $\beta$ -actin (1:2000; rabbit; Abcam) were detected with  
836 Alexa-coupled secondary antibodies and blots were quantified using the LI-COR scanning system (LI-COR  
837 Biosciences). The intensity of each Pax6 band was normalized to that of its corresponding  $\beta$ -actin band.

### 838 Immunostaining and in situ hybridization on tissue sections

839 Pregnant mice were killed by cervical dislocation and embryonic brains were dissected into 4%  
840 paraformaldehyde (PFA); postnatal mice were perfused transcardially with 4% PFA; cultured cortical slices  
841 were placed in 4% PFA. Samples were fixed overnight at 4°C and cryosections were cut usually at 10 $\mu$ m or  
842 at 2 $\mu$ m in some cases.

843 **Immunostaining:** Primary antibodies used in this study were as follows. Anti-Ascl1 (mouse; BD Bioscience);  
844 anti-Bromodeoxyuridine (BrdU) (mouse; clone B44, BD Bioscience); anti-Caspase 3 (rabbit; Millipore); anti-  
845 Crabp1 (rabbit; Cell Signalling); anti-Eomes (rabbit; Abcam); anti-Foxg1 (mouse; kindly provided by Steven  
846 Pollard, University of Edinburgh, UK; [\[188\]](#)-[Bulstrode et al., 2017](#)); anti-Green fluorescent protein (GFP)  
847 (rabbit or goat; Abcam); anti-Gsx2 (rabbit; Merck); anti-Histone H3 (phospho S10) (rabbit; Abcam); anti-  
848 mCherry (chicken; Abcam); anti-Olig2 (rabbit; Millipore); anti-Pax6 (mouse; clone AD2.38, described in  
849 [Engelkamp et al., 1999](#) [\[189\]](#)); anti-pSmad1/5/9 (rabbit; Cell Signalling); anti-Shh (rabbit; kindly provided by  
850 Genentech Inc.); anti-Slc17a7 (formerly Vglut1) (rabbit; Synaptic Systems); anti-Sox9 (rabbit; Millipore);  
851 anti-Turbo GFP (mouse; Origene).

852 For fluorescence immunostaining, sections were incubated with secondary antibodies (1:200) coupled with  
853 Alexa Fluor 488 (Abcam) or 568 (Abcam) or Cy3 (Abcam) and then incubated with diamidino-2-phenylindole  
854 (DAPI; 1:1000; Thermo Fisher Scientific) before being mounted with Vectashield HardSet (Vector  
855 Laboratories) or ProLon Gold Antifade Mountant (Thermo Fisher Scientific).

856 For colorimetric immunostaining, sections were incubated with biotinylated secondary antibodies followed  
857 by Avidin Biotin Complex (ABC kit, Vector laboratories) and then diaminobenzidine (DAB, Vector  
858 Laboratories). Sections were mounted in DPX (Sigma).

859 **In situ hybridization:** Riboprobes used in this study were as follows. *Ascl1* and *Gad1* (kindly provided by  
860 Francois Guillemot, Francis Crick Institute, UK); *Dlx1* (kindly provided by Yorick Gitton, INSERM Institut de la  
861 Vision, France); *Foxg1* (kindly provided by Vassiliki Fotaki, University of Edinburgh, UK); *Gsx2* (kindly  
862 provided by Kenneth Campbell, Cincinnati Children's hospital, USA); *Gsx1* and *Neurog2* (kindly provided by  
863 Thomas Theil, University of Edinburgh, UK); *Prdm13* (kindly provided by Tomomi Shimogori, Riken Centre  
864 for Brain Science, Japan). Templates for *Robo3*, *Rlbp1*, *Pde1b*, *Igsf11*, *Heg1* and *Neurod4* riboprobes were  
865 synthesised from mouse embryonic brain cDNA using the following PCR primers (convention: gene, forward  
866 primer, reverse primer). *Heg1*, 5'-ACTTCCAAATGTCCCATACAC-3', 5'-CCAGCCCAATCTATTAAGTGC-3';  
867 *Igsf11*, 5'-TCAGTGCCTCTCTCCG-3', 5'-CAGGCCACTTCACACAG-3'; *Neurod4*, 5'-  
868 TGGAAATGCTCGGAACCTTAA-3', 5'-TACAGGAACATCATAGCGGG-3'; *Pde1b*, 5'-GCTGACTGATGTGGCAGAAA-3',  
869 5'-AGAATCCCAATGGCTCCTCT-3'; *Rlbp1*, 5'-TTCTCTGCGCTTCATC-3', 5'-TTGGGATGAGGTGCCACT-3';  
870 *Robo3*, 5'-GCTGTCTCCGTGATGATTT-3', 5'-AAATTGTGGTGGGACGTGAA-3'.

871 Riboprobes were labelled with digoxigenin (DIG) or dinitrophenol (DNP). DIG labelled probes were  
872 synthesised using a DIG RNA labelling mix (Roche). DNP labelled probes were synthesised using a similar  
873 process but with the DIG labelling mix replaced by a 20x NTP stock solution (20mM each ATP, GTP, CTP,  
874 13mM UTP, Thermo Fisher Scientific) and a 20x DNP-11UTP stock solution (7mM; Perkin Elmer). For  
875 fluorescence in situ hybridisation, probes were detected using an anti-DIG peroxidase (Roche) or anti-DNP  
876 peroxidase (Tyramide Signal Amplification (TSA) Plus DNP (HRP) kit, Akoya Bioscience) followed by TSA-plus  
877 cyanine 3 or TSA-plus fluorescein (Akoya Bioscience). When required, amplification was achieved using TSA  
878 Biotin (Akoya Bioscience). For fluorescence double in situ hybridization, the probes were detected  
879 sequentially, and the slides were incubated in 10 mM HCl before detection of the second probe. When  
880 fluorescence in situ hybridisation was followed by immunofluorescence, a microwave antigen retrieval step  
881 (20 minutes in 10mM sodium citrate) was required at the end of the in situ hybridisation protocol prior to  
882 proceeding with immunostaining.

#### 883 **Bulk RNAseq analysis of Pax6 cKO, Pax6 Gsx2 double cKO and control cortex**

884 Pregnant mice were killed by cervical dislocation following isoflurane overdose and embryos were  
885 removed. Quality control prior to RNAseq involved the use of immunohistochemistry on one cerebral  
886 hemisphere from every Pax6 cKO or Pax6 Gsx2 double cKO (dCKO) embryo and from all control littermates  
887 to check for efficient deletion of Pax6 or Pax6 and Gsx2. The other hemisphere from brains that passed this  
888 quality control was processed for RNAseq as follows. The EGFP reporter was used to guide the dissection to  
889 ensure only EGFP+ cortex was included. The rostral and caudal halves of each cortex were separated and  
890 frozen on dry ice. Cortical pieces from three E13.5 embryos or four E12.5 embryos were pooled to produce  
891 each sample. Total RNA was extracted from each pool using an RNeasy+ Micro kit (Qiagen). Poly-A mRNA  
892 was purified and TruSeq RNA-Seq libraries (Illumina) were prepared and sequenced (100 base paired-end;  
893 Illumina, HiSeq v3).

894 Sequencing gave an average of 108 million reads per sample. Following adapter trimming and standard  
895 quality checks, reads were aligned using STAR v. 2.4.0a to GRCm38.p3 (mm10) genome build obtained from  
896 Ensembl release 77. Reads were counted using featureCounts v. 1.4.5-p from the Subread package and only  
897 fragments with both reads properly aligned to exon regions were counted.

898 DESeq2 (Love et al., 2014) [190] and edgeR [191] (Robinson et al., 2010) were used to identify genes that  
899 were differentially expressed (DE) between conditions. When using DESeq2, package functions were used  
900 with default parameters and DE genes were defined as those with adjusted p-value  $\leq 0.05$  after Benjamini-  
901 Hochberg correction for multiple testing. When using edgeR, sample dispersion was estimated using

902 default parameters and pairwise Exact Tests were used to compare expression under different conditions:  
903 DE genes were defined as those with false discovery rate (FDR)  $\leq 0.05$ . We included all genes identified by  
904 either of these packages for further consideration as DE genes (most DE genes were identified by both  
905 packages).

#### 906 **Single cell RNAseq (scRNAseq) analysis of *Pax6* cKO and control cortex**

907 Pregnant mice were killed by cervical dislocation following isoflurane overdose and embryos were  
908 removed. Embryos were placed in ice-cold Earle's Balanced Salt Solution (EBSS) and examined under a  
909 fluorescence stereomicroscope for the presence of EGFP. EGFP-positive brains were used for the scRNAseq  
910 experiment; EGFP-negative brains from littermates were used as negative controls for EGFP signal  
911 calibration in subsequent fluorescence-activated cell sorting (FACS). The rostral half of the cortex from one  
912 hemisphere of each GFP-positive brain was isolated and used for tissue dissociation; the other hemisphere  
913 was fixed with 4% PFA and used in immunohistochemistry to check for efficient deletion of *Pax6*. The tails  
914 from the embryos were collected for genotyping to confirm *Pax6*<sup>fl<sup>ox</sup></sup> copy number.

915 Tissue was dissociated in 30 U/mL papain reagent containing 0.4% DNase (Worthington) for 30 mins at 37C.  
916 Samples were gently triturated using glass pipettes (BrainBits LLC) and sieved through a 40 $\mu$ m cell strainer  
917 (pluriSelect) to remove cell clumps. Dissociated cells were resuspended in basic sorting medium  
918 containing 2% heat-inactivated fetal bovine serum. Trypan blue was added to sample aliquots to allow  
919 quantification of cell density and viability. EGFP-positive cortical cells were selected using the FACSaria II  
920 (BD Biosciences). Cells were stained with DAPI to select against cell debris, cell doublets and dead cells. The  
921 system was then calibrated with EGFP-negative cells, before selecting approximately 20,000 EGFP-positive  
922 cells for each sample. FACSDiva 8.0.1 software (BD Biosciences) was used to process all flow cytometry  
923 data.

924 Three embryos from a pregnant mouse were used to prepare each E13.5 library. For E14.5 libraries, *Pax6*  
925 cKO embryos from three pregnant mice and control embryos from two pregnant mice were pooled  
926 together. All libraries from E13.5 and E14.5 were produced from male embryos; none of the cells across all  
927 four libraries expressed *Xist*.

928 The 10x Genomics Chromium Controller and Single Cell 3' Reagent Kits (v.2 for E13.5; v.3 for E14.5) were  
929 used for library construction, as per manufacturer's instructions. Cell density and viability were quantified  
930 using an automated cell counter as part of the quality control before loading onto the controller chip. Each  
931 sample was its own library. For each library, 3000-4000 cells were targeted for capture. Each library was  
932 constructed with a specific sample barcode and standard Illumina paired-end constructs. Two libraries from  
933 each embryonic age were sequenced simultaneously using the Illumina NovaSeq 6000 S1 flow cell. Raw  
934 sequencing reads were processed through the CellRanger pipeline (v.2 at E13.5; v.3 at E14.5; 10x  
935 Genomics) to produce a gene-cell count matrix using the mm10 mouse genome as reference.  
936 Approximately 60,000-100,000 reads per cell were generated to achieve optimal sequencing depth.

937 All data were subjected to SoupX (Young and Behjati, 2020)[192] to remove ambient RNA captured in  
938 droplets. To filter out cells giving low-quality data, cut-offs on unique molecular identifier (UMI), gene  
939 count and mitochondrial gene percentage were applied. Cells with gene counts > 3 standard deviations  
940 from the mean were excluded: depending on sequencing depth, cells expressing <~1000 and >~5500 genes  
941 were typically excluded. Cells expressing extremely high numbers of mitochondrial genes (>5% at E13.5;  
942 >10% at E14.5) were also excluded.

943 Clustering analysis was performed using the Seurat v.3.0 bioinformatics pipeline  
944 (<https://github.com/satijalab/seurat>). For each dataset, a Seurat object was created. UMI counts were  
945 natural log-normalized using log1p with scale factor of 10,000 using the NormalizeData function. Individual  
946 gene expression on Uniform Manifold Approximation and Projection (UMAP) was constructed with natural  
947 log-normalized expression using the FeaturePlot function. Expression values for each gene across all cells  
948 was standardized using z-score transformation implemented in the ScaleData function. A cell cycle phase  
949 was assigned to each cell using the Seurat pipeline. The datasets were not regressed with cell cycle scores  
950 as this might have hindered identification of the physiological relevance of cell cycle in the temporal  
951 progression of cortical neurogenesis. For integrated analysis across the control and *Pax6* cKO datasets,



952 normalization and feature selection for highly variable genes in each library were performed  
953 independently. Based on the selected features, the control and *Pax6* cKO datasets were passed through the  
954 FindIntegrationAnchors function to identify the cross-dataset anchors for data integration. The resulting  
955 integration anchors were then implemented in the IntegratedData function, producing an integrated Seurat  
956 object. Next, the most variable genes in the integrated dataset were identified and used for principal  
957 component analysis. The most statistically significant principal components were used as inputs for non-  
958 linear dimensionality reduction using UMAP implemented in the FindCluster function at a resolution  
959 between 0.8 and 1.6 to determine cellular clusters based on k-nearest neighbours and shared nearest  
960 neighbour (SNN) graphs. Top cluster marker genes were identified and differential expression analysis  
961 (DEA) across two different cellular clusters was carried out using Model-based Analysis of Single-cell  
962 Transcriptomics (MAST) implemented in the FindAllMarkers function.

963 Cell lineage or pseudotime inference was carried out using the Slingshot algorithm  
964 (<https://github.com/kstreet13/slingshot>) (Street et al., 2018)[91]. A matrix with reduced dimensionality and  
965 cell clustering assignments was taken as input by Slingshot. With the radial glial progenitor (RGP) as the  
966 initial cell state (or root node), lineage trajectories and branch points were inferred by connecting the  
967 cluster medoids with a minimum spanning tree. Patterns of gene expression along pseudotime were  
968 computed using the tradeSeq algorithm (<https://statomics.github.io/tradeSeq/index.html>) [93](Van den  
969 Berge et al., 2020). Gene expression along pseudotime was normalized using log1p.

970 RNA velocity estimation was generated using the Velocityto (<https://github.com/velocityto-team>) and scVelo  
971 (<https://github.com/theislab/scvelo>) software packages. Count matrices with cells that had passed quality  
972 control were used as inputs for Velocityto. All velocity embeddings were estimated using the stochastic model.  
973 For visualization purposes, the RNA velocity embeddings were visualized using the UMAP coordinates  
974 produced from the previous cell clustering analysis in Seurat.

#### 975 **BrdU and Ethynyldeoxyuridine (EdU) labelling**

976 Pregnant females were given a single intraperitoneal dose of BrdU or EdU (10mg mL<sup>-1</sup>; Thermo Fisher  
977 Scientific). Subsequent immunohistochemistry was as described above. Cells labelled with EdU were  
978 visualised using a Click-iT EdU Alexa Fluor 647 Imaging Kit (Thermo Fisher Scientific).

#### 979 **Whole-cell electrophysiology**

980 Postnatal mice were anesthetized with isoflurane and sacrificed by decapitation, the brain was quickly  
981 removed into artificial cerebrospinal fluid (aCSF) (80 mM NaCl, 2.5 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 25 mM  
982 NaHCO<sub>3</sub>, 10 mM glucose, 90 mM sucrose, 0.5 mM CaCl<sub>2</sub>, 4.5 mM MgSO<sub>4</sub>) and 400 μm coronal slices were  
983 prepared in ice-cold aCSF solution using a vibrating microtome (VT1200S, Leica, Germany). Slices were  
984 transferred to aCSF solution for 30 minutes at 35 °C and current clamp whole-cell recordings were performed  
985 using a Multiclamp 700A amplifier (Molecular Devices, Palo Alto, USA). Signals were filtered online at 10 kHz  
986 and digitized at 40 kHz and traces stored on the computer using Signal 2 software (Cambridge Electronic  
987 Design, UK). Borosilicate glass electrodes (Harvard Apparatus, UK) with a resistance of 3.5-7.5 MΩ (Digitimer  
988 Research Instruments, UK) were filled with the following solution: 135 mM KMeSO<sub>4</sub>, 8 mM NaCl, 10 mM  
989 HEPES, 0.5 mM EGTA, 0.5 mM Na-GTP, and 4 mM Mg-ATP, 0.5 mM EGTA, pH 7.3, osmolarity adjusted to 285  
990 mOsm. The chamber was perfused at a rate of 3-4mL/min with carbonated (95% O<sub>2</sub>, 5% CO<sub>2</sub>) external  
991 solution containing: 130 mM NaCl, 2.5 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 25 mM NaHCO<sub>3</sub>, 10 mM glucose, 2.5 mM  
992 CaCl<sub>2</sub>, 1.5 mM MgSO<sub>4</sub> at 32-35 °C. Access resistance was monitored online throughout the recording and if it  
993 dropped >20% the recording was discarded and no further analysis was carried out. In current clamp small  
994 incremental voltage steps (10/25 pA) were applied for 500 ms to measure cell intrinsic properties. Membrane  
995 potential was held at -70mV. Feature extraction was done blind to genotype using custom scripts written in  
996 Signal 2. Some raw .csf recordings of cortical cells were lost and are no longer available.

997 Action potential (AP) features were extracted from single APs at rheobase. AP threshold was defined as the  
998 time at membrane potential at which the slope first exceeded 30 V/s. AP amplitude was defined as height  
999 from AP threshold to peak. Afterhyperpolarization (AHP) amplitude (mV) was defined as potential difference  
1000 between AP threshold and AHP trough. AP latency was defined as the time between start of current step and  
1001 first AP peak. Properties of trains of APs were determined in response to a current step double rheobase.

1002 First-second adaptation ratio and first-last adaptation ratio were calculated by dividing instantaneous  
1003 frequency of the second/last AP by the first AP instantaneous frequency (this measures the interval between  
1004 spikes). Spikelet amplitude (mV) was defined as the difference between peak voltage and steady-state  
1005 voltage during the current step. Input resistance and membrane time constant ( $\tau$ ) were measured using  
1006 the average of 20 membrane potential responses to negative current steps (-10 or -25 pA) lasting 500ms.  
1007 Membrane time constant ( $\tau$ ) was calculated by fitting a single exponential (10%-90%) to the membrane  
1008 potential response curve. Capacitance was then calculated using  $\tau/\text{input resistance} = \text{capacitance}$ . To test  
1009 the effects of tetrodotoxin (TTX) on spikelets, we used spikelet-inducing current steps (square pulses 0.5s  
1010 long; 60 sweeps over 60s) while the chamber was perfused with external solution either containing TTX  
1011 (300nM) or without TTX, to ensure there was no spikelet wane with persistent stimulation. To show TTX  
1012 blockade of spikelets, which occurred over 30 sweeps, we compared the average amplitudes of spikelets over  
1013 the first and last 10 sweeps.

1014 Data were analysed statistically and by unsupervised hierarchical clustering. For pairwise comparisons, N's  
1015 were animals. Data was analysed in R (packages: cluster, ggpubr, dendextend, Nbclust, PairedData and  
1016 tidyverse). Pre-analysis routines were carried out to inspect data normality by plotting residual plots  
1017 (qqplots). If data was not normally distributed, a non-parametric test was used. Data for clustering was scaled  
1018 using base R scale function. For unsupervised clustering, the agglomerative Ward's linkage method was used  
1019 after calculating Euclidean distances to minimize the variance within clusters [193](Ward, 1963). Data  
1020 features used for clustering: AHP amplitude, AP halfwidth, AP threshold, input resistance, capacitance,  
1021 number of spikes in response to 500ms current step at double rheobase current, first-spike latency, first to  
1022 second AP adaptation ratio and first to last AP adaptation ratio. Silhouette coefficients were calculated using  
1023 Nbclust R package. Signal analysis scripts available at Marcos Tiago, pax6\_codes (2019-2021) online GitHub  
1024 repository (<https://github.com/TiagoMarcos>).

#### 1025 **In utero injection and electroporation**

1026 Pregnant mice were maintained under inhaled isoflurane anaesthesia for the duration of the procedure.  
1027 The uterine horns were exposed. In some experiments, 1-2  $\mu\text{l}$  of Vismodegib (5mM solution in DMSO;  
1028 Stratech) or DMSO alone was injected into the lateral ventricle of each embryo's brain with a glass  
1029 micropipette. In other experiments, plasmids were injected into the lateral ventricle of each embryo's brain  
1030 at 1 to 4  $\text{mg mL}^{-1}$ , the embryo in the uterus was placed between tweezer-type electrodes (CUY650;  
1031 Nepagene) and an electroporator (CUY21E; Nepagene) was used to deliver 6 pulses (30 V, 50 ms each, 950  
1032 ms apart). In both cases, the uterine horns were replaced, the abdominal wall was sutured and animals  
1033 recovered. Processing was as described above.

1034 Plasmids used in this study were: CAG-FoxG1-IRES-mCherry (kindly provided by Goishi Myioshi, Tokyo  
1035 Women's Medical University, Japan); Scrambled shRNA control in pGFP-V-RS shRNA Vector (TR30013,  
1036 Origene); Smoothened shRNA in pGFP-V-RS shRNA Vector (TG510788, Origene).

#### 1037 **Organotypic slice cultures**

1038 Pregnant mice were killed by cervical dislocation following isoflurane overdose and embryos were  
1039 removed. Embryonic brains were embedded in 3.5% (w/v) low melting point agarose (Lonza) in phosphate  
1040 buffered saline. Coronal sections were cut at a thickness of 300 $\mu\text{m}$  using a vibratome. The slices were  
1041 transferred onto a polycarbonate culture membrane (Whatman) floating on minimum essential medium  
1042 (MEM; Gibco) supplemented with fetal bovine serum (FBS) and incubated at 37°C, 5%  $\text{CO}_2$ . After an hour of  
1043 incubation, the FBS-supplemented medium was replaced with serum-free neurobasal medium (Gibco)  
1044 supplemented with B27 (1:50 dilution; Gibco) and N2 supplement (1:100 dilution; Gibco).

1045 In some experiments, after an hour of incubation, the ventral telencephalon of one of the hemispheres was  
1046 removed from the section while the other hemisphere was left intact. In other experiments, after an hour  
1047 of incubation, pharmacological treatments were carried out. For Bmp4 treatment, Bmp4 (R&D Systems) or  
1048 vehicle alone was added to the culture medium to achieve a range of concentrations while maintaining the  
1049 concentration of all other components constant. Cyclopamine treatment was done in one of two ways.  
1050 Either Affi-gel agarose beads (Bio-Rad) were soaked overnight in cyclopamine (4  $\text{mg mL}^{-1}$ ; Toronto Research  
1051 Chemicals) or vehicle alone and transferred onto the cortex; or cyclopamine (10 $\mu\text{M}$ ) or vehicle alone were

1052 added in solution to the culture medium. After culture at 37°C, 5% CO<sub>2</sub>, telencephalic slices were processed  
1053 for qRT-PCR, immunohistochemistry or in situ hybridization as described above.

#### 1054 **Dissociated cell culture**

1055 Pregnant mice were killed by cervical dislocation and embryos were removed. Tissue samples were taken  
1056 from each embryo for genotyping to identify whether they were *Pax6* cKO or control [185](Simpson et al.,  
1057 2009). GFP+ cortices were dissociated using a papain dissociation kit (Worthington) and trituration using  
1058 glass pipettes (BrainBits LLC). Cells were cultured on poly-L-ornithine and laminin-coated coverslips in 24-  
1059 well plates at 150,000 cells per well in serum-free 2i Medium (Merck). After 24h, Smoothened Agonist  
1060 (SAG; Abcam) dissolved in DMSO was added to make final SAG concentrations of 1.25nM, 2.5nM, 5nM,  
1061 10nM, 20nM, 40nM, 80nM or 160nM. An equivalent number of cultures of each genotype had DMSO only  
1062 added to give each of the concentrations present at each of the SAG concentrations (0.025%, 0.05%, 0.1%,  
1063 0.2%, 0.4%, 0.8%, 1.6% and 3.2%). Some cultures had both 160nm SAG and 10mM EdU added. Cells were  
1064 fixed with 4% PFA 48h later.

1065 Antibodies for immunocytochemistry included anti-Tubb3 (1:500; chicken; Novus Biologicals); the others  
1066 were as described above. DIG labelled *Dlx1* probes were synthesized and used for fluorescence in situ  
1067 hybridization as described above. EdU was detected using a Click-iT EdU Alexa Fluor 647 Imaging Kit  
1068 (Thermo Fisher Scientific). Cells were counterstained with DAPI (1:1000) and coverslips were mounted with  
1069 Vectashield HardSet (Vector Laboratories).

1070 All cultures were imaged at x20 and imported to Fiji software (<https://imagej.net/software/fiji/>) for cell  
1071 counting. Each coverslip was divided into 25 areas (Fig-S17 Fig) and counting was done using the Cell  
1072 Counter plug-in in 5 areas selected at random using a random number generator.

#### 1073 **Microscopy**

1074 Imaging was carried out using Leica brightfield or epifluorescence microscopes or a Nikon A1R confocal  
1075 microscope. Microscope images were acquired using the Leica Application Suite X (LAS X) or Nikon NIS-  
1076 Elements software.

1077

1078 **FIGURE LEGENDS**

1079  
1080 **Figure 1: Aberrant cell types and ectopic gene expression in *Pax6* cKO cortex**

1081 **(A)** The experimental procedure: tamoxifen (TAM) was administered at E9.5; E13.5 and E14.5 rostral (R)  
1082 cortex was dissociated into single cell suspension; viable GFP+ cells were selected by fluorescence activated  
1083 cell sorting (FACS) for single cell RNA sequencing (scRNAseq).

1084 **(B)** Uniform manifold approximation and projection (UMAP) plot of the scRNAseq data from *Pax6* cKO and  
1085 control cells at E13.5. Data from the two genotypes were analysed together and then split for visualization.  
1086 RGP, radial glial progenitor; aRGP, atypical RGP; IP, intermediate progenitor; DLN, deep layer neuron; CRC,  
1087 Cajal-Retzius cell.

1088 **(C)** UMAP plots showing  $\log_{10}$  normalized expression of selected genes that were ectopically expressed in  
1089 E13.5 *Pax6* cKO cortex.

1090 **(D)** UMAP plots of the scRNAseq data from *Pax6* cKO and control cells at E14.5. Data from the two  
1091 genotypes were analysed together and then split for visualization. RGP, radial glial progenitor; aP, atypical  
1092 progenitor; eGC-P and eCG-N, proliferating or non-proliferating ectopic GABAergic cells; IP, intermediate  
1093 progenitor; DM-IP and DM-SLN, intermediate progenitor or superficial layer neuron in dorsomedial cortex;  
1094 SLN-L2/3 and SLN-L4, layer 2/3 or layer 4 superficial layer neurons; DLN-L5 and DLN-L6, layer 5 or layer 6  
1095 deep layer neurons; CRC, Cajal-Retzius cell.

1096 **(E)** UMAP plots showing  $\log_{10}$  normalized expression of cell type-selective marker genes at E14.5.

1097  
1098 **Figure 2: Development of abnormal cell lineages in *Pax6* cKO cortex**

1099 **(A,B)** RNA velocity analysis of individual E14.5 control and *Pax6* cKO cortical cells. Abbreviations: see Fig-  
1100 1D.

1101 **(C)** Enlargement of the boxed area in (B) showing RNA velocity analysis of individual aP control and *Pax6*  
1102 cKO cells and UMAP plots of *Neurog2*, *Eomes*, *Gsx2* and *Dlx1* expression in aPs.

1103  
1104 **Figure 3: Distinct spatiotemporal patterns of gene expression changes in *Pax6* cKO cortex**

1105 **(A-C)** Flattened surface views of the cortex, oriented as in (A), to show the variation in the relative intensity  
1106 of *Ascl1* and *Neurog2* staining across control and *Pax6* cKO cortex at E13.5 and E14.5. Method in Fig-S8B  
1107 Fig.

1108 **(D)** Colorimetric and fluorescence immunoreactivity for *Eomes* in control and *Pax6* cKO cortex at E14.5  
1109 (with GFP labelling *Emx1*-lineage cells). Scale bars: 0.1mm.

1110 **(E)** Flattened surface views of the cortex, oriented as in (A), to show the variation in the density of *Eomes*+  
1111 cells in control and *Pax6* cKO cortex at E13.5 and E14.5. Dashed black line: pallial-subpallial boundary.

1112 **(F)** Immunoreactivity for *Eomes* and in situ hybridization for *Prdm13* in control and *Pax6* cKO cortex at  
1113 E13.5. Arrowheads indicate double-labelled cells. Scale bars: 0.1mm.

1114 **(G)** Flattened surface views of the cortex, oriented as in (A), to show the variation in the relative intensity of  
1115 *Prdm13* staining in *Pax6* cKO cortex at E13.5 and E14.5.

1116 **(H)** Flattened surface views of the cortex oriented as in (A), showing the densities of *Gsx2*+ and *Dlx1*+ cells  
1117 in control and *Pax6* cKO cortex at E12.5, E13.5 and E14.5 following tamoxifen administration at E8.5, E9.5  
1118 or E10.5.

1119  
1120 **Figure 4: The proliferation, coalescence and electrophysiological properties of *Gsx2*-lineage eGCs**

1121 **(A)** Major pseudotemporal trajectories inferred from E14.5 *Pax6* cKO scRNAseq data (one leading to eGC-  
1122 Ps, one to eGC-Ns and one to cortical glutamatergic neurons) and expression of the marker of proliferating  
1123 cells, *Mki67*, along each.

1124 **(B)** The experimental procedure for EdU labelling. The *Emx1-Cre<sup>ERT2</sup>* allele with tamoxifen<sup>E9.5</sup> was used to  
1125 delete *Pax6* (embryos carried a *Btg2*-GFP transgene); 5-ethynyl-2'-deoxyuridine (EdU) was given at E13.5,  
1126 30 minutes before death; 20 coronal sections equally spaced through the brain were immunoreacted for  
1127 EdU, *Gsx2* and GFP; counts were made in the boxed area.

1128 **(C)** Fluorescence quadruple-staining for *Gsx2*, EdU, GFP (marking *Btg2*-expressing cells) and DAPI in E13.5  
1129 *Pax6* cKO cortex after the procedure in (B). Scale bar: 0.1mm.

1130 **(D)** Fluorescence double-staining for Sox9 and GFP (marking *Btg2*-expressing cells) in E13.5 *Pax6* cKO cortex  
1131 after tamoxifen<sup>E9.5</sup>. Scale bar: 0.1mm.

1132 **(E)** Fluorescence double-staining for *Gsx2* and GFP (marking *Btg2*-expressing cells) in E13.5 and E14.5 *Pax6*  
1133 cKO cortex after tamoxifen<sup>E9.5</sup>. Scale bar: 0.1mm.

1134 **(F)** Eomes immunoreactivity and methyl green counterstaining in control and E16.5 *Pax6* cKO cortex after  
1135 tamoxifen<sup>E9.5</sup>. Scale bar: 0.1mm.

1136 **(G)** Fluorescence immunoreactivity for GFP (*Emx1*-lineage) and in situ hybridization for *Gad1+* cells in E18.5  
1137 *Pax6* cKO cortex after tamoxifen<sup>E9.5</sup>. Scale bars: 0.1mm and 0.01mm.

1138 **(H)** Quantifications of the total numbers of *Gad1+* cells in the lateral cortical plate (CP; red: they were GFP-  
1139 subcortically-derived), of *Gad1-* cells in the CP (green: GFP+, cortical-born) and of cells in the *Pax6* cKO sub-  
1140 CP masses (pink: *Gad1+*, GFP+) in control and *Pax6* cKO E18.5 embryos after tamoxifen at E9.5 (for  
1141 quantification method, see [Fig-S11F Fig](#)). Total numbers of cells were greater in *Pax6* cKO cortex ( $p < 0.05$ )  
1142 and numbers of lateral CP cells were reduced ( $p < 0.02$ ) (averages  $\pm$  sem; Student's paired t-tests;  $n = 4$   
1143 embryos of each genotype, from 4 independent litters) ([Source Data Table 43S4 Data](#)).

1144 **(I)** The experimental procedure for electrophysiology (J-P). The *Emx1-Cre* allele was used to delete *Pax6*;  
1145 embryos carried a GFP reporter transgene. Recordings were from sub-CP masses at P3-10.

1146 **(J)** Sub-CP mass in P7 slice prepared for electrophysiology: the cortex was GFP+ and the sub-CP mass was  
1147 intensely so. Scale bar: 0.5mm.

1148 **(K,L)** Examples of responses of sub-CP mass cells to current injections (square steps, magnitudes colour-  
1149 coded, 500ms duration). Membrane voltages were held at -70mV. Some cells produced small spikelets (J),  
1150 others did not (K).

1151 **(M)** Tetrodotoxin (TTX; 300nM) reduced spikelet amplitudes; examples of entire response and spikelet  
1152 alone before and after TTX application; effects of TTX were significant ( $p = 0.035$ , Wilcoxon signed rank test;  
1153  $n = 6$  cells) ([Sheet A in Source Data Table 54A55A Data](#)).

1154 **(N-P)** Passive electrical properties of P3-P10 sub-CP mass cells compared to P5-P7 cortical cells from layer 5  
1155 of somatosensory area 1 ( $n = 66$  sub-CP mass cells, [Sheet B in Source Data Table 54B55B Data](#);  $n = 49$  cortex  
1156 cells, data for these CP cells are in [Table 55S5 Table](#)). Sub-CP mass cells had significantly lower capacitance  
1157 ( $p = 2.2 \times 10^{-16}$ , Mann-Whitney test) and significantly higher input resistance ( $p = 2 \times 10^{-10}$ , Mann-Whitney test)  
1158 and resting membrane potential ( $p = 2.2 \times 10^{-16}$ , Mann-Whitney test). For capacitance, values were  
1159 significantly higher among sub-CP mass cells that produced spikelets ( $n = 22$  cells;  $n = 44$  produced no  
1160 spikelet) ( $p = 1.9 \times 10^{-9}$ , Mann-Whitney test).

1161  
1162 **Figure 5. The production of eGCs did not require *Gsx2* activation**

1163 **(A)** The experimental procedure for (B-E): tamoxifen (TAM) was administered at E9.5 to generate control  
1164 embryos with functional alleles of both *Pax6* and *Gsx2*, a single cKO of *Pax6* or a double cKO (dcKO) of *Pax6*  
1165 and *Gsx2*; brains were analysed at E13.5, E14.5 or E16.5.

1166 **(B)** Colorimetric immunoreactivity for Gsx2 and in situ hybridization for *Dlx1* in *Pax6* cKO and *Pax6 Gsx2*  
1167 dcKO at E14.5. Scale bar: 0.1mm.

1168 **(C)** Colorimetric in situ hybridization for *Gad1* in *Pax6* cKO and *Pax6 Gsx2* dcKO at E16.5. Scale bar: 0.1mm.

1169 **(D)** Fluorescence in situ hybridization for *Gsx2* and immunoreactivity for Eomes in *Pax6* cKO and *Pax6 Gsx2*  
1170 dcKO at E14.5. Scale bar: 0.01mm.

1171 **(E)** Colorimetric and fluorescence in situ hybridizations for *Robo3*, colorimetric immunoreactivity for Gsx2  
1172 and fluorescence immunoreactivity for GFP in control, *Pax6* cKO and *Pax6 Gsx2* dcKO at E13.5. Scale bars:  
1173 0.1mm and 0.01mm.

1174 **(F)** The experimental procedure for (G): tamoxifen (TAM) was administered at E9.5 to generate control  
1175 embryos with a functional allele of *Gsx2* or a cKO of *Gsx2* throughout the embryo; brains were analysed at  
1176 E13.5.

1177 **(G)** Colorimetric in situ hybridizations for *Robo3* in control and *Gsx2* cKO at E13.5. Scale bar: 0.1mm.

1178

1179 **Fig. 6. Extracellular signals promoted eGC production in *Pax6* cKOs cortex**

1180 **(A)** The experimental procedure for (B-F): tamoxifen (TAM) was given at E9.5 to generate *Pax6* cKOs, with  
1181 Cre deleted cells expressing GFP; coronal slices were cultured on E13.5 with the ventral telencephalon  
1182 removed on one side; after 2 days in vitro (DIV) sections from cultured slices were cut and processed.  
1183 Gsx2+ GFP+ cells were counted in 3 regions of interest (ROI) on each side.

1184 **(B,C)** GFP immunoreactivity and in situ hybridizations for *Gad1* in sections prepared as in (A). Scale bars:  
1185 0.1mm and 0.01mm.

1186 **(D)** Average ( $\pm$ sem) numbers of immigrant *Gad1*+ interneurons (i.e. GFP non-expressing) per section were  
1187 lower on the side lacking ventral telencephalon (n=3 independent cultures; Student's paired t-test) ([Sheet A](#)  
1188 [in Source-Data-Table 6SAS6A Data](#)).

1189 **(E)** Gsx2 immunoreactivity in sections prepared as in (A). Scale bar: 0.1mm.

1190 **(F)** Average ( $\pm$ sem) proportions of GFP+ cells that were Gsx2+ in each ROI in (A) (n=3 independent cultures;  
1191 Student's paired t-tests; n.s., not significant) ([Sheet B in Source-Data-Table 6BS6B Data](#)).

1192 **(G)** Immunoreactivity for Shh in control telencephalic sections at E13.5 and E15.5 (see [Fig-S15B Fig](#) for  
1193 evidence of antibody specificity). Scale bar: 0.1mm.

1194 **(H)** The experimental procedure for (I,J): vismodegib or vehicle alone was injected into the ventricle of  
1195 E14.5 *Pax6* cKO embryos made using *Emx1-Cre*; central regions of lateral cortex from coronal sections at  
1196 three rostral-to-caudal levels were analysed at E15.5.

1197 **(I)** Gsx2 immunoreactivity in boxed region in (H). PZ: proliferative zone; sub-CPM: sub-cortical plate masses.  
1198 Scale bar: 0.1mm.

1199 **(J)** Average ( $\pm$ sem) proportions of cells in the PZs and CPMs that were Gsx2+ (n=5 embryos from 3 litters  
1200 given vehicle alone; n=6 embryos from 3 litters given vismodegib; Student's t-tests) ([Sheet A in Source-Data-](#)  
1201 [Table 76AS7A Data](#)).

1202 **(K)** The experimental procedure for (L,M): constructs expressing *Smo* shRNA + GFP or scrambled shRNA +  
1203 GFP were electroporated into the cortex of E14.5 *Pax6* cKO embryos made using *Emx1-Cre*; electroporated  
1204 cells were analysed at E15.5 (as in [Fig-S15D Fig](#)).

1205 **(L)** Gsx2 and GFP immunoreactivity in electroporated regions. Scale bar: 0.01mm.

1206 **(M)** Cumulative frequency distributions of the intensity of Gsx2 immunoreactivity in electroporated cells  
1207 (GFP+; green) and surrounding randomly selected non-electroporated cells (GFP-; black) for the two  
1208 constructs (see K and [Fig-S15D Fig](#)) (n=3 embryos from 3 litters given *Smo* shRNA; n=4 embryos from 3  
1209 litters given scrambled shRNA; Kolmogorov-Smirnov tests) ([Sheet B in Source-Data-Table 76BS7B Data](#)).

1210 **(N)** The experimental procedure for (O): tamoxifen (TAM) was given at E9.5 to generate *Pax6* cKOs and Cre  
1211 deleted cells expressed GFP; coronal slices of telencephalon were cultured on E13.5; cyclopamine or vehicle  
1212 alone were added either on beads or in solution (10 $\mu$ M); slices were cultured for 2 DIV.

1213 **(O)** Sections from cultured slices obtained as in (N) were immunoreacted for Gsx2 and GFP. Ctx: cortex;  
1214 PSPB, pallial-subpallial boundary; LGE, lateral ganglionic eminence; Hem: cortical hem. Scale bar: 0.1mm.

1215

#### 1216 **Figure 7: Foxg1 required cell autonomously for eGC production**

1217 **(A)** A hypothesis: Pax6 suppresses specifically Foxg1-permitted Shh-induced generation of eGCs without  
1218 interfering with other effects of Shh pathway activation in these cells.

1219 **(B)** The experimental procedure for (C-E): tamoxifen (TAM) was administered at E9.5 to generate *Pax6* cKOs  
1220 in which neither, one or both *Foxg1* allele(s) were also deleted (for alleles, see [Fig-S16A Fig](#)); brains were  
1221 analysed at E13.5, E14.5 or E16.5.

1222 **(C)** Immunoreactivity for Gsx2 and GFP and in situ hybridizations for *Gad1* and *Dlx1* in E14.5 cortex from  
1223 *Pax6* cKO embryos in which neither, one or both *Foxg1* allele(s) were deleted by tamoxifen at E9.5. Scale  
1224 bar: 0.1mm.

1225 **(D)** Densities of Gsx2+ cells in the lateral cortex of E14.5 embryos with the three genotypes in (C) (averages  
1226  $\pm$  sem; n=3 embryos of each genotype, from 3 independent litters) ([Sheet C in Source-Data Table 76CS7C](#)  
1227 [Data](#)).

1228 **(E)** High magnification images from (C): at least the majority of residual *Gad1+* (green) cells in *Pax6 Foxg1*  
1229 double KOs (arrows) were GFP-negative (i.e. not white) of subcortical origin (non-*Emx1*-lineage). Scale bar:  
1230 0.01mm.

1231 **(F)** The experimental procedure for (G): *Pax6 Foxg1* double cKO cortex made using *Emx1-Cre*, avoiding the  
1232 need for tamoxifen; a construct expressing Foxg1 and mCherry was electroporated into the cortex on  
1233 E14.5; coronal sections were analysed on E16.5.

1234 **(G)** Results of experiment in (F): expression and co-expression of Foxg1, Gsx2, Olig2, mCherry and GFP  
1235 protein and *Dlx1* mRNA in coronal sections. Scale bars: 0.1mm.

1236

#### 1237 **Figure 8: Pax6 deletion affected concentration-response of cortical cells to Shh pathway activation**

1238 **(A)** The experimental procedure for (B-G): tamoxifen (TAM) was given at E9.5 to generate *Pax6* cKO and  
1239 control embryos, with Cre activation revealed by GFP expression; E13.5 cortex was dissociated, cells were  
1240 treated with SAG or vehicle alone, and with EdU in some cases, after 1 day in vitro (DIV), and were analysed  
1241 after a further 2DIV.

1242 **(B)** Examples of labelling of E13.5 control and *Pax6* cKO cells grown in dissociated culture with 5nM or  
1243 50nM SAG. Labelling was for DAPI and GFP with Gsx2, *Dlx1* or Olig2. Scale bar: 0.01mm.

1244 **(C)** Graphs of concentration-responses to SAG (measured as percentages of GFP+ cells expressing Gsx2,  
1245 *Dlx1* or Olig2). Data are averages ( $\pm$ sem; n=3 independent experiments each), with EC<sub>50</sub>s for each response  
1246 curve. Two-way analyses of variance were conducted. For Gsx2: significant effects of genotype  
1247 (f(1,32)=798.9, p<0.001) and SAG concentration (f(7,32)=1138, p<0.001) and significant interaction effect  
1248 (f(7,32)=123.5, p<0.001). For *Dlx1*: significant effects of genotype (f(1,32)=763.6, p<0.001) and SAG  
1249 concentration (f(7,32)=1011, p<0.001) and significant interaction effect (f(7,32)=91.90, p<0.001). For Olig2:  
1250 significant effects of genotype (f(1,32)=177.4, p<0.001) and SAG concentration (f(7,32)=415.1, p<0.001) and  
1251 significant interaction effect (f(1,32)=15.88, p<0.001) ([Sheets A-C in Source-Data Table 87A-C S8A-C Data](#)).

1252 **(D)** Examples of labelling of E13.5 control and *Pax6* cKO cells grown in dissociated culture with 160nM SAG.  
1253 Labelling was for DAPI, GFP, Gsx2 and Tubb3. Examples include GFP+ cells that were: Gsx2+, Tubb3-; Gsx2+,  
1254 Tubb3+; Gsx2-, Tubb3+. Scale bar: 0.01mm.



1255 (E) Average percentages ( $\pm$ sem; n=4 independent experiments each) of GFP+ control or *Pax6* cKO cells with  
1256 or without 160nM SAG that expressed *Tubb3*, *Gsx2* or both (Sheet D in [Source-Data-Table-87D87D Data](#)).

1257 (F) Examples of labelling of E13.5 control and *Pax6* cKO cells grown in dissociated culture with 160nM SAG.  
1258 Labelling was for DAPI, GFP and EdU. Examples include GFP+ cells that were: *Gsx2*+, EdU+; *Gsx2*+, EdU-.  
1259 Scale bar: 0.01mm.

1260 (G) Average percentages ( $\pm$ sem; n=4 independent experiments each) of GFP+ cells that contained EdU  
1261 among the *Gsx2*+ and *Gsx2*- populations in cultures from control and *Pax6* cKO cortex treated with SAG.  
1262 Total numbers, across all cultures, of GFP+ cells that contained EdU over total numbers of GFP+ cells are  
1263 stated for each condition (Sheet E in [Source-Data-Table-87E87E Data](#)).

1264  
1265 **Figure 9:- Morphogen regulation of ectopic gene expression following Pax6 loss**

1266 (A) The experimental procedure for (B-E): tamoxifen (TAM) was administered at E9.5 to delete either one  
1267 (control) or both (cKO) *Pax6* allele(s), with Cre deleted cells expressing GFP; coronal slices were cultured on  
1268 E13.5 with *Bmp4* or vehicle alone for 2 days in vitro (DIV); slices were analysed using qRT-PCR or sectioned.

1269 (B) Concentration-response measured using qRT-PCR: *Gsx2* levels (averages  $\pm$ sem; values were relative to  
1270 the average level in control cortex treated with 0 *Bmp4*) in control and *Pax6* cKO slices with increasing  
1271 concentrations of *Bmp4* (n=3 independent cultures at each concentration). Two-way ANOVA showed  
1272 significant effects of genotype ( $p < 0.001$ ), of *Bmp4* concentration ( $p < 0.005$ ) and an interaction effect  
1273 ( $p < 0.01$ ). Differences between genotypes at each *Bmp4* concentration were tested with Bonferroni's  
1274 method for comparison of means (\*\*\*\*,  $p < 0.001$ ) ([Source-Data-Table-98S9 Data](#)).

1275 (C) Immunoreactivity for *Gsx2* and GFP in telencephalic slices from *Pax6* cKOs cultured with vehicle alone or  
1276 *Bmp4*. Scale bar: 0.1mm.

1277 (D) Concentration-response measured using qRT-PCR: *Prdm13* levels (averages  $\pm$ sem; values are relative to  
1278 the average level in *Pax6* cKO cortex treated with 0 *Bmp4*) in control and *Pax6* cKO slices with increasing  
1279 concentrations of *Bmp4* (n=3 independent cultures at each concentration). Two-way ANOVA showed  
1280 significant effects of genotype ( $p < 0.005$ ), of *Bmp4* concentration ( $p < 0.05$ ) and an interaction effect  
1281 ( $p < 0.05$ ). Differences between genotypes at each *Bmp4* concentration were tested with Bonferroni's  
1282 method for comparison of means (\*\*\*,  $p < 0.005$ ) ([Source-Data-Table-98S9 Data](#)).

1283 (E) In situ hybridizations for *Prdm13* and immunoreactivity for GFP in telencephalic slices from *Pax6* cKOs  
1284 cultured with vehicle alone or *Bmp4*. Green arrows indicate *Prdm13* expression in lateral cortex. Scale bar:  
1285 0.1mm.

1286 (F) A hypothesis of how *Shh* and *Bmp4* might combine to generate the observed spatial patterns of *Gsx2*  
1287 and *Prdm13* expression in the embryonic cortex after *Pax6* deletion. Deletion might increase the probability  
1288 of *Gsx2* being activated in cells exposed to physiological levels of *Shh* above a threshold (broken line). In  
1289 medial cortex, exposure the levels of *Bmp* above a threshold (central broken line) might reduce the  
1290 probability of *Gsx2* activation. Cells exposed to intermediate levels of *Bmp* (between upper and lower  
1291 broken lines) might have an increased probability of expressing *Prdm13*.

1292 (G) Waddington's epigenetic landscape analogy, used to illustrate our main conclusions. A saddle-node  
1293 bifurcation illustrates *Pax6*'s normal action, closing a valley on the left (RGP: radial glial progenitor). *Pax6*  
1294 deletion opens this valley, creating a subcritical pitchfork bifurcation where cells emerging from the  
1295 transition state can enter either of two valleys (eGC: ectopic GABAergic cell). Increasing exposure to *Shh*  
1296 tilts the landscape to the left making it more likely that the cell will enter the open valley on the left;  
1297 increasing exposure to *Bmp* has the opposite effect.

1298  
1299 **ACKNOWLEDGEMENTS**

1300 [We thank Ugo Borello, Matt Colligan, Petrina Georgala, Anisha Kubasik-Thayil, Da Mi, Soham Mitra, Elena](#)  
1301 [Purlyte, Thomas Theil, Dafni Triantafyllou and staff in Bioresearch and Veterinary Services and Edinburgh](#)  
1302 [Genomics for their contributions.](#)

1303

1304

1305 **REFERENCES**

1306

- 1307 [1. Britten RJ, Davidson EH. Gene regulation for higher cells: a theory. Science. 1969 Jul 25;165\(3891\):349-](#)  
1308 [57. doi: 10.1126/science.165.3891.349. PMID: 5789433.](#)
- 1309 [2. Davidson EH. Emerging properties of animal gene regulatory networks. Nature. 2010 Dec](#)  
1310 [16;468\(7326\):911-20. doi: 10.1038/nature09645. PMID: 21164479; PMCID: PMC3967874.](#)
- 1311 [3. Waddington, CH. Experiments on the Development of Chick and Duck Embryos, Cultivated in Vitro. Philos](#)  
1312 [Trans R Soc Lond B Biol Sci. 1932 221:179-230.](#)
- 1313 [4. Waddington CH. Experiments on Embryonic Induction: III. A Note on Inductions by Chick Primitive Streak](#)  
1314 [Transplanted to the Rabbit Embryo. J Exp Biol. 1934 11:224-227.](#)
- 1315 [5. Perkins TJ, Swain PS. Strategies for cellular decision-making. Mol Syst Biol. 2009;5:326. doi:](#)  
1316 [10.1038/msb.2009.83. Epub 2009 Nov 17. PMID: 19920811; PMCID: PMC2795477.](#)
- 1317 [6. Anderson SA, Eisenstat DD, Shi L, Rubenstein JL. Interneuron migration from basal forebrain to](#)  
1318 [neocortex: dependence on Dlx genes. Science. 1997 Oct 17;278\(5337\):474-6. doi:](#)  
1319 [10.1126/science.278.5337.474. PMID: 9334308.](#)
- 1320 [7. Anderson SA, Marín O, Horn C, Jennings K, Rubenstein JL. Distinct cortical migrations from the medial](#)  
1321 [and lateral ganglionic eminences. Development. 2001 Feb;128\(3\):353-63. doi: 10.1242/dev.128.3.353.](#)  
1322 [PMID: 11152634.](#)
- 1323 [8. Anderson SA, Kaznowski CE, Horn C, Rubenstein JL, McConnell SK. Distinct origins of neocortical](#)  
1324 [projection neurons and interneurons in vivo. Cereb Cortex. 2002 Jul;12\(7\):702-9. doi:](#)  
1325 [10.1093/cercor/12.7.702. PMID: 12050082.](#)
- 1326 [9. Lim L, Mi D, Llorca A, Marín O. Development and Functional Diversification of Cortical Interneurons.](#)  
1327 [Neuron. 2018 Oct 24;100\(2\):294-313. doi: 10.1016/j.neuron.2018.10.009. PMID: 30359598; PMCID:](#)  
1328 [PMC6290988.](#)
- 1329 [10. Stoykova A, Gruss P. Roles of Pax-genes in developing and adult brain as suggested by expression](#)  
1330 [patterns. J Neurosci. 1994 Mar;14\(3 Pt 2\):1395-412. doi: 10.1523/JNEUROSCI.14-03-01395.1994. PMID:](#)  
1331 [8126546; PMCID: PMC6577564.](#)
- 1332 [11. Carić D, Gooday D, Hill RE, McConnell SK, Price DJ. Determination of the migratory capacity of](#)  
1333 [embryonic cortical cells lacking the transcription factor Pax-6. Development. 1997 Dec;124\(24\):5087-96.](#)  
1334 [doi: 10.1242/dev.124.24.5087. PMID: 9362466.](#)
- 1335 [12. Mastick GS, Davis NM, Andrew GL, Easter SS Jr. Pax-6 functions in boundary formation and axon](#)  
1336 [guidance in the embryonic mouse forebrain. Development. 1997 May;124\(10\):1985-97. doi:](#)  
1337 [10.1242/dev.124.10.1985. PMID: 9169845.](#)
- 1338 [13. Callaerts P, Halder G, Gehring WJ. PAX-6 in development and evolution. Annu Rev Neurosci.](#)  
1339 [1997;20:483-532. doi: 10.1146/annurev.neuro.20.1.483. PMID: 9056723.](#)
- 1340 [14. Simpson TI, Price DJ. Pax6; a pleiotropic player in development. Bioessays. 2002 Nov;24\(11\):1041-51.](#)  
1341 [doi: 10.1002/bies.10174. PMID: 12386935.](#)
- 1342 [15. Shimamura K, Rubenstein JL. Inductive interactions direct early regionalization of the mouse forebrain.](#)  
1343 [Development. 1997 Jul;124\(14\):2709-18. doi: 10.1242/dev.124.14.2709. PMID: 9226442.](#)
- 1344 [16. Toresson H, Potter SS, Campbell K. Genetic control of dorsal-ventral identity in the telencephalon:](#)  
1345 [opposing roles for Pax6 and Gsh2. Development. 2000 Oct;127\(20\):4361-71. doi: 10.1242/dev.127.20.4361.](#)  
1346 [PMID: 11003836.](#)
- 1347 [17. Yun K, Potter S, Rubenstein JL. Gsh2 and Pax6 play complementary roles in dorsoventral patterning of](#)  
1348 [the mammalian telencephalon. Development. 2001 Jan;128\(2\):193-205. doi: 10.1242/dev.128.2.193. PMID:](#)  
1349 [11124115.](#)

- 1350 [18. Heins N, Malatesta P, Cecconi F, Nakafuku M, Tucker KL, Hack MA, et al. Glial cells generate neurons: the role of the transcription factor Pax6. Nat Neurosci. 2002 Apr;5\(4\):308-15. doi: 10.1038/nn828. Erratum in: Nat Neurosci 2002 May;5\(5\):500. PMID: 11896398.](#)
- 1353 [19. Scardigli R, Bäumer N, Gruss P, Guillemot F, Le Roux I. Direct and concentration-dependent regulation of the proneural gene Neurogenin2 by Pax6. Development. 2003 Jul;130\(14\):3269-81. doi: 10.1242/dev.00539. PMID: 12783797.](#)
- 1356 [20. Schuurmans C, Armant O, Nieto M, Stenman JM, Britz O, Klenin N, et al. Sequential phases of cortical specification involve Neurogenin-dependent and -independent pathways. EMBO J. 2004 Jul 21;23\(14\):2892-902. doi: 10.1038/sj.emboj.7600278. Epub 2004 Jul 1. PMID: 15229646; PMCID: PMC514942.](#)
- 1359 [21. Kroll TT, O'Leary DD. Ventralized dorsal telencephalic progenitors in Pax6 mutant mice generate GABA interneurons of a lateral ganglionic eminence fate. Proc Natl Acad Sci U S A. 2005 May 17;102\(20\):7374-9. doi: 10.1073/pnas.0500819102. Epub 2005 May 6. PMID: 15878992; PMCID: PMC1129108.](#)
- 1362 [22. Holm PC, Mader MT, Haubst N, Wizenmann A, Sigvardsson M, Götz M. Loss- and gain-of-function analyses reveal targets of Pax6 in the developing mouse telencephalon. Mol Cell Neurosci. 2007 Jan;34\(1\):99-119. doi: 10.1016/j.mcn.2006.10.008. Epub 2006 Dec 8. PMID: 17158062.](#)
- 1365 [23. Quinn JC, Molinek M, Martynoga BS, Zaki PA, Faedo A, Bulfone A, et al. Pax6 controls cerebral cortical cell number by regulating exit from the cell cycle and specifies cortical cell identity by a cell autonomous mechanism. Dev Biol. 2007 Feb 1;302\(1\):50-65. doi: 10.1016/j.ydbio.2006.08.035. Epub 2006 Aug 22. PMID: 16979618; PMCID: PMC2384163.](#)
- 1369 [24. Guo T, Liu G, Du H, Wen Y, Wei S, Li Z, et al. Dlx1/2 are Central and Essential Components in the Transcriptional Code for Generating Olfactory Bulb Interneurons. Cereb Cortex. 2019 Dec 17;29\(11\):4831-4849. doi: 10.1093/cercor/bhz018. PMID: 30796806; PMCID: PMC6917526.](#)
- 1372 [25. Angevine JB Jr, Sidman RL. Autoradiographic study of cell migration during histogenesis of cerebral cortex in the mouse. Nature. 1961 Nov 25;192:766-8. doi: 10.1038/192766b0. PMID: 17533671.](#)
- 1374 [26. Caviness VS Jr. Neocortical histogenesis in normal and reeler mice: a developmental study based upon \[3H\]thymidine autoradiography. Brain Res. 1982 Jul;256\(3\):293-302. doi: 10.1016/0165-3806\(82\)90141-9. PMID: 7104762.](#)
- 1377 [27. Smart IH, Smart M. Growth patterns in the lateral wall of the mouse telencephalon: I. Autoradiographic studies of the histogenesis of the isocortex and adjacent areas. J Anat. 1982 Mar;134\(Pt 2\):273-98. PMID: 7076556; PMCID: PMC1167918.](#)
- 1380 [28. del Rio JA, Soriano E. Immunocytochemical detection of 5'-bromodeoxyuridine incorporation in the central nervous system of the mouse. Brain Res Dev Brain Res. 1989 Oct 1;49\(2\):311-7. doi: 10.1016/0165-3806\(89\)90033-3. PMID: 2805336.](#)
- 1383 [29. Gillies K, Price DJ. The fates of cells in the developing cerebral cortex of normal and methylazoxymethanol acetate-lesioned mice. Eur J Neurosci. 1993 Jan 1;5\(1\):73-84. doi: 10.1111/j.1460-9568.1993.tb00207.x. PMID: 8261092.](#)
- 1386 [30. Noctor SC, Martínez-Cerdeño V, Ivic L, Kriegstein AR. Cortical neurons arise in symmetric and asymmetric division zones and migrate through specific phases. Nat Neurosci. 2004 Feb;7\(2\):136-44. doi: 10.1038/nn1172. Epub 2004 Jan 4. PMID: 14703572.](#)
- 1389 [31. Vasistha NA, García-Moreno F, Arora S, Cheung AF, Arnold SJ, Robertson EJ, et al. Cortical and Clonal Contribution of Tbr2 Expressing Progenitors in the Developing Mouse Brain. Cereb Cortex. 2015 Oct;25\(10\):3290-302. doi: 10.1093/cercor/bhu125. Epub 2014 Jun 13. PMID: 24927931; PMCID: PMC4585488.](#)
- 1393 [32. Villalba A, Götz M, Borrell V. The regulation of cortical neurogenesis. Curr Top Dev Biol. 2021;142:1-66. doi: 10.1016/bs.ctdb.2020.10.003. Epub 2020 Dec 26. PMID: 33706916.](#)

- 1395 [33. Kessar N, Fogarty M, Iannarelli P, Grist M, Wegner M, Richardson WD. Competing waves of](#)  
1396 [oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. \*Nat Neurosci\*. 2006](#)  
1397 [Feb;9\(2\):173-9. doi: 10.1038/nn1620. Epub 2005 Dec 25. PMID: 16388308; PMCID: PMC6328015.](#)
- 1398 [34. Manuel M, Georgala PA, Carr CB, Chanas S, Kleinian DA, Martynoga B, et al. Controlled overexpression](#)  
1399 [of Pax6 in vivo negatively autoregulates the Pax6 locus, causing cell-autonomous defects of late cortical](#)  
1400 [progenitor proliferation with little effect on cortical arealization. \*Development\*. 2007 Feb;134\(3\):545-55.](#)  
1401 [doi: 10.1242/dev.02764. Epub 2007 Jan 3. PMID: 17202185; PMCID: PMC2386558.](#)
- 1402 [35. Mi D, Carr CB, Georgala PA, Huang YT, Manuel MN, Jeanes E, et al. Pax6 exerts regional control of](#)  
1403 [cortical progenitor proliferation via direct repression of Cdk6 and hypophosphorylation of pRb. \*Neuron\*.](#)  
1404 [2013 Apr 24;78\(2\):269-84. doi: 10.1016/j.neuron.2013.02.012. PMID: 23622063; PMCID: PMC3898967.](#)
- 1405 [36. Quintana-Urzaingui I, Kozić Z, Mitra S, Tian T, Manuel M, Mason JO, et al. Tissue-Specific Actions of Pax6](#)  
1406 [on Proliferation and Differentiation Balance in Developing Forebrain Are Foxg1 Dependent. \*iScience\*. 2018](#)  
1407 [Dec 21;10:171-191. doi: 10.1016/j.isci.2018.11.031. Epub 2018 Nov 22. PMID: 30529950; PMCID:](#)  
1408 [PMCG287089.](#)
- 1409 [37. Miyoshi G, Hjerling-Leffler J, Karayannis T, Sousa VH, Butt SJ, Battiste J, et al. Genetic fate mapping](#)  
1410 [reveals that the caudal ganglionic eminence produces a large and diverse population of superficial cortical](#)  
1411 [interneurons. \*J Neurosci\*. 2010 Feb 3;30\(5\):1582-94. doi: 10.1523/JNEUROSCI.4515-09.2010. PMID:](#)  
1412 [20130169; PMCID: PMC2826846.](#)
- 1413 [38. Sun J, Rockowitz S, Xie Q, Ashery-Padan R, Zheng D, Cvekl A. Identification of in vivo DNA-binding](#)  
1414 [mechanisms of Pax6 and reconstruction of Pax6-dependent gene regulatory networks during forebrain and](#)  
1415 [lens development. \*Nucleic Acids Res\*. 2015 Aug 18;43\(14\):6827-46. doi: 10.1093/nar/gkv589. Epub 2015 Jul](#)  
1416 [2. PMID: 26138486; PMCID: PMC4538810.](#)
- 1417 [39. Corbin JG, Gaiano N, Machold RP, Langston A, Fishell G. The Gsh2 homeodomain gene controls multiple](#)  
1418 [aspects of telencephalic development. \*Development\*. 2000 Dec;127\(23\):5007-20. doi:](#)  
1419 [10.1242/dev.127.23.5007. PMID: 11060228.](#)
- 1420 [40. Fode C, Ma Q, Casarosa S, Ang SL, Anderson DJ, Guillemot F. A role for neural determination genes in](#)  
1421 [specifying the dorsoventral identity of telencephalic neurons. \*Genes Dev\*. 2000 Jan 1;14\(1\):67-80. PMID:](#)  
1422 [10640277; PMCID: PMC316337.](#)
- 1423 [41. Yun K, Fischman S, Johnson J, Hrade de Angelis M, Weinmaster G, Rubenstein JL. Modulation of the](#)  
1424 [notch signaling by Mash1 and Dlx1/2 regulates sequential specification and differentiation of progenitor](#)  
1425 [cell types in the subcortical telencephalon. \*Development\*. 2002 Nov;129\(21\):5029-40. doi:](#)  
1426 [10.1242/dev.129.21.5029. PMID: 12397111.](#)
- 1427 [42. Castro DS, Skowronska-Krawczyk D, Armant O, Donaldson IJ, Parras C, Hunt C, et al. Proneural bHLH and](#)  
1428 [Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. \*Dev\*](#)  
1429 [Cell. 2006 Dec;11\(6\):831-44. doi: 10.1016/j.devcel.2006.10.006. PMID: 17141158.](#)
- 1430 [43. Castro DS, Martynoga B, Parras C, Ramesh V, Pacary E, Johnston C, et al. A novel function of the](#)  
1431 [proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets.](#)  
1432 [\*Genes Dev\*. 2011 May 1;25\(9\):930-45. doi: 10.1101/gad.627811. PMID: 21536733; PMCID: PMC3084027.](#)
- 1433 [44. Petryniak MA, Potter GB, Rowitch DH, Rubenstein JL. Dlx1 and Dlx2 control neuronal versus](#)  
1434 [oligodendroglial cell fate acquisition in the developing forebrain. \*Neuron\*. 2007 Aug 2;55\(3\):417-33. doi:](#)  
1435 [10.1016/j.neuron.2007.06.036. PMID: 17678855; PMCID: PMC2039927.](#)
- 1436 [45. Long JE, Swan C, Liang WS, Cobos I, Potter GB, Rubenstein JL. Dlx1&2 and Mash1 transcription factors](#)  
1437 [control striatal patterning and differentiation through parallel and overlapping pathways. \*J Comp Neurol\*.](#)  
1438 [2009 Feb 1;512\(4\):556-72. doi: 10.1002/cne.21854. PMID: 19030180; PMCID: PMC2761428.](#)
- 1439 [46. Pinto L, Drechsel D, Schmid MT, Ninkovic J, Irmeler M, Brill MS, et al. AP2gamma regulates basal](#)  
1440 [progenitor fate in a region- and layer-specific manner in the developing cortex. \*Nat Neurosci\*. 2009](#)  
1441 [Oct;12\(10\):1229-37. doi: 10.1038/nn.2399. Epub 2009 Sep 13. Erratum in: \*Nat Neurosci\*. 2009](#)  
1442 [Oct;12\(10\):1237. Erratum in: \*Nat Neurosci\*. 2010 May;13\(5\):649. PMID: 19749747.](#)

1443 [47. Waclaw RR, Wang B, Pei Z, Ehrman LA, Campbell K. Distinct temporal requirements for the homeobox](#)  
1444 [gene Gsx2 in specifying striatal and olfactory bulb neuronal fates. \*Neuron\*. 2009 Aug 27;63\(4\):451-65. doi:](#)  
1445 [10.1016/j.neuron.2009.07.015. PMID: 19709628; PMCID: PMC2772064.](#)

1446 [48. Nishida K, Hoshino M, Kawaguchi Y, Murakami F. Ptf1a directly controls expression of immunoglobulin](#)  
1447 [superfamily molecules Neph1 and Neph3 in the developing central nervous system. \*J Biol Chem\*. 2010 Jan](#)  
1448 [1;285\(1\):373-80. doi: 10.1074/jbc.M109.060657. Epub 2009 Nov 2. PMID: 19887377; PMCID: PMC2804185.](#)

1449 [49. Seibt J, Armant O, Le Digarcher A, Castro D, Ramesh V, Journot L, et al. Expression at the imprinted \*dlk1-\*](#)  
1450 [\*gtl2\* locus is regulated by proneural genes in the developing telencephalon. \*PLoS One\*. 2012;7\(11\):e48675.](#)  
1451 [doi: 10.1371/journal.pone.0048675. Epub 2012 Nov 6. PMID: 23139813; PMCID: PMC3490856.](#)

1452 [50. Kikkawa T, Obayashi T, Takahashi M, Fukuzaki-Dohi U, Numayama-Tsuruta K, Osumi N. \*Dmrta1\*](#)  
1453 [regulates proneural gene expression downstream of Pax6 in the mammalian telencephalon. \*Genes Cells\*.](#)  
1454 [2013 Aug;18\(8\):636-49. doi: 10.1111/gtc.12061. Epub 2013 May 16. PMID: 23679989.](#)

1455 [51. Kovach C, Dixit R, Li S, Mattar P, Wilkinson G, Elsen GE, et al. \*Neurog2\* simultaneously activates and](#)  
1456 [represses alternative gene expression programs in the developing neocortex. \*Cereb Cortex\*. 2013](#)  
1457 [Aug;23\(8\):1884-900. doi: 10.1093/cercor/bhs176. Epub 2012 Jun 26. PMID: 22735158.](#)

1458 [52. Wang B, Long JE, Flandin P, Pla R, Waclaw RR, Campbell K, et al. Loss of \*Gsx1\* and \*Gsx2\* function rescues](#)  
1459 [distinct phenotypes in \*Dlx1/2\* mutants. \*J Comp Neurol\*. 2013 May 1;521\(7\):1561-84. doi:](#)  
1460 [10.1002/cne.23242. PMID: 23042297; PMCID: PMC3615175.](#)

1461 [53. Le TN, Zhou QP, Cobos I, Zhang S, Zagozewski J, Japoni S, et al. GABAergic Interneuron Differentiation in](#)  
1462 [the Basal Forebrain Is Mediated through Direct Regulation of Glutamic Acid Decarboxylase Isoforms by \*Dlx\*](#)  
1463 [Homeobox Transcription Factors. \*J Neurosci\*. 2017 Sep 6;37\(36\):8816-8829. doi: 10.1523/JNEUROSCI.2125-](#)  
1464 [16.2017. Epub 2017 Aug 8. PMID: 28821666; PMCID: PMC6596671.](#)

1465 [54. Sessa A, Ciabatti E, Drechsel D, Massimino L, Colasante G, Giannelli S, et al. The \*Tbr2\* Molecular Network](#)  
1466 [Controls Cortical Neuronal Differentiation Through Complementary Genetic and Epigenetic Pathways.](#)  
1467 [\*Cereb Cortex\*. 2017 Jun 1;27\(6\):3378-3396. doi: 10.1093/cercor/bhw270. Erratum in: \*Cereb Cortex\*. 2017](#)  
1468 [Dec 1;27\(12\):5715. PMID: 27600842.](#)

1469 [55. Pla R, Stanco A, Howard MA, Rubin AN, Vogt D, Mortimer N, et al. \*Dlx1\* and \*Dlx2\* Promote Interneuron](#)  
1470 [GABA Synthesis, Synaptogenesis, and Dendritogenesis. \*Cereb Cortex\*. 2018 Nov 1;28\(11\):3797-3815. doi:](#)  
1471 [10.1093/cercor/bhx241. PMID: 29028947; PMCID: PMC6188538.](#)

1472 [56. Sansom SN, Griffiths DS, Faedo A, Kleinjan DJ, Ruan Y, Smith J, et al. The level of the transcription factor](#)  
1473 [Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. \*PLoS\*](#)  
1474 [Genet. 2009 Jun;5\(6\):e1000511. doi: 10.1371/journal.pgen.1000511. Epub 2009 Jun 12. PMID: 19521500;](#)  
1475 [PMCID: PMC2686252.](#)

1476 [57. Xie Q, Yang Y, Huang J, Ninkovic J, Walcher T, Wolf L, et al. Pax6 interactions with chromatin and](#)  
1477 [identification of its novel direct target genes in lens and forebrain. \*PLoS One\*. 2013;8\(1\):e54507. doi:](#)  
1478 [10.1371/journal.pone.0054507. Epub 2013 Jan 14. PMID: 23342162; PMCID: PMC3544819.](#)

1479 [58. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament](#)  
1480 [protein. \*Cell\*. 1990 Feb 23;60\(4\):585-95. doi: 10.1016/0092-8674\(90\)90662-x. PMID: 1689217.](#)

1481 [59. Weisenborn DM, Prieto EW, Celio MR. Localization of calretinin in cells of layer I \(Cajal-Retzius cells\) of](#)  
1482 [the developing cortex of the rat. \*Brain Res Dev Brain Res\*. 1994 Oct 14;82\(1-2\):293-7. doi: 10.1016/0165-](#)  
1483 [3806\(94\)90171-6. PMID: 7842518.](#)

1484 [60. Bulfone A, Smiga SM, Shimamura K, Peterson A, Puelles L, Rubenstein JL. T-brain-1: a homolog of](#)  
1485 [Brachyury whose expression defines molecularly distinct domains within the cerebral cortex. \*Neuron\*. 1995](#)  
1486 [Jul;15\(1\):63-78. doi: 10.1016/0896-6273\(95\)90065-9. PMID: 7619531.](#)

1487 [61. Hevner RF, Shi L, Justice N, Hsueh Y, Sheng M, Smiga S, et al. \*Tbr1\* regulates differentiation of the](#)  
1488 [preplate and layer 6. \*Neuron\*. 2001 Feb;29\(2\):353-66. doi: 10.1016/s0896-6273\(01\)00211-2. PMID:](#)  
1489 [11239428.](#)

1490 [62. Englund C, Fink A, Lau C, Pham D, Daza RA, Bulfone A, et al. Pax6, Tbr2, and Tbr1 are expressed](#)  
1491 [sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex.](#)  
1492 [J Neurosci. 2005 Jan 5;25\(1\):247-51. doi: 10.1523/JNEUROSCI.2899-04.2005. PMID: 15634788; PMCID:](#)  
1493 [PMC6725189.](#)

1494 [63. Lai T, Jabaudon D, Molyneaux BJ, Azim E, Arlotta P, Menezes JR, et al. SOX5 controls the sequential](#)  
1495 [generation of distinct corticofugal neuron subtypes. Neuron. 2008 Jan 24;57\(2\):232-47. doi:](#)  
1496 [10.1016/j.neuron.2007.12.023. PMID: 18215621.](#)

1497 [64. Leone DP, Srinivasan K, Chen B, Alcamo E, McConnell SK. The determination of projection neuron](#)  
1498 [identity in the developing cerebral cortex. Curr Opin Neurobiol. 2008 Feb;18\(1\):28-35. doi:](#)  
1499 [10.1016/j.conb.2008.05.006. Epub 2008 May 26. PMID: 18508260; PMCID: PMC2483251.](#)

1500 [65. Kaplan ES, Ramos-Laguna KA, Mihalas AB, Daza RAM, Hevner RF. Neocortical Sox9+ radial glia generate](#)  
1501 [glutamatergic neurons for all layers, but lack discernible evidence of early laminar fate restriction. Neural](#)  
1502 [Dev. 2017 Aug 16;12\(1\):14. doi: 10.1186/s13064-017-0091-4. PMID: 28814327; PMCID: PMC5559824.](#)

1503 [66. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using](#)  
1504 [DAVID bioinformatics resources. Nat Protoc. 2009;4\(1\):44-57. doi: 10.1038/nprot.2008.211. PMID:](#)  
1505 [19131956.](#)

1506 [67. Huang da W, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens R, et al. Extracting biological meaning](#)  
1507 [from large gene lists with DAVID. Curr Protoc Bioinformatics. 2009 Sep;Chapter 13:Unit 13.11. doi:](#)  
1508 [10.1002/0471250953.bi1311s27. PMID: 19728287.](#)

1509 [68. Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the](#)  
1510 [nervous system. Neuron. 1990 Apr;4\(4\):477-85. doi: 10.1016/0896-6273\(90\)90106-p. PMID: 1969743.](#)

1511 [69. Radler-Pohl A, Gebel S, Sachsenmaier C, König H, Krämer M, Oehler T, et al. The activation and activity](#)  
1512 [control of AP-1 \(fos/jun\). Ann N Y Acad Sci. 1993 Jun 11;684:127-48. doi: 10.1111/j.1749-](#)  
1513 [6632.1993.tb32277.x. PMID: 8317826.](#)

1514 [70. Karin M, Liu Zg, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997 Apr;9\(2\):240-6. doi:](#)  
1515 [10.1016/s0955-0674\(97\)80068-3. PMID: 9069263.](#)

1516 [71. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system:](#)  
1517 [control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev. 1998](#)  
1518 [Dec;28\(3\):370-490. doi: 10.1016/s0165-0173\(98\)00018-6. PMID: 9858769.](#)

1519 [72. Raivich G, Behrens A. Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain.](#)  
1520 [Prog Neurobiol. 2006 Apr;78\(6\):347-63. doi: 10.1016/j.pneurobio.2006.03.006. Epub 2006 May 22. PMID:](#)  
1521 [16716487.](#)

1522 [73. Tuvikene J, Pruunsild P, Orav E, Esvald EE, Timmusk T. AP-1 Transcription Factors Mediate BDNF-Positive](#)  
1523 [Feedback Loop in Cortical Neurons. J Neurosci. 2016 Jan 27;36\(4\):1290-305. doi: 10.1523/JNEUROSCI.3360-](#)  
1524 [15.2016. PMID: 26818516; PMCID: PMC6604814.](#)

1525 [74. Yao J, Liu Y, Husain J, Lo R, Palaparti A, Henderson J, et al. Combinatorial expression patterns of](#)  
1526 [individual TLE proteins during cell determination and differentiation suggest non-redundant functions for](#)  
1527 [mammalian homologs of Drosophila Groucho. Dev Growth Differ. 1998 Apr;40\(2\):133-46. doi:](#)  
1528 [10.1046/j.1440-169x.1998.00003.x. PMID: 9572356.](#)

1529 [75. Zimmer C, Tiveron MC, Bodmer R, Cremer H. Dynamics of Cux2 expression suggests that an early pool](#)  
1530 [of SVZ precursors is fated to become upper cortical layer neurons. Cereb Cortex. 2004 Dec;14\(12\):1408-20.](#)  
1531 [doi: 10.1093/cercor/bhh102. Epub 2004 Jul 6. PMID: 15238450.](#)

1532 [76. Alcamo EA, Chirivella L, Dautzenberg M, Dobrova G, Fariñas I, Grosschedl R, et al. Satb2 regulates](#)  
1533 [callosal projection neuron identity in the developing cerebral cortex. Neuron. 2008 Feb 7;57\(3\):364-77. doi:](#)  
1534 [10.1016/j.neuron.2007.12.012. PMID: 18255030.](#)



1535 [77. Britanova O, de Juan Romero C, Cheung A, Kwan KY, Schwark M, Gyorgy A, et al. \*Satb2\* is a postmitotic](#)  
1536 [determinant for upper-layer neuron specification in the neocortex. \*Neuron\*. 2008 Feb 7;57\(3\):378-92. doi:](#)  
1537 [10.1016/j.neuron.2007.12.028. PMID: 18255031.](#)

1538 [78. Tuoc TC, Radyushkin K, Tonchev AB, Piñon MC, Ashery-Padan R, Molnár Z, et al. Selective cortical](#)  
1539 [layering abnormalities and behavioral deficits in cortex-specific \*Pax6\* knock-out mice. \*J Neurosci\*. 2009 Jul](#)  
1540 [1;29\(26\):8335-49. doi: 10.1523/JNEUROSCI.5669-08.2009. PMID: 19571125; PMCID: PMC6665651.](#)

1541 [79. Georgala PA, Manuel M, Price DJ. The generation of superficial cortical layers is regulated by levels of](#)  
1542 [the transcription factor \*Pax6\*. \*Cereb Cortex\*. 2011 Jan;21\(1\):81-94. doi: 10.1093/cercor/bhq061. Epub 2010](#)  
1543 [Apr 22. PMID: 20413449; PMCID: PMC3000564.](#)

1544 [80. Bulchand S, Subramanian L, Tole S. Dynamic spatiotemporal expression of LIM genes and cofactors in](#)  
1545 [the embryonic and postnatal cerebral cortex. \*Dev Dyn\*. 2003 Mar;226\(3\):460-9. doi: 10.1002/dvdy.10235.](#)  
1546 [PMID: 12619132.](#)

1547 [81. Le TN, Du G, Fonseca M, Zhou QP, Wigle JT, Eisenstat DD. \*Dlx\* homeobox genes promote cortical](#)  
1548 [interneuron migration from the basal forebrain by direct repression of the semaphorin receptor \*neuropilin-\*](#)  
1549 [2. \*J Biol Chem\*. 2007 Jun 29;282\(26\):19071-81. doi: 10.1074/jbc.M607486200. Epub 2007 Jan 26. PMID:](#)  
1550 [17259176.](#)

1551 [82. Lin YL, Persaud SD, Nhieu J, Wei LN. Cellular Retinoic Acid-Binding Protein 1 Modulates Stem Cell](#)  
1552 [Proliferation to Affect Learning and Memory in Male Mice. \*Endocrinology\*. 2017 Sep 1;158\(9\):3004-3014.](#)  
1553 [doi: 10.1210/en.2017-00353. PMID: 28911165; PMCID: PMC5659671.](#)

1554 [83. Flames N, Pla R, Gelman DM, Rubenstein JL, Puelles L, Marín O. Delineation of multiple subpallial](#)  
1555 [progenitor domains by the combinatorial expression of transcriptional codes. \*J Neurosci\*. 2007 Sep](#)  
1556 [5;27\(36\):9682-95. doi: 10.1523/JNEUROSCI.2750-07.2007. PMID: 17804629; PMCID: PMC4916652.](#)

1557 [84. Pan ZZ. Transcriptional control of \*Gad2\*. \*Transcription\*. 2012 Mar- Apr;3\(2\):68-72. doi:](#)  
1558 [10.4161/trns.19511. Epub 2012 Mar 1. PMID: 22414751; PMCID: PMC3337827.](#)

1559 [85. Wei S, Du H, Li Z, Tao G, Xu Z, Song X, et al. Transcription factors \*Sp8\* and \*Sp9\* regulate the development](#)  
1560 [of caudal ganglionic eminence-derived cortical interneurons. \*J Comp Neurol\*. 2019 Dec 1;527\(17\):2860-](#)  
1561 [2874. doi: 10.1002/cne.24712. Epub 2019 May 17. PMID: 31070778.](#)

1562 [86. Mayer C, Hafemeister C, Bandler RC, Machold R, Batista Brito R, Jaglin X, et al. Developmental](#)  
1563 [diversification of cortical inhibitory interneurons. \*Nature\*. 2018 Mar 22;555\(7697\):457-462. doi:](#)  
1564 [10.1038/nature25999. Epub 2018 Mar 5. PMID: 29513653; PMCID: PMC6052457.](#)

1565 [87. La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, et al. RNA velocity of single cells.](#)  
1566 [\*Nature\*. 2018 Aug;560\(7719\):494-498. doi: 10.1038/s41586-018-0414-6. Epub 2018 Aug 8. PMID:](#)  
1567 [30089906; PMCID: PMC6130801.](#)

1568 [88. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to transient cell states through](#)  
1569 [dynamical modeling. \*Nat Biotechnol\*. 2020 Dec;38\(12\):1408-1414. doi: 10.1038/s41587-020-0591-3. Epub](#)  
1570 [2020 Aug 3. PMID: 32747759.](#)

1571 [89. Zhang Y, Liu G, Guo T, Liang XG, Du H, Yang L, et al. Cortical Neural Stem Cell Lineage Progression Is](#)  
1572 [Regulated by Extrinsic Signaling Molecule Sonic Hedgehog. \*Cell Rep\*. 2020 Mar 31;30\(13\):4490-4504.e4. doi:](#)  
1573 [10.1016/j.celrep.2020.03.027. PMID: 32234482; PMCID: PMC7197103.](#)

1574 [90. Miyoshi G, Butt SJ, Takebayashi H, Fishell G. Physiologically distinct temporal cohorts of cortical](#)  
1575 [interneurons arise from telencephalic \*Olig2\*-expressing precursors. \*J Neurosci\*. 2007 Jul 18;27\(29\):7786-98.](#)  
1576 [doi: 10.1523/JNEUROSCI.1807-07.2007. PMID: 17634372; PMCID: PMC6672881.](#)

1577 [91. Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, et al. Slingshot: cell lineage and pseudotime](#)  
1578 [inference for single-cell transcriptomics. \*BMC Genomics\*. 2018 Jun 19;19\(1\):477. doi: 10.1186/s12864-018-](#)  
1579 [4772-0. PMID: 29914354; PMCID: PMC6007078.](#)

1580 [92. Tritschler S, Büttner M, Fischer DS, Lange M, Bergen V, Lickert H, et al. Concepts and limitations for](#)  
1581 [learning developmental trajectories from single cell genomics. \*Development\*. 2019 Jun](#)  
1582 [27;146\(12\):dev170506. doi: 10.1242/dev.170506. PMID: 31249007.](#)

1583 [93. Van den Berge K, Roux de Bézieux H, Street K, Saelens W, Cannoodt R, Saeys Y, et al. Trajectory-based](#)  
1584 [differential expression analysis for single-cell sequencing data. \*Nat Commun\*. 2020 Mar 5;11\(1\):1201. doi:](#)  
1585 [10.1038/s41467-020-14766-3. PMID: 32139671; PMCID: PMC7058077.](#)

1586 [94. Gao P, Postiglione MP, Krieger TG, Hernandez L, Wang C, Han Z, et al. Deterministic progenitor behavior](#)  
1587 [and unitary production of neurons in the neocortex. \*Cell\*. 2014 Nov 6;159\(4\):775-88. doi:](#)  
1588 [10.1016/j.cell.2014.10.027. PMID: 25417155; PMCID: PMC4225456.](#)

1589 [95. Mihalas AB, Hevner RF. Clonal analysis reveals laminar fate multipotency and daughter cell apoptosis of](#)  
1590 [mouse cortical intermediate progenitors. \*Development\*. 2018 Sep 14;145\(17\):dev164335. doi:](#)  
1591 [10.1242/dev.164335. PMID: 30217810; PMCID: PMC6141770.](#)

1592 [96. Iacopetti P, Michelini M, Stuckmann I, Oback B, Aaku-Saraste E, Huttner WB. Expression of the](#)  
1593 [antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that switch](#)  
1594 [from proliferative to neuron-generating division. \*Proc Natl Acad Sci U S A\*. 1999 Apr 13;96\(8\):4639-44. doi:](#)  
1595 [10.1073/pnas.96.8.4639. PMID: 10200315; PMCID: PMC16385.](#)

1596 [97. Haubensak W, Attardo A, Denk W, Huttner WB. Neurons arise in the basal neuroepithelium of the early](#)  
1597 [mammalian telencephalon: a major site of neurogenesis. \*Proc Natl Acad Sci U S A\*. 2004 Mar 2;101\(9\):3196-](#)  
1598 [201. doi: 10.1073/pnas.0308600100. Epub 2004 Feb 12. PMID: 14963232; PMCID: PMC365766.](#)

1599 [98. Connors BW, Gutnick MJ. Intrinsic firing patterns of diverse neocortical neurons. \*Trends Neurosci\*. 1990](#)  
1600 [Mar;13\(3\):99-104. doi: 10.1016/0166-2236\(90\)90185-d. PMID: 1691879.](#)

1601 [99. Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C. Interneurons of the neocortical](#)  
1602 [inhibitory system. \*Nat Rev Neurosci\*. 2004 Oct;5\(10\):793-807. doi: 10.1038/nrn1519. PMID: 15378039.](#)

1603 [100. Scala F, Kobak D, Bernabucci M, Bernaerts Y, Cadwell CR, Castro JR, et al. Phenotypic variation of](#)  
1604 [transcriptomic cell types in mouse motor cortex. \*Nature\*. 2021 Oct;598\(7879\):144-150. doi:](#)  
1605 [10.1038/s41586-020-2907-3. Epub 2020 Nov 12. PMID: 33184512; PMCID: PMC8113357.](#)

1606 [101. Luhmann HJ, Reiprich RA, Hanganu I, Kilb W. Cellular physiology of the neonatal rat cerebral cortex:](#)  
1607 [intrinsic membrane properties, sodium and calcium currents. \*J Neurosci Res\*. 2000 Nov 15;62\(4\):574-84.](#)  
1608 [doi: 10.1002/1097-4547\(20001115\)62:4<574::AID-JNR12>3.0.CO;2-0. PMID: 11070501.](#)

1609 [102. Daw MI, Ashby MC, Isaac JT. Coordinated developmental recruitment of latent fast spiking](#)  
1610 [interneurons in layer IV barrel cortex. \*Nat Neurosci\*. 2007 Apr;10\(4\):453-61. doi: 10.1038/nn1866. Epub](#)  
1611 [2007 Mar 11. PMID: 17351636.](#)

1612 [103. Yang JW, Kilb W, Kirischuk S, Unichenko P, Stüttgen MC, Luhmann HJ. Development of the whisker-to-](#)  
1613 [barrel cortex system. \*Curr Opin Neurobiol\*. 2018 Dec;53:29-34. doi: 10.1016/j.conb.2018.04.023. Epub 2018](#)  
1614 [May 5. PMID: 29738998.](#)

1615 [104. Elliott AA, Elliott JR. Characterization of TTX-sensitive and TTX-resistant sodium currents in small cells](#)  
1616 [from adult rat dorsal root ganglia. \*J Physiol\*. 1993 Apr;463:39-56. doi: 10.1113/jphysiol.1993.sp019583.](#)  
1617 [PMID: 8246189; PMCID: PMC1175332.](#)

1618 [105. Bean BP. The action potential in mammalian central neurons. \*Nat Rev Neurosci\*. 2007 Jun;8\(6\):451-65.](#)  
1619 [doi: 10.1038/nrn2148. PMID: 17514198.](#)

1620 [106. LoTurco JJ, Blanton MG, Kriegstein AR. Initial expression and endogenous activation of NMDA channels](#)  
1621 [in early neocortical development. \*J Neurosci\*. 1991 Mar;11\(3\):792-9. doi: 10.1523/JNEUROSCI.11-03-](#)  
1622 [00792.1991. PMID: 1825846; PMCID: PMC6575351.](#)

1623 [107. Destexhe A, Rudolph M, Paré D. The high-conductance state of neocortical neurons in vivo. \*Nat Rev\*](#)  
1624 [Neurosci. 2003 Sep;4\(9\):739-51. doi: 10.1038/nrn1198. Erratum in: \*Nat Rev Neurosci\*. 2003 Dec;4\(12\):1019.](#)  
1625 [PMID: 12951566.](#)

1626 [108. Tyzio R, Ivanov A, Bernard C, Holmes GL, Ben-Ari Y, Khazipov R. Membrane potential of CA3](#)  
1627 [hippocampal pyramidal cells during postnatal development. J Neurophysiol. 2003 Nov;90\(5\):2964-72. doi:](#)  
1628 [10.1152/jn.00172.2003. Epub 2003 Jul 16. PMID: 12867526.](#)

1629 [109. Toresson H, Campbell K. A role for Gsh1 in the developing striatum and olfactory bulb of Gsh2 mutant](#)  
1630 [mice. Development. 2001 Dec;128\(23\):4769-80. doi: 10.1242/dev.128.23.4769. PMID: 11731457](#)

1631 [110. Barber M, Di Meglio T, Andrews WD, Hernández-Miranda LR, Murakami F, Chédotal A, et al. The role](#)  
1632 [of Robo3 in the development of cortical interneurons. Cereb Cortex. 2009 Jul;19 Suppl 1\(Suppl 1\):i22-31.](#)  
1633 [doi: 10.1093/cercor/bhp041. Epub 2009 Apr 14. PMID: 19366869; PMCID: PMC2693537.](#)

1634 [111. Andjelic S, Gallopin T, Cauli B, Hill EL, Roux L, Badr S, et al. Glutamatergic nonpyramidal neurons from](#)  
1635 [neocortical layer VI and their comparison with pyramidal and spiny stellate neurons. J Neurophysiol. 2009](#)  
1636 [Feb;101\(2\):641-54. doi: 10.1152/jn.91094.2008. Epub 2008 Dec 3. PMID: 19052106; PMCID: PMC2657076.](#)

1637 [112. Soldado-Magraner S, Brandalise F, Honnuraiah S, Pfeiffer M, Moulinier M, Gerber U, et al.](#)  
1638 [Conditioning by subthreshold synaptic input changes the intrinsic firing pattern of CA3 hippocampal](#)  
1639 [neurons. J Neurophysiol. 2020 Jan 1;123\(1\):90-106. doi: 10.1152/jn.00506.2019. Epub 2019 Nov 13. PMID:](#)  
1640 [31721636.](#)

1641 [113. Butt SJ, Sousa VH, Fuccillo MV, Hjerling-Leffler J, Miyoshi G, Kimura S, et al. The requirement of Nkx2-1](#)  
1642 [in the temporal specification of cortical interneuron subtypes. Neuron. 2008 Sep 11;59\(5\):722-32. doi:](#)  
1643 [10.1016/j.neuron.2008.07.031. PMID: 18786356; PMCID: PMC2562525.](#)

1644 [114. Komada M, Saitsu H, Kinboshi M, Miura T, Shiota K, Ishibashi M. Hedgehog signaling is involved in](#)  
1645 [development of the neocortex. Development. 2008 Aug;135\(16\):2717-27. doi: 10.1242/dev.015891. Epub](#)  
1646 [2008 Jul 9. PMID: 18614579.](#)

1647 [115. Baudoin JP, Viou L, Launay PS, Luccardini C, Espeso Gil S, Kiyasova V, et al. Tangentially migrating](#)  
1648 [neurons assemble a primary cilium that promotes their reorientation to the cortical plate. Neuron. 2012](#)  
1649 [Dec 20;76\(6\):1108-22. doi: 10.1016/j.neuron.2012.10.027. PMID: 23259947.](#)

1650 [116. Winkler CC, Yabut OR, Fregoso SP, Gomez HG, Dwyer BE, Pleasure SJ, et al. The Dorsal Wave of](#)  
1651 [Neocortical Oligodendrogenesis Begins Embryonically and Requires Multiple Sources of Sonic Hedgehog. J](#)  
1652 [Neurosci. 2018 Jun 6;38\(23\):5237-5250. doi: 10.1523/JNEUROSCI.3392-17.2018. Epub 2018 May 8. PMID:](#)  
1653 [29739868; PMCID: PMC5990977.](#)

1654 [117. Chau KF, Springel MW, Broadbelt KG, Park HY, Topal S, Lun MP, et al. Progressive Differentiation and](#)  
1655 [Instructive Capacities of Amniotic Fluid and Cerebrospinal Fluid Proteomes following Neural Tube Closure.](#)  
1656 [Dev Cell. 2015 Dec 21;35\(6\):789-802. doi: 10.1016/j.devcel.2015.11.015. PMID: 26702835; PMCID:](#)  
1657 [PMC4691285.](#)

1658 [118. Morinello E, Pignatello M, Villabruna L, Goelzer P, Bürgin H. Embryofetal development study of](#)  
1659 [vismodegib, a hedgehog pathway inhibitor, in rats. Birth Defects Res B Dev Reprod Toxicol. 2014](#)  
1660 [Apr;101\(2\):135-43. doi: 10.1002/bdrb.21093. Epub 2014 Apr 1. PMID: 24692404.](#)

1661 [119. Danesin C, Peres JN, Johansson M, Snowden V, Cording A, Papalopulu N, et al. Integration of](#)  
1662 [telencephalic Wnt and hedgehog signaling center activities by Foxg1. Dev Cell. 2009 Apr;16\(4\):576-87. doi:](#)  
1663 [10.1016/j.devcel.2009.03.007. PMID: 19386266.](#)

1664 [120. Manuel M, Martynoga B, Yu T, West JD, Mason JO, Price DJ. The transcription factor Foxg1 regulates](#)  
1665 [the competence of telencephalic cells to adopt subpallial fates in mice. Development. 2010 Feb;137\(3\):487-](#)  
1666 [97. doi: 10.1242/dev.039800. PMID: 20081193; PMCID: PMC2858907.](#)

1667 [121. Goodrich LV, Johnson RL, Milenkovic L, McMahon JA, Scott MP. Conservation of the](#)  
1668 [hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog.](#)  
1669 [Genes Dev. 1996 Feb 1;10\(3\):301-12. doi: 10.1101/gad.10.3.301. PMID: 8595881.](#)

1670 [122. Marigo V, Tabin CJ. Regulation of patched by sonic hedgehog in the developing neural tube. Proc Natl](#)  
1671 [Acad Sci U S A. 1996 Sep 3;93\(18\):9346-51. doi: 10.1073/pnas.93.18.9346. PMID: 8790332; PMCID:](#)  
1672 [PMC38430.](#)

1673 [123. Lee J, Platt KA, Censullo P, Ruiz i Altaba A. Gli1 is a target of Sonic hedgehog that induces ventral](#)  
1674 [neural tube development. Development. 1997 Jul;124\(13\):2537-52. doi: 10.1242/dev.124.13.2537. PMID:](#)  
1675 [9216996.](#)

1676 [124. Wijgerde M, McMahon JA, Rule M, McMahon AP. A direct requirement for Hedgehog signaling for](#)  
1677 [normal specification of all ventral progenitor domains in the presumptive mammalian spinal cord. Genes](#)  
1678 [Dev. 2002 Nov 15;16\(22\):2849-64. doi: 10.1101/gad.1025702. PMID: 12435628; PMCID: PMC187482.](#)

1679 [125. Bai CB, Auerbach W, Lee JS, Stephen D, Joyner AL. Gli2, but not Gli1, is required for initial Shh signaling](#)  
1680 [and ectopic activation of the Shh pathway. Development. 2002 Oct;129\(20\):4753-61. doi:](#)  
1681 [10.1242/dev.129.20.4753. PMID: 12361967.](#)

1682 [126. Bai CB, Stephen D, Joyner AL. All mouse ventral spinal cord patterning by hedgehog is Gli dependent](#)  
1683 [and involves an activator function of Gli3. Dev Cell. 2004 Jan;6\(1\):103-15. doi: 10.1016/s1534-](#)  
1684 [5807\(03\)00394-0. PMID: 14723851.](#)

1685 [127. Svård J, Heby-Henricson K, Persson-Lek M, Rozell B, Lauth M, Bergström A, et al. Genetic elimination of](#)  
1686 [Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway.](#)  
1687 [Dev Cell. 2006 Feb;10\(2\):187-97. doi: 10.1016/j.devcel.2005.12.013. Erratum in: Dev Cell. 2006](#)  
1688 [Mar;10\(3\):409. Henricson, Karin Heby \[corrected to Heby-Henricson, Karin\]. PMID: 16459298.](#)

1689 [128. Endoh-Yamagami S, Evangelista M, Wilson D, Wen X, Theunissen JW, Phamluong K, et al. The](#)  
1690 [mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh signal transduction during](#)  
1691 [development. Curr Biol. 2009 Aug 11;19\(15\):1320-6. doi: 10.1016/j.cub.2009.06.046. Epub 2009 Jul 9.](#)  
1692 [PMID: 19592253.](#)

1693 [129. Liem KF Jr, He M, Ocbina PJ, Anderson KV. Mouse Kif7/Costal2 is a cilia- associated protein that](#)  
1694 [regulates Sonic hedgehog signaling. Proc Natl Acad Sci U S A. 2009 Aug 11;106\(32\):13377-82. doi:](#)  
1695 [10.1073/pnas.0906944106. Epub 2009 Jul 29. PMID: 19666503; PMCID: PMC2726420.](#)

1696 [130. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation of Smoothed activity.](#)  
1697 [Proc Natl Acad Sci U S A. 2002 Oct 29;99\(22\):14071-6. doi: 10.1073/pnas.182542899. Epub 2002 Oct 21.](#)  
1698 [PMID: 12391318; PMCID: PMC137838.](#)

1699 [131. Heine VM, Griveau A, Chapin C, Ballard PL, Chen JK, Rowitch DH. A small- molecule smoothed](#)  
1700 [agonist prevents glucocorticoid-induced neonatal cerebellar injury. Sci Transl Med. 2011 Oct](#)  
1701 [19;3\(105\):105ra104. doi: 10.1126/scitranslmed.3002731. PMID: 22013124; PMCID: PMC3694585.](#)

1702 [132. Radonjić NV, Memi F, Ortega JA, Glidden N, Zhan H, Zecevic N. The Role of Sonic Hedgehog in the](#)  
1703 [Specification of Human Cortical Progenitors In Vitro. Cereb Cortex. 2016 Jan;26\(1\):131-43. doi:](#)  
1704 [10.1093/cercor/bhu183. Epub 2014 Aug 21. PMID: 25146370; PMCID: PMC4677972.](#)

1705 [133. Gaiano N, Kohtz JD, Turnbull DH, Fishell G. A method for rapid gain-of- function studies in the mouse](#)  
1706 [embryonic nervous system. Nat Neurosci. 1999 Sep;2\(9\):812-9. doi: 10.1038/12186. PMID: 10461220.](#)

1707 [134. Rallu M, Machold R, Gaiano N, Corbin JG, McMahon AP, Fishell G. Dorsoventral patterning is](#)  
1708 [established in the telencephalon of mutants lacking both Gli3 and Hedgehog signaling. Development. 2002](#)  
1709 [Nov;129\(21\):4963-74. doi: 10.1242/dev.129.21.4963. PMID: 12397105.](#)

1710 [135. Quinn JC, Molinek M, Mason JO, Price DJ. Gli3 is required autonomously for dorsal telencephalic cells](#)  
1711 [to adopt appropriate fates during embryonic forebrain development. Dev Biol. 2009 Mar 1;327\(1\):204-15.](#)  
1712 [doi: 10.1016/j.ydbio.2008.12.008. Epub 2008 Dec 24. PMID: 19121302.](#)

1713 [136. Shikata Y, Okada T, Hashimoto M, Ellis T, Matsumaru D, Shiroishi T, et al. Ptch1-mediated dosage-](#)  
1714 [dependent action of Shh signaling regulates neural progenitor development at late gestational stages. Dev](#)  
1715 [Biol. 2011 Jan 15;349\(2\):147-59. doi: 10.1016/j.ydbio.2010.10.014. Epub 2010 Oct 20. PMID: 20969845.](#)

1716 [137. Yabut OR, Fernandez G, Huynh T, Yoon K, Pleasure SJ. Suppressor of Fused Is Critical for Maintenance](#)  
1717 [of Neuronal Progenitor Identity during Corticogenesis. Cell Rep. 2015 Sep 29;12\(12\):2021-34. doi:](#)  
1718 [10.1016/j.celrep.2015.08.031. Epub 2015 Sep 17. PMID: 26387942; PMCID: PMC4591209.](#)

- 1719 [138. Furuta Y, Piston DW, Hogan BL. Bone morphogenetic proteins \(BMPs\) as regulators of dorsal forebrain](#)  
1720 [development. Development. 1997 Jun;124\(11\):2203-12. doi: 10.1242/dev.124.11.2203. PMID: 9187146.](#)
- 1721 [139. Gulacsi A, Lillien L. Sonic hedgehog and bone morphogenetic protein regulate interneuron](#)  
1722 [development from dorsal telencephalic progenitors in vitro. J Neurosci. 2003 Oct 29;23\(30\):9862-72. doi:](#)  
1723 [10.1523/JNEUROSCI.23-30-09862.2003. PMID: 14586015; PMCID: PMC6740884.](#)
- 1724 [140. Cheng X, Hsu CM, Currle DS, Hu JS, Barkovich AJ, Monuki ES. Central roles of the roof plate in](#)  
1725 [telencephalic development and holoprosencephaly. J Neurosci. 2006 Jul 19;26\(29\):7640-9. doi:](#)  
1726 [10.1523/JNEUROSCI.0714-06.2006. PMID: 16855091; PMCID: PMC6674267.](#)
- 1727 [141. Hu JS, Doan LT, Currle DS, Paff M, Rheem JY, Schreyer R, et al. Border formation in a Bmp gradient](#)  
1728 [reduced to single dissociated cells. Proc Natl Acad Sci U S A. 2008 Mar 4;105\(9\):3398-403. doi:](#)  
1729 [10.1073/pnas.0709100105. Epub 2008 Feb 21. PMID: 18292231; PMCID: PMC2265170.](#)
- 1730 [142. Doan LT, Javier AL, Furr NM, Nguyen KL, Cho KW, Monuki ES. A Bmp reporter with ultrasensitive](#)  
1731 [characteristics reveals that high Bmp signaling is not required for cortical hem fate. PLoS One.](#)  
1732 [2012;7\(9\):e44009. doi: 10.1371/journal.pone.0044009. Epub 2012 Sep 11. PMID: 22984456; PMCID:](#)  
1733 [PMC3439469.](#)
- 1734 [143. Lehtinen MK, Zappaterra MW, Chen X, Yang YJ, Hill AD, Lun M, et al. The cerebrospinal fluid provides a](#)  
1735 [proliferative niche for neural progenitor cells. Neuron. 2011 Mar 10;69\(5\):893-905. doi:](#)  
1736 [10.1016/j.neuron.2011.01.023. PMID: 21382550; PMCID: PMC3085909.](#)
- 1737 [144. Waddington CH. The Strategy of the Gene. 1st ed. London: George Allen and Unwin; 1957.](#)
- 1738 [145. Ferrell JE Jr. Bistability, bifurcations, and Waddington's epigenetic landscape. Curr Biol. 2012 Jun](#)  
1739 [5;22\(11\):R458-66. doi: 10.1016/j.cub.2012.03.045. PMID: 22677291; PMCID: PMC3372930.](#)
- 1740 [146. Moris N, Pina C, Arias AM. Transition states and cell fate decisions in epigenetic landscapes. Nat Rev](#)  
1741 [Genet. 2016 Nov;17\(11\):693-703. doi: 10.1038/nrg.2016.98. Epub 2016 Sep 12. PMID: 27616569.](#)
- 1742 [147. Huang S, Guo YP, May G, Enver T. Bifurcation dynamics in lineage-commitment in bipotent progenitor](#)  
1743 [cells. Dev Biol. 2007 May 15;305\(2\):695-713. doi: 10.1016/j.ydbio.2007.02.036. Epub 2007 Mar 3. PMID:](#)  
1744 [17412320.](#)
- 1745 [148. Walther C, Gruss P. Pax-6, a murine paired box gene, is expressed in the developing CNS.](#)  
1746 [Development. 1991 Dec;113\(4\):1435-49. doi: 10.1242/dev.113.4.1435. PMID: 1687460.](#)
- 1747 [149. Turque N, Plaza S, Radvanyi F, Carriere C, Saule S. Pax-QNR/Pax-6, a paired box- and homeobox-](#)  
1748 [containing gene expressed in neurons, is also expressed in pancreatic endocrine cells. Mol Endocrinol. 1994](#)  
1749 [Jul;8\(7\):929-38. doi: 10.1210/mend.8.7.7984154. PMID: 7984154.](#)
- 1750 [150. Robertshaw E, Matsumoto K, Lumsden A, Kiecker C. Irx3 and Pax6 establish differential competence](#)  
1751 [for Shh-mediated induction of GABAergic and glutamatergic neurons of the thalamus. Proc Natl Acad Sci U](#)  
1752 [S A. 2013 Oct 8;110\(41\):E3919-26. doi: 10.1073/pnas.1304311110. Epub 2013 Sep 24. PMID: 24065827;](#)  
1753 [PMCID: PMC3799351.](#)
- 1754 [151. Chi L, Fan B, Feng D, Chen Z, Liu Z, Hui Y, et al. The Dorsoventral Patterning of Human Forebrain](#)  
1755 [Follows an Activation/Transformation Model. Cereb Cortex. 2017 May 1;27\(5\):2941-2954. doi:](#)  
1756 [10.1093/cercor/bhw152. PMID: 27226442.](#)
- 1757 [152. Collinson JM, Hill RE, West JD. Different roles for Pax6 in the optic vesicle and facial epithelium](#)  
1758 [mediate early morphogenesis of the murine eye. Development. 2000 Mar;127\(5\):945-56. doi:](#)  
1759 [10.1242/dev.127.5.945. PMID: 10662634.](#)
- 1760 [153. Luan Q, Chen Q, Friedrich M. The Pax6 genes eyeless and twin of eyeless are required for global](#)  
1761 [patterning of the ocular segment in the Tribolium embryo. Dev Biol. 2014 Oct 15;394\(2\):367-81. doi:](#)  
1762 [10.1016/j.ydbio.2014.08.005. Epub 2014 Aug 19. PMID: 25149513.](#)
- 1763 [154. Caballero IM, Manuel MN, Molinek M, Quintana-Urzaizqui I, Mi D, Shimogori T, et al. Cell-autonomous](#)  
1764 [repression of Shh by transcription factor Pax6 regulates diencephalic patterning by controlling the central](#)

1765 [diencephalic organizer. Cell Rep. 2014 Sep 11;8\(5\):1405-18. doi: 10.1016/j.celrep.2014.07.051. Epub 2014](#)  
1766 [Aug 28. PMID: 25176648; PMCID: PMC4241467.](#)

1767 [155. Yabut OR, Ng HX, Yoon K, Arela JC, Ngo T, Pleasure SJ. The Neocortical Progenitor Specification](#)  
1768 [Program Is Established through Combined Modulation of SHH and FGF Signaling. J Neurosci. 2020 Sep](#)  
1769 [2;40\(36\):6872-6887. doi: 10.1523/JNEUROSCI.2888-19.2020. Epub 2020 Jul 31. PMID: 32737167; PMCID:](#)  
1770 [PMC7470916.](#)

1771 [156. Kalyani AJ, Piper D, Mujtaba T, Lucero MT, Rao MS. Spinal cord neuronal precursors generate multiple](#)  
1772 [neuronal phenotypes in culture. J Neurosci. 1998 Oct 1;18\(19\):7856-68. doi: 10.1523/JNEUROSCI.18-19-](#)  
1773 [07856.1998. PMID: 9742154; PMCID: PMC2966285.](#)

1774 [157. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic](#)  
1775 [Hedgehog. Neuron. 1999 Jan;22\(1\):103-14. doi: 10.1016/s0896-6273\(00\)80682-0. PMID: 10027293.](#)

1776 [158. Groves J, Placzek M, Fletcher AG. Of mitogens and morphogens: modelling Sonic Hedgehog](#)  
1777 [mechanisms in vertebrate development. Philos Trans R Soc Lond B Biol Sci. 2020 Oct](#)  
1778 [12;375\(1809\):20190660. doi: 10.1098/rstb.2019.0660. Epub 2020 Aug 24. PMID: 32829689; PMCID:](#)  
1779 [PMC7482217.](#)

1780 [159. Wolpert L. Positional information and the spatial pattern of cellular differentiation. J Theor Biol. 1969](#)  
1781 [Oct;25\(1\):1-47. doi: 10.1016/s0022-5193\(69\)80016-0. PMID: 4390734.](#)

1782 [160. Martí E, Bumcrot DA, Takada R, McMahon AP. Requirement of 19K form of Sonic hedgehog for](#)  
1783 [induction of distinct ventral cell types in CNS explants. Nature. 1995 May 25;375\(6529\):322-5. doi:](#)  
1784 [10.1038/375322a0. PMID: 7753196.](#)

1785 [161. Matisse MP, Wang H. Sonic hedgehog signaling in the developing CNS where it has been and where it is](#)  
1786 [going. Curr Top Dev Biol. 2011;97:75-117. doi: 10.1016/B978-0-12-385975-4.00010-3. PMID: 22074603.](#)

1787 [162. Voronova A, Yuzwa SA, Wang BS, Zahr S, Sval C, Wang J, et al. Migrating Interneurons Secrete](#)  
1788 [Fractalkine to Promote Oligodendrocyte Formation in the Developing Mammalian Brain. Neuron. 2017 May](#)  
1789 [3;94\(3\):500-516.e9. doi: 10.1016/j.neuron.2017.04.018. PMID: 28472653.](#)

1790 [163. Dahmane N, Sánchez P, Gitton Y, Palma V, Sun T, Beyna M, et al. The Sonic Hedgehog-Gli pathway](#)  
1791 [regulates dorsal brain growth and tumorigenesis. Development. 2001 Dec;128\(24\):5201-12. doi:](#)  
1792 [10.1242/dev.128.24.5201. PMID: 11748155.](#)

1793 [164. Viti J, Gulacsi A, Lillien L. Wnt regulation of progenitor maturation in the cortex depends on Shh or](#)  
1794 [fibroblast growth factor 2. J Neurosci. 2003 Jul 2;23\(13\):5919-27. doi: 10.1523/JNEUROSCI.23-13-](#)  
1795 [05919.2003. PMID: 12843296; PMCID: PMC6741239.](#)

1796 [165. Xu Q, Guo L, Moore H, Waclaw RR, Campbell K, Anderson SA. Sonic hedgehog signaling confers ventral](#)  
1797 [telencephalic progenitors with distinct cortical interneuron fates. Neuron. 2010 Feb 11;65\(3\):328-40. doi:](#)  
1798 [10.1016/j.neuron.2010.01.004. PMID: 20159447; PMCID: PMC2868511.](#)

1799 [166. Yabut OR, Pleasure SJ. Sonic Hedgehog Signaling Rises to the Surface: Emerging Roles in Neocortical](#)  
1800 [Development. Brain Plast. 2018 Aug 10;3\(2\):119-128. doi: 10.3233/BPL-180064. PMID: 30151337; PMCID:](#)  
1801 [PMC6091060.](#)

1802 [167. Delmotte Q, Hamze M, Medina I, Buhler E, Zhang J, Belgacem YH, et al. Smoothed receptor signaling](#)  
1803 [regulates the developmental shift of GABA polarity in rat somatosensory cortex. J Cell Sci. 2020 Oct](#)  
1804 [23;133\(20\):jcs247700. doi: 10.1242/jcs.247700. PMID: 32989040; PMCID: PMC7595691.](#)

1805 [168. Saxena M, Agnihotri N, Sen J. Perturbation of canonical and non-canonical BMP signaling affects](#)  
1806 [migration, polarity and dendritogenesis of mouse cortical neurons. Development. 2018 Jan](#)  
1807 [9;145\(1\):dev147157. doi: 10.1242/dev.147157. Erratum in: Development. 2020 Jan 23;147\(2\): PMID:](#)  
1808 [29180570.](#)

1809 [169. Hou S, Ho WL, Wang L, Kuo B, Park JY, Han YG. Biphasic Roles of Hedgehog Signaling in the Production](#)  
1810 [and Self-Renewal of Outer Radial Glia in the Ferret Cerebral Cortex. Cereb Cortex. 2021 Aug](#)  
1811 [26;31\(10\):4730-4741. doi: 10.1093/cercor/bhab119. PMID: 34002221; PMCID: PMC8408449.](#)



1812 [170. Hegarty SV, O'Keefe GW, Sullivan AM. BMP-Smad 1/5/8 signalling in the development of the nervous](#)  
1813 [system. Prog Neurobiol. 2013 Oct;109:28-41. doi: 10.1016/j.pneurobio.2013.07.002. Epub 2013 Jul 24.](#)  
1814 [PMID: 23891815.](#)

1815 [171. Raposo AASF, Vasconcelos FF, Drechsel D, Marie C, Johnston C, Dolle D, et al. Ascl1 Coordinately](#)  
1816 [Regulates Gene Expression and the Chromatin Landscape during Neurogenesis. Cell Rep. 2015 Mar](#)  
1817 [10;10\(9\):1544-1556. doi: 10.1016/j.celrep.2015.02.025. Epub 2015 Mar 5. PMID: 25753420; PMCID:](#)  
1818 [PMCS383937.](#)

1819 [172. Macdonald R, Barth KA, Xu Q, Holder N, Mikkola I, Wilson SW. Midline signalling is required for Pax](#)  
1820 [gene regulation and patterning of the eyes. Development. 1995 Oct;121\(10\):3267-78. doi:](#)  
1821 [10.1242/dev.121.10.3267. PMID: 7588061.](#)

1822 [173. Ericson J, Rashbass P, Schedl A, Brenner-Morton S, Kawakami A, van Heyningen V, et al. Pax6 controls](#)  
1823 [progenitor cell identity and neuronal fate in response to graded Shh signaling. Cell. 1997 Jul 11;90\(1\):169-](#)  
1824 [80. doi: 10.1016/s0092-8674\(00\)80323-2. PMID: 9230312.](#)

1825 [174. Danjo T, Eiraku M, Muguruma K, Watanabe K, Kawada M, Yanagawa Y, et al. Subregional specification](#)  
1826 [of embryonic stem cell-derived ventral telencephalic tissues by timed and combinatorial treatment with](#)  
1827 [extrinsic signals. J Neurosci. 2011 Feb 2;31\(5\):1919-33. doi: 10.1523/JNEUROSCI.5128-10.2011. PMID:](#)  
1828 [21289201; PMCID: PMC6623725.](#)

1829 [175. Echelard Y, Epstein DJ, St-Jacques B, Shen L, Mohler J, McMahon JA, et al. Sonic hedgehog, a member](#)  
1830 [of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993 Dec](#)  
1831 [31;75\(7\):1417-30. doi: 10.1016/0092-8674\(93\)90627-3. PMID: 7916661.](#)

1832 [176. Shimamura K, Hartigan DJ, Martinez S, Puelles L, Rubenstein JL. Longitudinal organization of the](#)  
1833 [anterior neural plate and neural tube. Development. 1995 Dec;121\(12\):3923-33. doi:](#)  
1834 [10.1242/dev.121.12.3923. PMID: 8575293.](#)

1835 [177. Gunhaga L, Jessell TM, Edlund T. Sonic hedgehog signaling at gastrula stages specifies ventral](#)  
1836 [telencephalic cells in the chick embryo. Development. 2000 Aug;127\(15\):3283-93. doi:](#)  
1837 [10.1242/dev.127.15.3283. PMID: 10887084.](#)

1838 [178. Rallu M, Corbin JG, Fishell G. Parsing the prosencephalon. Nat Rev Neurosci. 2002 Dec;3\(12\):943-51.](#)  
1839 [doi: 10.1038/nrn989. PMID: 12461551.](#)

1840 [179. Wong FK, Fei JF, Mora-Bermúdez F, Taverna E, Haffner C, Fu J, et al. Sustained Pax6 Expression](#)  
1841 [Generates Primate-like Basal Radial Glia in Developing Mouse Neocortex. PLoS Biol. 2015 Aug](#)  
1842 [7;13\(8\):e1002217. doi: 10.1371/journal.pbio.1002217. PMID: 26252244; PMCID: PMC4529158.](#)

1843 [180. Caronia G, Wilcoxon J, Feldman P, Grove EA. Bone morphogenetic protein signaling in the developing](#)  
1844 [telencephalon controls formation of the hippocampal dentate gyrus and modifies fear-related behavior. J](#)  
1845 [Neurosci. 2010 May 5;30\(18\):6291-301. doi: 10.1523/JNEUROSCI.0550-10.2010. PMID: 20445055; PMCID:](#)  
1846 [PMC2905858.](#)

1847 [181. Stenman J, Toresson H, Campbell K. Identification of two distinct progenitor populations in the lateral](#)  
1848 [ganglionic eminence: implications for striatal and olfactory bulb neurogenesis. J Neurosci. 2003 Jan](#)  
1849 [1;23\(1\):167-74. doi: 10.1523/JNEUROSCI.23-01-00167.2003. PMID: 12514213; PMCID: PMC6742158.](#)

1850 [182. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of](#)  
1851 [Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002 Apr](#)  
1852 [15;244\(2\):305-18. doi: 10.1006/dbio.2002.0597. PMID: 11944939.](#)

1853 [183. Gorski JA, Talley T, Qiu M, Puelles L, Rubenstein JL, Jones KR. Cortical excitatory neurons and glia, but](#)  
1854 [not GABAergic neurons, are produced in the Emx1-expressing lineage. J Neurosci. 2002 Aug 1;22\(15\):6309-](#)  
1855 [14. doi: 10.1523/JNEUROSCI.22-15-06309.2002. PMID: 12151506; PMCID: PMC6758181.](#)

1856 [184. Miyoshi G, Fishell G. Dynamic FoxG1 expression coordinates the integration of multipolar pyramidal](#)  
1857 [neuron precursors into the cortical plate. Neuron. 2012 Jun 21;74\(6\):1045-58. doi:](#)  
1858 [10.1016/j.neuron.2012.04.025. PMID: 22726835; PMCID: PMC3653132.](#)



1859 [185. Simpson TI, Pratt T, Mason JO, Price DJ. Normal ventral telencephalic expression of Pax6 is required for](#)  
1860 [normal development of thalamocortical axons in embryonic mice. \*Neural Dev.\* 2009 Jun 5;4:19. doi:](#)  
1861 [10.1186/1749-8104-4-19. PMID: 19500363; PMCID: PMC2699344.](#)

1862 [186. Hill RE, Favor J, Hogan BL, Ton CC, Saunders GF, Hanson IM, et al. Mouse small eye results from](#)  
1863 [mutations in a paired-like homeobox-containing gene. \*Nature.\* 1991 Dec 19;354\(6354\):522-5. doi:](#)  
1864 [10.1038/354522a0. Erratum in: \*Nature.\* 1992 Feb 20;355\(6362\):750. PMID: 1684639.](#)

1865 [187. Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, et al. Cyclopia and defective axial](#)  
1866 [patterning in mice lacking Sonic hedgehog gene function. \*Nature.\* 1996 Oct 3;383\(6599\):407-13. doi:](#)  
1867 [10.1038/383407a0. PMID: 8837770.](#)

1868 [188. Bulstrode H, Johnstone E, Marques-Torrejon MA, Ferguson KM, Bressan RB, Blin C, et al. Elevated](#)  
1869 [FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell](#)  
1870 [cycle and epigenetic regulators. \*Genes Dev.\* 2017 Apr 15;31\(8\):757-773. doi: 10.1101/gad.293027.116.](#)  
1871 [Epub 2017 May 2. PMID: 28465359; PMCID: PMC5435889.](#)

1872 [189. Engelkamp D, Rashbass P, Seawright A, van Heyningen V. Role of Pax6 in development of the](#)  
1873 [cerebellar system. \*Development.\* 1999 Aug;126\(16\):3585-96. doi: 10.1242/dev.126.16.3585. PMID:](#)  
1874 [10409504.](#)

1875 [190. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data](#)  
1876 [with DESeq2. \*Genome Biol.\* 2014;15\(12\):550. doi: 10.1186/s13059-014-0550-8. PMID: 25516281; PMCID:](#)  
1877 [PMC4302049.](#)

1878 [191. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression](#)  
1879 [analysis of digital gene expression data. \*Bioinformatics.\* 2010 Jan 1;26\(1\):139-40. doi:](#)  
1880 [10.1093/bioinformatics/btp616. Epub 2009 Nov 11. PMID: 19910308; PMCID: PMC2796818.](#)

1881 [192. Young MD, Behjati S. SoupX removes ambient RNA contamination from droplet- based single-cell RNA](#)  
1882 [sequencing data. \*Gigascience.\* 2020 Dec 26;9\(12\):giaa151. doi: 10.1093/gigascience/giaa151. PMID:](#)  
1883 [33367645; PMCID: PMC7763177.](#)

1884 [193. Ward JH. Hierarchical grouping to optimize an objective function. \*Journal of the American Statistical\*](#)  
1885 [Association. 1963 58:236–244.](#)

1886 [194. Kowalczyk MS, Tirosh I, Heckl D, Rao TN, Dixit A, Haas BJ, et al. Single-cell RNA-seq reveals changes in](#)  
1887 [cell cycle and differentiation programs upon aging of hematopoietic stem cells. \*Genome Res.\* 2015](#)  
1888 [Dec;25\(12\):1860-72. doi: 10.1101/gr.192237.115. Epub 2015 Oct 1. PMID: 26430063; PMCID: PMC4665007.](#)

1889 [195. Mi D, Manuel M, Huang YT, Mason JO, Price DJ. Pax6 Lengthens G1 Phase and Decreases Oscillating](#)  
1890 [Cdk6 Levels in Murine Embryonic Cortical Progenitors. \*Front Cell Neurosci.\* 2018 Nov 15;12:419. doi:](#)  
1891 [10.3389/fncel.2018.00419. PMID:30498434; PMCID: PMC6249377.](#)

1892 [196. Bitgood MJ, McMahon AP. Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell](#)  
1893 [interaction in the mouse embryo. \*Dev Biol.\* 1995 Nov;172\(1\):126-38. doi: 10.1006/dbio.1995.0010. PMID:](#)  
1894 [7589793.](#)

1895 [Alcamo, E. A., L. Chirivella, M. Dautzenberg, G. Dobрева, I. Fariñas, R. Grosschedl and S. K. McConnell](#)  
1896 [\(2008\). "Satb2 regulates callosal projection neuron identity in the developing cerebral cortex." \*Neuron\*](#)  
1897 [57\(3\): 364-377.](#)

1898 [Anderson, S. A., D. D. Eisenstat, L. Shi and J. L. Rubenstein \(1997\). "Interneuron migration from basal](#)  
1899 [forebrain to neocortex: dependence on Dlx genes." \*Science\* 278\(5337\): 474-476.](#)

1900 [Anderson, S. A., C. E. Kaznowski, C. Horn, J. L. Rubenstein and S. K. McConnell \(2002\). "Distinct origins of](#)  
1901 [neocortical projection neurons and interneurons in vivo." \*Cereb Cortex\* 12\(7\): 702-709.](#)

1902 [Anderson, S. A., O. Marín, C. Horn, K. Jennings and J. L. Rubenstein \(2001\). "Distinct cortical migrations from](#)  
1903 [the medial and lateral ganglionic eminences." \*Development\* 128\(3\): 353-363.](#)

1904 Andjelic, S., T. Gallopin, B. Cauli, E. L. Hill, L. Roux, S. Badr, E. Hu, G. Tamás and B. Lambolez (2009).  
1905 "Glutamatergic nonpyramidal neurons from neocortical layer VI and their comparison with pyramidal and  
1906 spiny stellate neurons." *J Neurophysiol* 101(2): 641-654.

1907 Angevine, J. B., Jr. and R. L. Sidman (1961). "Autoradiographic study of cell migration during histogenesis of  
1908 cerebral cortex in the mouse." *Nature* 192: 766-768.

1909 Bai, C. B., W. Auerbach, J. S. Lee, D. Stephen and A. L. Joyner (2002). "Gli2, but not Gli1, is required for initial  
1910 Shh signaling and ectopic activation of the Shh pathway." *Development* 129(20): 4753-4761.

1911 Bai, C. B., D. Stephen and A. L. Joyner (2004). "All mouse ventral spinal cord patterning by hedgehog is Gli  
1912 dependent and involves an activator function of Gli2." *Dev Cell* 6(1): 103-115.

1913 Barber, M., T. Di Meglio, W. D. Andrews, L. R. Hernández-Miranda, F. Murakami, A. Chédotal and J. G.  
1914 Parnavelas (2009). "The role of Robo3 in the development of cortical interneurons." *Cereb Cortex* 19 Suppl  
1915 1(Suppl 1): i22-31.

1916 Baudoin, J. P., L. Viou, P. S. Launay, C. Luccardini, S. Espeso Gil, V. Kiyasova, T. Irinopoulou, C. Alvarez, J. P.  
1917 Rio, T. Boudier, J. P. Lechaire, N. Kessar, N. Spassky and C. Métin (2012). "Tangentially migrating neurons  
1918 assemble a primary cilium that promotes their reorientation to the cortical plate." *Neuron* 76(6): 1108-  
1919 1122.

1920 Bean, B. P. (2007). "The action potential in mammalian central neurons." *Nat Rev Neurosci* 8(6): 451-465.

1921 Bergen, V., M. Lange, S. Peidli, F. A. Wolf and F. J. Theis (2020). "Generalizing RNA velocity to transient cell  
1922 states through dynamical modeling." *Nat Biotechnol* 38(12): 1408-1414.

1923 Bitgood, M. J. and A. P. McMahon (1995). "Hedgehog and Bmp genes are coexpressed at many diverse sites  
1924 of cell-cell interaction in the mouse embryo." *Dev Biol* 172(1): 126-138.

1925 Britanova, O., C. de Juan-Romero, A. Cheung, K. Y. Kwan, M. Schwark, A. Gyorgy, T. Vogel, S. Akopov, M.  
1926 Mitkovski, D. Agoston, N. Sestan, Z. Molnár and V. Tarabykin (2008). "Satb2 is a postmitotic determinant for  
1927 upper layer neuron specification in the neocortex." *Neuron* 57(3): 378-392.

1928 Bulchand, S., L. Subramanian and S. Tole (2003). "Dynamic spatiotemporal expression of LIM genes and  
1929 cofactors in the embryonic and postnatal cerebral cortex." *Dev Dyn* 226(3): 460-469.

1930 Bulfone, A., S. M. Smiga, K. Shimamura, A. Peterson, L. Puellas and J. L. Rubenstein (1995). "T brain-1: a  
1931 homolog of Brachyury whose expression defines molecularly distinct domains within the cerebral cortex."  
1932 *Neuron* 15(1): 63-78.

1933 Bulstrode, H., E. Johnstone, M. A. Marques-Torres, K. M. Ferguson, R. B. Bressan, C. Blin, V. Grant, S.  
1934 Gogolek, E. Gangoso, S. Gargica, C. Ender, V. Fotaki, D. Sproul, P. Bertone and S. M. Pollard (2017).  
1935 "Elevated FOXP1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional  
1936 control of cell cycle and epigenetic regulators." *Genes Dev* 31(8): 757-773.

1937 Butt, S. J., V. H. Sousa, M. V. Fuccillo, J. Hjerling-Leffler, G. Miyoshi, S. Kimura and G. Fishell (2008). "The  
1938 requirement of Nkx2-1 in the temporal specification of cortical interneuron subtypes." *Neuron* 59(5): 722-  
1939 732.

1940 Caballero, I. M., M. N. Manuel, M. Molinek, I. Quintana-Urzaínqui, D. Mi, T. Shimogori and D. J. Price (2014).  
1941 "Cell autonomous repression of Shh by transcription factor Pax6 regulates diencephalic patterning by  
1942 controlling the central diencephalic organizer." *Cell Rep* 8(5): 1405-1418.

1943 Callaerts, P., G. Halder and W. J. Gehring (1997). "PAX-6 in development and evolution." *Annu Rev Neurosci*  
1944 20: 483-532.

1945 Carić, D., D. Gooday, R. E. Hill, S. K. McConnell and D. J. Price (1997). "Determination of the migratory  
1946 capacity of embryonic cortical cells lacking the transcription factor Pax-6." *Development* 124(24): 5087-  
1947 5096.

1948 Caronia, G., J. Wilcoxon, P. Feldman and E. A. Grove (2010). "Bone morphogenetic protein signaling in the  
1949 developing telencephalon controls formation of the hippocampal dentate gyrus and modifies fear-related  
1950 behavior." *J Neurosci* 30(18): 6291-6301.

1951 Castro, D. S., B. Martynoga, C. Parras, V. Ramesh, E. Pacary, C. Johnston, D. Drechsel, M. Lebel Potter, L. G.  
1952 Garcia, C. Hunt, D. Dolle, A. Bithell, L. Ettwiller, N. Buckley and F. Guillemot (2011). "A novel function of the  
1953 proneural factor *Ascl1* in progenitor proliferation identified by genome-wide characterization of its  
1954 targets." *Genes Dev* 25(9): 930-945.

1955 Castro, D. S., D. Skowronska-Krawczyk, O. Armant, I. J. Donaldson, C. Parras, C. Hunt, J. A. Critchley, L.  
1956 Nguyen, A. Gessler, B. Göttgens, J. M. Matter and F. Guillemot (2006). "Proneural bHLH and Brn proteins  
1957 coregulate a neurogenic program through cooperative binding to a conserved DNA motif." *Dev Cell* 11(6):  
1958 831-844.

1959 Caviness, V. S., Jr. (1982). "Neocortical histogenesis in normal and reeler mice: a developmental study  
1960 based upon [<sup>3</sup>H]thymidine autoradiography." *Brain Res* 256(3): 293-302.

1961 Chau, K. F., M. W. Springel, K. G. Broadbelt, H. Y. Park, S. Topal, M. P. Lun, H. Mullan, T. Maynard, H. Steen,  
1962 A. S. LaMantia and M. K. Lehtinen (2015). "Progressive Differentiation and Instructive Capacities of  
1963 Amniotic Fluid and Cerebrospinal Fluid Proteomes following Neural Tube Closure." *Dev Cell* 35(6): 789-802.

1964 Chen, J. K., J. Taipale, K. E. Young, T. Maiti and P. A. Beachy (2002). "Small molecule modulation of  
1965 *Smoothened* activity." *Proc Natl Acad Sci U S A* 99(22): 14071-14076.

1966 Cheng, X., C. M. Hsu, D. S. Currie, J. S. Hu, A. J. Barkovich and E. S. Monuki (2006). "Central roles of the roof  
1967 plate in telencephalic development and holoprosencephaly." *J Neurosci* 26(29): 7640-7649.

1968 Chi, L., B. Fan, D. Feng, Z. Chen, Z. Liu, Y. Hui, X. Xu, L. Ma, Y. Fang, Q. Zhang, G. Jin, L. Liu, F. Guan and X.  
1969 Zhang (2017). "The Dorsoventral Patterning of Human Forebrain Follows an Activation/Transformation  
1970 Model." *Cereb Cortex* 27(5): 2941-2954.

1971 Chiang, C., Y. Litingtung, E. Lee, K. E. Young, J. L. Corden, H. Westphal and P. A. Beachy (1996). "Cyclopia and  
1972 defective axial patterning in mice lacking *Sonic hedgehog* gene function." *Nature* 383(6599): 407-413.

1973 Collinson, J. M., R. E. Hill and J. D. West (2000). "Different roles for *Pax6* in the optic vesicle and facial  
1974 epithelium mediate early morphogenesis of the murine eye." *Development* 127(5): 945-956.

1975 Connors, B. W. and M. J. Gutnick (1990). "Intrinsic firing patterns of diverse neocortical neurons." *Trends*  
1976 *Neurosci* 13(3): 99-104.

1977 Corbin, J. G., N. Gaiano, R. P. Machold, A. Langston and G. Fishell (2000). "The *Gsh2* homeodomain gene  
1978 controls multiple aspects of telencephalic development." *Development* 127(23): 5007-5020.

1979 Dahmane, N., P. Sánchez, Y. Gitton, V. Palma, T. Sun, M. Beyna, H. Weiner and A. Ruiz i Altaba (2001). "The  
1980 *Sonic Hedgehog*-Gli pathway regulates dorsal brain growth and tumorigenesis." *Development* 128(24):  
1981 5201-5212.

1982 Danesin, C., J. N. Peres, M. Johansson, V. Snowden, A. Cording, N. Papalopulu and C. Houart (2009).  
1983 "Integration of telencephalic Wnt and hedgehog signaling center activities by *Foxg1*." *Dev Cell* 16(4): 576-  
1984 587.

1985 Danjo, T., M. Eiraku, K. Muguruma, K. Watanabe, M. Kawada, Y. Yanagawa, J. L. Rubenstein and Y. Sasai  
1986 (2011). "Subregional specification of embryonic stem cell derived ventral telencephalic tissues by timed  
1987 and combinatorial treatment with extrinsic signals." *J Neurosci* 31(5): 1919-1933.

1988 Daw, M. I., M. C. Ashby and J. T. Isaac (2007). "Coordinated developmental recruitment of latent fast  
1989 spiking interneurons in layer IV barrel cortex." *Nat Neurosci* 10(4): 453-461.

1990 del Rio, J. A. and E. Soriano (1989). "Immunocytochemical detection of 5' bromodeoxyuridine incorporation  
1991 in the central nervous system of the mouse." *Brain Res Dev Brain Res* 49(2): 311-317.

1992 Delmotte, Q., M. Hamze, I. Medina, E. Buhler, J. Zhang, Y. H. Belgacem and C. Porcher (2020). "Smoothed  
1993 receptor signaling regulates the developmental shift of GABA polarity in rat somatosensory cortex." *J Cell*  
1994 *Sci* 133(20).

1995 Destexhe, A., M. Rudolph and D. Paré (2003). "The high-conductance state of neocortical neurons in vivo." *Nat Rev Neurosci* 4(9): 739-751.

1997 Doan, L. T., A. L. Javier, N. M. Furr, K. L. Nguyen, K. W. Cho and E. S. Monuki (2012). "A Bmp reporter with  
1998 ultrasensitive characteristics reveals that high Bmp signaling is not required for cortical hem fate." *PLoS*  
1999 *One* 7(9): e44009.

2000 Echelard, Y., D. J. Epstein, B. St Jacques, L. Shen, J. Mohler, J. A. McMahon and A. P. McMahon (1993).  
2001 "Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of  
2002 CNS polarity." *Cell* 75(7): 1417-1430.

2003 Elliott, A. A. and J. R. Elliott (1993). "Characterization of TTX-sensitive and TTX-resistant sodium currents in  
2004 small cells from adult rat dorsal root ganglia." *J Physiol* 463: 39-56.

2005 Endoh Yamagami, S., M. Evangelista, D. Wilson, X. Wen, J. W. Theunissen, K. Phamluong, M. Davis, S. J.  
2006 Scales, M. J. Solloway, F. J. de Sauvage and A. S. Peterson (2009). "The mammalian *Cos2* homolog *Kif7* plays  
2007 an essential role in modulating Hh signal transduction during development." *Curr Biol* 19(15): 1320-1326.

2008 Engelkamp, D., P. Rashbass, A. Seawright and V. van Heyningen (1999). "Role of Pax6 in development of the  
2009 cerebellar system." *Development* 126(16): 3585-3596.

2010 Englund, C., A. Fink, C. Lau, D. Pham, R. A. Daza, A. Bulfone, T. Kowalczyk and R. F. Hevner (2005). "Pax6,  
2011 Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic  
2012 neurons in developing neocortex." *J Neurosci* 25(1): 247-251.

2013 Ericson, J., P. Rashbass, A. Schedl, S. Brenner-Morton, A. Kawakami, V. van Heyningen, T. M. Jessell and J.  
2014 Briscoe (1997). "Pax6 controls progenitor cell identity and neuronal fate in response to graded Shh  
2015 signaling." *Cell* 90(1): 169-180.

2016 Ferrell, J. E., Jr. (2012). "Bistability, bifurcations, and Waddington's epigenetic landscape." *Curr Biol* 22(11):  
2017 R458-466.

2018 Flames, N., R. Pla, D. M. Gelman, J. L. Rubenstein, L. Puellas and O. Marín (2007). "Delineation of multiple  
2019 subpallial progenitor domains by the combinatorial expression of transcriptional codes." *J Neurosci* 27(36):  
2020 9682-9695.

2021 Fode, C., Q. Ma, S. Casarosa, S. L. Ang, D. J. Anderson and F. Guillemot (2000). "A role for neural  
2022 determination genes in specifying the dorsoventral identity of telencephalic neurons." *Genes Dev* 14(1): 67-  
2023 80.

2024 Furuta, Y., D. W. Piston and B. L. Hogan (1997). "Bone morphogenetic proteins (BMPs) as regulators of  
2025 dorsal forebrain development." *Development* 124(11): 2203-2212.

2026 Gaiano, N., J. D. Kohtz, D. H. Turnbull and G. Fishell (1999). "A method for rapid gain-of-function studies in  
2027 the mouse embryonic nervous system." *Nat Neurosci* 2(9): 812-819.

2028 Gao, P., M. P. Postiglione, T. G. Krieger, L. Hernandez, C. Wang, Z. Han, C. Streicher, E. Papusheva, R.  
2029 Insolera, K. Chugh, O. Kodish, K. Huang, B. D. Simons, L. Luo, S. Hippenmeyer and S. H. Shi (2014).  
2030 "Deterministic progenitor behavior and unitary production of neurons in the neocortex." *Cell* 159(4): 775-  
2031 788.

2032 Georgala, P. A., M. Manuel and D. J. Price (2011). "The generation of superficial cortical layers is regulated  
2033 by levels of the transcription factor Pax6." *Cereb Cortex* 21(1): 81-94.

2034 Gillies, K. and D. J. Price (1993). "The fates of cells in the developing cerebral cortex of normal and  
2035 methylazoxymethanol acetate-lesioned mice." *Eur J Neurosci* 5(1): 73-84.

2036 Goodrich, L. V., R. L. Johnson, L. Milenkovic, J. A. McMahon and M. P. Scott (1996). "Conservation of the  
2037 hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog."  
2038 *Genes Dev* 10(3): 301-312.

2039 Gorski, J. A., T. Talley, M. Qiu, L. Puellas, J. L. Rubenstein and K. R. Jones (2002). "Cortical excitatory neurons  
2040 and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage." *J Neurosci* 22(15):  
2041 6309-6314.

2042 Groves, I., M. Placzek and A. G. Fletcher (2020). "Of mitogens and morphogens: modelling Sonic Hedgehog  
2043 mechanisms in vertebrate development." *Philos Trans R Soc Lond B Biol Sci* 375(1809): 20190660.

2044 Gulacsi, A. and L. Lillien (2003). "Sonic hedgehog and bone morphogenetic protein regulate interneuron  
2045 development from dorsal telencephalic progenitors in vitro." *J Neurosci* 23(30): 9862-9872.

2046 Gunhaga, L., T. M. Jessell and T. Edlund (2000). "Sonic hedgehog signaling at gastrula stages specifies  
2047 ventral telencephalic cells in the chick embryo." *Development* 127(15): 3283-3293.

2048 Guo, T., G. Liu, H. Du, Y. Wen, S. Wei, Z. Li, G. Tao, Z. Shang, X. Song, Z. Zhang, Z. Xu, Y. You, B. Chen, J. L.  
2049 Rubenstein and Z. Yang (2019). "Dlx1/2 are Central and Essential Components in the Transcriptional Code  
2050 for Generating Olfactory Bulb Interneurons." *Cereb Cortex* 29(11): 4831-4849.

2051 Haubensak, W., A. Attardo, W. Denk and W. B. Huttner (2004). "Neurons arise in the basal neuroepithelium  
2052 of the early mammalian telencephalon: a major site of neurogenesis." *Proc Natl Acad Sci U S A* 101(9):  
2053 3196-3201.

2054 Hayashi, S. and A. P. McMahon (2002). "Efficient recombination in diverse tissues by a tamoxifen inducible  
2055 form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse." *Dev Biol* 244(2):  
2056 305-318.

2057 Hegarty, S. V., G. W. O'Keefe and A. M. Sullivan (2013). "BMP-Smad 1/5/8 signalling in the development of  
2058 the nervous system." *Prog Neurobiol* 109: 28-41.

2059 Heine, V. M., A. Griveau, C. Chapin, P. L. Ballard, J. K. Chen and D. H. Rowitch (2011). "A small molecule  
2060 smoothened agonist prevents glucocorticoid-induced neonatal cerebellar injury." *Sci Transl Med* 3(105):  
2061 105ra104.

2062 Heins, N., P. Malatesta, F. Cecconi, M. Nakafuku, K. L. Tucker, M. A. Hack, P. Chapouton, Y. A. Barde and M.  
2063 Götz (2002). "Glial cells generate neurons: the role of the transcription factor Pax6." *Nat Neurosci* 5(4): 308-  
2064 315.

2065 Herdegen, T. and J. D. Leah (1998). "Inducible and constitutive transcription factors in the mammalian  
2066 nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins." *Brain Res Brain  
2067 Res Rev* 28(3): 370-490.

2068 Hevner, R. F., L. Shi, N. Justice, Y. Hsueh, M. Sheng, S. Smiga, A. Bulfone, A. M. Goffinet, A. T. Campagnoni  
2069 and J. L. Rubenstein (2001). "Tbr1 regulates differentiation of the preplate and layer 6." *Neuron* 29(2): 353-  
2070 366.

2071 Hill, R. E., J. Favor, B. L. Hogan, C. C. Ton, G. F. Saunders, I. M. Hanson, J. Prosser, T. Jordan, N. D. Hastie and  
2072 V. van Heyningen (1991). "Mouse small eye results from mutations in a paired-like homeobox-containing  
2073 gene." *Nature* 354(6354): 522-525.

2074 Holm, P. C., M. T. Mader, N. Haubst, A. Wizenmann, M. Sigvardsson and M. Götz (2007). "Loss and gain of  
2075 function analyses reveal targets of Pax6 in the developing mouse telencephalon." *Mol Cell Neurosci* 34(1):  
2076 99-119.

2077 Hou, S., W. L. Ho, L. Wang, B. Kuo, J. Y. Park and Y. G. Han (2021). "Biphasic Roles of Hedgehog Signaling in  
2078 the Production and Self-Renewal of Outer Radial Glia in the Ferret Cerebral Cortex." *Cereb Cortex* 31(10):  
2079 4730-4741.

2080 Hu, J. S., L. T. Doan, D. S. Curre, M. Paff, J. Y. Rheem, R. Schreyer, B. Robert and E. S. Monuki (2008).  
2081 "Border formation in a Bmp gradient reduced to single dissociated cells." *Proc Natl Acad Sci U S A* 105(9):  
2082 3398-3403.

2083 Huang da, W., B. T. Sherman and R. A. Lempicki (2009). "Systematic and integrative analysis of large gene  
2084 lists using DAVID bioinformatics resources." *Nat Protoc* 4(1): 44-57.

2085 Huang da, W., B. T. Sherman, X. Zheng, J. Yang, T. Imamichi, R. Stephens and R. A. Lempicki (2009).  
2086 "Extracting biological meaning from large gene lists with DAVID." *Curr Protoc Bioinformatics Chapter 13:*  
2087 *Unit 13.11.*

2088 Huang, S., Y. P. Guo, G. May and T. Enver (2007). "Bifurcation dynamics in lineage commitment in bipotent  
2089 progenitor cells." *Dev Biol* 305(2): 695-713.

2090 Iacopetti, P., M. Michelini, I. Stuckmann, B. Oback, E. Aaku-Saraste and W. B. Huttner (1999). "Expression of  
2091 the antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that  
2092 switch from proliferative to neuron-generating division." *Proc Natl Acad Sci U S A* 96(8): 4639-4644.

2093 Kalyani, A. J., D. Piper, T. Mujtaba, M. T. Lucero and M. S. Rao (1998). "Spinal cord neuronal precursors  
2094 generate multiple neuronal phenotypes in culture." *J Neurosci* 18(19): 7856-7868.

2095 Kaplan, E. S., K. A. Ramos-Laguna, A. B. Mihalas, R. A. M. Daza and R. F. Hevner (2017). "Neocortical Sox9+  
2096 radial glia generate glutamatergic neurons for all layers, but lack discernible evidence of early laminar fate  
2097 restriction." *Neural Dev* 12(1): 14.

2098 Karin, M., Z. Liu and E. Zandi (1997). "AP-1 function and regulation." *Curr Opin Cell Biol* 9(2): 240-246.

2099 Kessaris, N., M. Fogarty, P. Iannarelli, M. Grist, M. Wegner and W. D. Richardson (2006). "Competing waves  
2100 of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage." *Nat Neurosci* 9(2):  
2101 173-179.

2102 Kikkawa, T., T. Obayashi, M. Takahashi, U. Fukuzaki-Dohi, K. Numayama-Tsuruta and N. Osumi (2013).  
2103 "Dmrt1 regulates proneural gene expression downstream of Pax6 in the mammalian telencephalon."  
2104 *Genes Cells* 18(8): 636-649.

2105 Komada, M., H. Saitsu, M. Kinboshi, T. Miura, K. Shiota and M. Ishibashi (2008). "Hedgehog signaling is  
2106 involved in development of the neocortex." *Development* 135(16): 2717-2727.

2107 Kovach, C., R. Dixit, S. Li, P. Mattar, G. Wilkinson, G. E. Elsen, D. M. Kurrasch, R. F. Hevner and C.  
2108 Schuurmans (2013). "Neurog2 simultaneously activates and represses alternative gene expression  
2109 programs in the developing neocortex." *Cereb Cortex* 23(8): 1884-1900.

2110 Kowalczyk, M. S., I. Tirosh, D. Heckl, T. N. Rao, A. Dixit, B. J. Haas, R. K. Schneider, A. J. Wagers, B. L. Ebert  
2111 and A. Regev (2015). "Single cell RNA seq reveals changes in cell cycle and differentiation programs upon  
2112 aging of hematopoietic stem cells." *Genome Res* 25(12): 1860-1872.

2113 Kroll, T. T. and D. D. O'Leary (2005). "Ventralized dorsal telencephalic progenitors in Pax6 mutant mice  
2114 generate GABA interneurons of a lateral ganglionic eminence fate." *Proc Natl Acad Sci U S A* 102(20): 7374-  
2115 7379.

2116 La-Manno, G., R. Soldatov, A. Zeisel, E. Braun, H. Hochgerner, V. Petukhov, K. Lidschreiber, M. E. Kastrioti, P.  
2117 Lönnnerberg, A. Furlan, J. Fan, L. E. Borm, Z. Liu, D. van Bruggen, J. Guo, X. He, R. Barker, E. Sundström, G.  
2118 Castelo-Branco, P. Cramer, I. Adameyko, S. Linnarsson and P. V. Kharchenko (2018). "RNA velocity of single  
2119 cells." *Nature* 560(7719): 494-498.

2120 Lai, T., D. Jabaudon, B. J. Molyneaux, E. Azim, P. Arlotta, J. R. Menezes and J. D. Macklis (2008). "SOX5  
2121 controls the sequential generation of distinct corticofugal neuron subtypes." *Neuron* 57(2): 232-247.

2122 Le, T. N., G. Du, M. Fonseca, Q. P. Zhou, J. T. Wigle and D. D. Eisenstat (2007). "Dlx homeobox genes  
2123 promote cortical interneuron migration from the basal forebrain by direct repression of the semaphorin  
2124 receptor neuropilin-2." *J Biol Chem* 282(26): 19071-19081.

2125 Le, T. N., Q. P. Zhou, I. Cobos, S. Zhang, J. Zagozewski, S. Japoni, J. Vriend, T. Parkinson, G. Du, J. L.  
2126 Rubenstein and D. D. Eisenstat (2017). "GABAergic Interneuron Differentiation in the Basal Forebrain Is  
2127 Mediated through Direct Regulation of Glutamic Acid Decarboxylase Isoforms by Dlx Homeobox  
2128 Transcription Factors." *J Neurosci* 37(36): 8816-8829.

2129 Lee, J., K. A. Platt, P. Censullo and A. Ruiz i Altaba (1997). "Gli1 is a target of Sonic hedgehog that induces  
2130 ventral neural tube development." *Development* 124(13): 2537-2552.

2131 Lehtinen, M. K., M. W. Zappaterra, X. Chen, Y. J. Yang, A. D. Hill, M. Lun, T. Maynard, D. Gonzalez, S. Kim, P.  
2132 Ye, A. J. D'Ercole, E. T. Wong, A. S. LaMantia and C. A. Walsh (2011). "The cerebrospinal fluid provides a  
2133 proliferative niche for neural progenitor cells." *Neuron* 69(5): 893-905.

2134 Lendahl, U., L. B. Zimmerman and R. D. McKay (1990). "CNS stem cells express a new class of intermediate  
2135 filament protein." *Cell* 60(4): 585-595.

2136 Leone, D. P., K. Srinivasan, B. Chen, E. Alcamo and S. K. McConnell (2008). "The determination of projection  
2137 neuron identity in the developing cerebral cortex." *Curr Opin Neurobiol* 18(1): 28-35.

2138 Liem, K. F., Jr., M. He, P. J. Oebina and K. V. Anderson (2009). "Mouse Kif7/Costal2 is a cilia-associated  
2139 protein that regulates Sonic hedgehog signaling." *Proc Natl Acad Sci U S A* 106(32): 13377-13382.

2140 Lim, L., D. Mi, A. Llorca and O. Marín (2018). "Development and Functional Diversification of Cortical  
2141 Interneurons." *Neuron* 100(2): 294-313.

2142 Lin, Y. L., S. D. Persaud, J. Nhieu and L. N. Wei (2017). "Cellular Retinoic Acid-Binding Protein 1 Modulates  
2143 Stem Cell Proliferation to Affect Learning and Memory in Male Mice." *Endocrinology* 158(9): 3004-3014.

2144 Long, J. E., C. Swan, W. S. Liang, I. Cobos, G. B. Potter and J. L. Rubenstein (2009). "Dlx1&2 and Mash1  
2145 transcription factors control striatal patterning and differentiation through parallel and overlapping  
2146 pathways." *J Comp Neurol* 512(4): 556-572.

2147 LeTurco, J. J., M. G. Blanton and A. R. Kriegstein (1991). "Initial expression and endogenous activation of  
2148 NMDA channels in early neocortical development." *J Neurosci* 11(3): 792-799.

2149 Love, M. I., W. Huber and S. Anders (2014). "Moderated estimation of fold change and dispersion for RNA-  
2150 seq data with DESeq2." *Genome Biol* 15(12): 550.

2151 Luan, Q., Q. Chen and M. Friedrich (2014). "The Pax6 genes eyeless and twin of eyeless are required for  
2152 global patterning of the ocular segment in the Tribolium embryo." *Dev Biol* 394(2): 367-381.

2153 Luhmann, H. J., R. A. Reiprich, I. Hanganu and W. Kilb (2000). "Cellular physiology of the neonatal rat  
2154 cerebral cortex: intrinsic membrane properties, sodium and calcium currents." *J Neurosci Res* 62(4): 574-  
2155 584.

2156 Macdonald, R., K. A. Barth, Q. Xu, N. Holder, I. Mikkola and S. W. Wilson (1995). "Midline signalling is  
2157 required for Pax gene regulation and patterning of the eyes." *Development* 121(10): 3267-3278.

2158 Manuel, M., P. A. Georgala, C. B. Carr, S. Chanas, D. A. Kleinjan, B. Martynoga, J. O. Mason, M. Molinek, J.  
2159 Pinson, T. Pratt, J. C. Quinn, T. I. Simpson, D. A. Tyas, V. van Heyningen, J. D. West and D. J. Price (2007).  
2160 "Controlled overexpression of Pax6 in vivo negatively autoregulates the Pax6 locus, causing cell-  
2161 autonomous defects of late cortical progenitor proliferation with little effect on cortical arealization."  
2162 *Development* 134(3): 545-555.

2163 Manuel, M., B. Martynoga, T. Yu, J. D. West, J. O. Mason and D. J. Price (2010). "The transcription factor  
2164 Foxg1 regulates the competence of telencephalic cells to adopt subpallial fates in mice." *Development*  
2165 137(3): 487-497.

2166 Marigo, V. and C. J. Tabin (1996). "Regulation of patched by sonic hedgehog in the developing neural tube."  
2167 *Proc Natl Acad Sci U S A* 93(18): 9346-9351.

2168 Markram, H., M. Toledo-Rodriguez, Y. Wang, A. Gupta, G. Silberberg and C. Wu (2004). "Interneurons of the  
2169 neocortical inhibitory system." *Nat Rev Neurosci* 5(10): 793-807.



2170 Marti, E., D. A. Bumerot, R. Takada and A. P. McMahon (1995). "Requirement of 19K form of Sonic  
2171 hedgehog for induction of distinct ventral cell types in CNS explants." *Nature* 375(6529): 322-325.

2172 Mastick, G. S., N. M. Davis, G. L. Andrew and S. S. Easter, Jr. (1997). "Pax-6 functions in boundary formation  
2173 and axon guidance in the embryonic mouse forebrain." *Development* 124(10): 1985-1997.

2174 Matisse, M. P. and H. Wang (2011). "Sonic hedgehog signaling in the developing CNS where it has been and  
2175 where it is going." *Curr Top Dev Biol* 97: 75-117.

2176 Mayer, C., C. Hafemeister, R. C. Bandler, R. Machold, R. Batista Brito, X. Jaglin, K. Allaway, A. Butler, G.  
2177 Fishell and R. Satija (2018). "Developmental diversification of cortical inhibitory interneurons." *Nature*  
2178 555(7697): 457-462.

2179 Mi, D., C. B. Carr, P. A. Georgala, Y. T. Huang, M. N. Manuel, E. Jeanes, E. Niisato, S. N. Sansom, F. J. Livesey,  
2180 T. Theil, K. Hasenpusch-Theil, T. I. Simpson, J. O. Mason and D. J. Price (2013). "Pax6 exerts regional control  
2181 of cortical progenitor proliferation via direct repression of Cdk6 and hypophosphorylation of pRb." *Neuron*  
2182 78(2): 269-284.

2183 Mi, D., M. Manuel, Y. T. Huang, J. O. Mason and D. J. Price (2018). "Pax6 Lengthens G1 Phase and Decreases  
2184 Oscillating Cdk6 Levels in Murine Embryonic Cortical Progenitors." *Front Cell Neurosci* 12: 419.

2185 Mihalas, A. B. and R. F. Hevner (2018). "Clonal analysis reveals laminar fate multipotency and daughter cell  
2186 apoptosis of mouse cortical intermediate progenitors." *Development* 145(17):

2187 Miyoshi, G., S. J. Butt, H. Takebayashi and G. Fishell (2007). "Physiologically distinct temporal cohorts of  
2188 cortical interneurons arise from telencephalic Olig2-expressing precursors." *J Neurosci* 27(29): 7786-7798.

2189 Miyoshi, G. and G. Fishell (2012). "Dynamic FoxG1 expression coordinates the integration of multipolar  
2190 pyramidal neuron precursors into the cortical plate." *Neuron* 74(6): 1045-1058.

2191 Miyoshi, G., J. Hjerling-Leffler, T. Karayannis, V. H. Sousa, S. J. Butt, J. Battiste, J. E. Johnson, R. P. Machold  
2192 and G. Fishell (2010). "Genetic fate mapping reveals that the caudal ganglionic eminence produces a large  
2193 and diverse population of superficial cortical interneurons." *J Neurosci* 30(5): 1582-1594.

2194 Morinello, E., M. Pignatello, L. Villabruna, P. Goelzer and H. Bürgin (2014). "Embryofetal development study  
2195 of vismodegib, a hedgehog pathway inhibitor, in rats." *Birth Defects Res B Dev Reprod Toxicol* 101(2): 135-  
2196 143.

2197 Moris, N., C. Pina and A. M. Arias (2016). "Transition states and cell fate decisions in epigenetic landscapes." *Nat Rev Genet* 17(11): 693-703.

2199 Nishida, K., M. Hoshino, Y. Kawaguchi and F. Murakami (2010). "Ptf1a directly controls expression of  
2200 immunoglobulin superfamily molecules Nephin and Neph3 in the developing central nervous system." *J*  
2201 *Biol Chem* 285(1): 373-380.

2202 Noctor, S. C., V. Martínez-Cerdeño, L. Ivic and A. R. Kriegstein (2004). "Cortical neurons arise in symmetric  
2203 and asymmetric division zones and migrate through specific phases." *Nat Neurosci* 7(2): 136-144.

2204 Ortega, J. A., N. V. Radonjić and N. Zecevic (2013). "Sonic hedgehog promotes generation and maintenance  
2205 of human forebrain Olig2 progenitors." *Front Cell Neurosci* 7: 254.

2206 Pan, Z. Z. (2012). "Transcriptional control of Gad2." *Transcription* 3(2): 68-72.

2207 Perkins, T. J. and P. S. Swain (2009). "Strategies for cellular decision-making." *Mol Syst Biol* 5: 326.

2208 Petryniak, M. A., G. B. Potter, D. H. Rowitch and J. L. Rubenstein (2007). "Dlx1 and Dlx2 control neuronal  
2209 versus oligodendroglial cell fate acquisition in the developing forebrain." *Neuron* 55(3): 417-433.

2210 Pinto, L., D. Drechsel, M. T. Schmid, J. Ninkovic, M. Irmiler, M. S. Brill, L. Restani, L. Gianfranceschi, C. Cerri,  
2211 S. N. Weber, V. Tarabykin, K. Baer, F. Guillemot, J. Beckers, N. Zecevic, C. Dehay, M. Caleo, H. Schorle and  
2212 M. Götz (2009). "AP2gamma regulates basal progenitor fate in a region- and layer-specific manner in the  
2213 developing cortex." *Nat Neurosci* 12(10): 1229-1237.

2214 Pla, R., A. Stanco, M. A. Howard, A. N. Rubin, D. Vogt, N. Mortimer, I. Cobos, G. B. Potter, S. Lindtner, J. D.  
2215 Price, A. S. Nord, A. Visel, C. E. Schreiner, S. C. Baraban, D. H. Rowitch and J. L. R. Rubenstein (2018). "Dlx1  
2216 and Dlx2 Promote Interneuron GABA Synthesis, Synaptogenesis, and Dendritogenesis." *Cereb Cortex*  
2217 28(11): 3797-3815.

2218 Quinn, J. C., M. Molinek, B. S. Martynoga, P. A. Zaki, A. Faedo, A. Bulfone, R. F. Hevner, J. D. West and D. J.  
2219 Price (2007). "Pax6 controls cerebral cortical cell number by regulating exit from the cell cycle and specifies  
2220 cortical cell identity by a cell autonomous mechanism." *Dev Biol* 302(1): 50-65.

2221 Quinn, J. C., M. Molinek, J. O. Mason and D. J. Price (2009). "Gli3 is required autonomously for dorsal  
2222 telencephalic cells to adopt appropriate fates during embryonic forebrain development." *Dev Biol* 327(1):  
2223 204-215.

2224 Quintana-Urzaínqui, I., Z. Kozić, S. Mitra, T. Tian, M. Manuel, J. O. Mason and D. J. Price (2018). "Tissue-  
2225 Specific Actions of Pax6 on Proliferation and Differentiation Balance in Developing Forebrain Are Foxg1  
2226 Dependent." *iScience* 10: 171-191.

2227 Radler-Pohl, A., S. Gebel, C. Sachsenmaier, H. König, M. Krämer, T. Oehler, M. Streile, H. Ponta, U. Rapp, H.  
2228 J. Rahmsdorf and et al. (1993). "The activation and activity control of AP-1 (fos/jun)." *Ann N Y Acad Sci* 684:  
2229 127-148.

2230 Radonjić, N. V., F. Memi, J. A. Ortega, N. Glidden, H. Zhan and N. Zecevic (2016). "The Role of Sonic  
2231 Hedgehog in the Specification of Human Cortical Progenitors In Vitro." *Cereb Cortex* 26(1): 131-143.

2232 Raivich, G. and A. Behrens (2006). "Role of the AP-1 transcription factor c-Jun in developing, adult and  
2233 injured brain." *Prog Neurobiol* 78(6): 347-363.

2234 Rallu, M., R. Machold, N. Gaiano, J. G. Corbin, A. P. McMahon and G. Fishell (2002). "Dorsoventral  
2235 patterning is established in the telencephalon of mutants lacking both Gli3 and Hedgehog signaling."  
2236 *Development* 129(21): 4963-4974.

2237 Rallu, M., J. G. Corbin and G. Fishell (2002b). "Parsing the prosencephalon." *Nat Rev Neurosci* 3(12): 943-  
2238 951.

2239 Raposo, A., F. F. Vasconcelos, D. Drechsel, C. Marie, C. Johnston, D. Dolle, A. Bithell, S. Gillotin, D. L. C. van  
2240 den Berg, L. Ettwiller, P. Flicek, G. E. Crawford, C. M. Parras, B. Berninger, N. J. Buckley, F. Guillemot and D.  
2241 S. Castro (2015). "Ascl1 Coordinately Regulates Gene Expression and the Chromatin Landscape during  
2242 Neurogenesis." *Cell Rep* 10(9): 1544-1556.

2243 Robertshaw, E., K. Matsumoto, A. Lumsden and C. Kiecker (2013). "Irx3 and Pax6 establish differential  
2244 competence for Shh-mediated induction of GABAergic and glutamatergic neurons of the thalamus." *Proc*  
2245 *Natl Acad Sci U S A* 110(41): E3919-3926.

2246 Robinson, M. D., D. J. McCarthy and G. K. Smyth (2010). "edgeR: a Bioconductor package for differential  
2247 expression analysis of digital gene expression data." *Bioinformatics* 26(1): 139-140.

2248 Sansom, S. N., D. S. Griffiths, A. Faedo, D. J. Kleinjan, Y. Ruan, J. Smith, V. van Heyningen, J. L. Rubenstein  
2249 and F. J. Livesey (2009). "The level of the transcription factor Pax6 is essential for controlling the balance  
2250 between neural stem cell self-renewal and neurogenesis." *PLoS Genet* 5(6): e1000511.

2251 Saxena, M., N. Agnihotri and J. Sen (2018). "Perturbation of canonical and non-canonical BMP signaling  
2252 affects migration, polarity and dendritogenesis of mouse cortical neurons." *Development* 145(1).

2253 Scala, F., D. Kobak, M. Bernabucci, Y. Bernaerts, C. R. Cadwell, J. R. Castro, L. Hartmanis, X. Jiang, S.  
2254 Laturnus, E. Miranda, S. Mulherkar, Z. H. Tan, Z. Yao, H. Zeng, R. Sandberg, P. Berens and A. S. Tolias (2021).  
2255 "Phenotypic variation of transcriptomic cell types in mouse motor cortex." *Nature* 598(7879): 144-150.

2256 Seardigli, R., N. Bäumer, P. Gruss, F. Guillemot and I. Le Roux (2003). "Direct and concentration-dependent  
2257 regulation of the proneural gene Neurogenin2 by Pax6." *Development* 130(14): 3269-3281.

2258 Schuurmans, C., O. Armant, M. Nieto, J. M. Stenman, O. Britz, N. Klenin, C. Brown, L. M. Langevin, J. Seibt,  
2259 H. Tang, J. M. Cunningham, R. Dyck, C. Walsh, K. Campbell, F. Polleux and F. Guillemot (2004). "Sequential

2260 phases of cortical specification involve Neurogenin-dependent and independent pathways." *Embo j* 23(14):  
2261 2892-2902.

2262 Seibt, J., O. Armant, A. Le Digarcher, D. Castro, V. Ramesh, L. Journot, F. Guillemot, P. Vanderhaeghen and  
2263 T. Bouschet (2012). "Expression at the imprinted *dlk1-gtl2* locus is regulated by proneural genes in the  
2264 developing telencephalon." *PLoS One* 7(11): e48675.

2265 Sessa, A., E. Ciabatti, D. Drechsel, L. Massimino, G. Colasante, S. Giannelli, T. Satoh, S. Akira, F. Guillemot  
2266 and V. Broccoli (2017). "The Tbr2 Molecular Network Controls Cortical Neuronal Differentiation Through  
2267 Complementary Genetic and Epigenetic Pathways." *Cereb Cortex* 27(6): 3378-3396.

2268 Sheng, M. and M. E. Greenberg (1990). "The regulation and function of *c-fos* and other immediate early  
2269 genes in the nervous system." *Neuron* 4(4): 477-485.

2270 Shikata, Y., T. Okada, M. Hashimoto, T. Ellis, D. Matsumaru, T. Shiroishi, M. Ogawa, B. Wainwright and J.  
2271 Motoyama (2011). "Ptc1-mediated dosage-dependent action of Shh signaling regulates neural progenitor  
2272 development at late-gestational stages." *Dev Biol* 349(2): 147-159.

2273 Shimamura, K., D. J. Hartigan, S. Martinez, L. Puellas and J. L. Rubenstein (1995). "Longitudinal organization  
2274 of the anterior neural plate and neural tube." *Development* 121(12): 3923-3933.

2275 Shimamura, K. and J. L. Rubenstein (1997). "Inductive interactions direct early regionalization of the mouse  
2276 forebrain." *Development* 124(14): 2709-2718.

2277 Simpson, T. I., T. Pratt, J. O. Mason and D. J. Price (2009). "Normal ventral telencephalic expression of Pax6  
2278 is required for normal development of thalamocortical axons in embryonic mice." *Neural Dev* 4: 19.

2279 Simpson, T. I. and D. J. Price (2002). "Pax6; a pleiotropic player in development." *Bioessays* 24(11): 1041-  
2280 1051.

2281 Smart, I. H. and M. Smart (1982). "Growth patterns in the lateral wall of the mouse telencephalon: I.  
2282 Autoradiographic studies of the histogenesis of the isocortex and adjacent areas." *J Anat* 134(Pt 2): 273-  
2283 298.

2284 Soldado-Magraner, S., F. Brandalise, S. Honnuraiah, M. Pfeiffer, M. Moulinier, U. Gerber and R. Douglas  
2285 (2020). "Conditioning by subthreshold synaptic input changes the intrinsic firing pattern of CA3  
2286 hippocampal neurons." *J Neurophysiol* 123(1): 90-106.

2287 Stenman, J., H. Toresson and K. Campbell (2003). "Identification of two distinct progenitor populations in  
2288 the lateral ganglionic eminence: implications for striatal and olfactory bulb neurogenesis." *J Neurosci* 23(1):  
2289 167-174.

2290 Stoykova, A. and P. Gruss (1994). "Roles of Pax genes in developing and adult brain as suggested by  
2291 expression patterns." *J Neurosci* 14(3 Pt 2): 1395-1412.

2292 Street, K., D. Risso, R. B. Fletcher, D. Das, J. Ngai, N. Yosef, E. Purdom and S. Dudoit (2018). "Slingshot: cell  
2293 lineage and pseudotime inference for single-cell transcriptomics." *BMC Genomics* 19(1): 477.

2294 Sultan, K. T., K. N. Brown and S. H. Shi (2013). "Production and organization of neocortical interneurons." *Front Cell Neurosci* 7: 221.

2296 Sun, J., S. Rockowitz, Q. Xie, R. Ashery-Padan, D. Zheng and A. Cvekl (2015). "Identification of in vivo DNA-  
2297 binding mechanisms of Pax6 and reconstruction of Pax6-dependent gene regulatory networks during  
2298 forebrain and lens development." *Nucleic Acids Res* 43(14): 6827-6846.

2299 Svärd, J., K. Heby-Henricson, M. Persson-Lek, B. Rozell, M. Lauth, A. Bergström, J. Ericson, R. Toftgård and S.  
2300 Teglund (2006). "Genetic elimination of Suppressor of fused reveals an essential repressor function in the  
2301 mammalian Hedgehog signaling pathway." *Dev Cell* 10(2): 187-197.

2302 Toresson, H., S. S. Potter and K. Campbell (2000). "Genetic control of dorsal-ventral identity in the  
2303 telencephalon: opposing roles for Pax6 and Gsh2." *Development* 127(20): 4361-4371.

2304 Tritschler, S., M. Büttner, D. S. Fischer, M. Lange, V. Bergen, H. Lickert and F. J. Theis (2019). "Concepts and  
2305 limitations for learning developmental trajectories from single cell genomics." *Development* 146(12).

2306 Tuoc, T. C., K. Radyushkin, A. B. Tonchev, M. C. Piñon, R. Ashery-Padan, Z. Molnár, M. S. Davidoff and A.  
2307 Stoykova (2009). "Selective cortical layering abnormalities and behavioral deficits in cortex-specific Pax6  
2308 knock-out mice." *J Neurosci* 29(26): 8335-8349.

2309 Turque, N., S. Plaza, F. Radvanyi, C. Carriere and S. Saule (1994). "Pax-QNR/Pax 6, a paired-box and  
2310 homeobox containing gene expressed in neurons, is also expressed in pancreatic endocrine cells." *Mol*  
2311 *Endocrinol* 8(7): 929-938.

2312 Tuvikene, J., P. Pruunsild, E. Orav, E. E. Esvald and T. Timmusk (2016). "AP-1 Transcription Factors Mediate  
2313 BDNF-Positive Feedback Loop in Cortical Neurons." *J Neurosci* 36(4): 1290-1305.

2314 Tyzio, R., A. Ivanov, C. Bernard, G. L. Holmes, Y. Ben-Ari and R. Khazipov (2003). "Membrane potential of  
2315 CA3 hippocampal pyramidal cells during postnatal development." *J Neurophysiol* 90(5): 2964-2972.

2316 Van den Berge, K., H. Roux de Bézieux, K. Street, W. Saelens, R. Cannoodt, Y. Saeys, S. Dudoit and L.  
2317 Clement (2020). "Trajectory-based differential expression analysis for single-cell sequencing data." *Nat*  
2318 *Commun* 11(1): 1201.

2319 Vasistha, N. A., F. García-Moreno, S. Arora, A. F. Cheung, S. J. Arnold, E. J. Robertson and Z. Molnár (2015).  
2320 "Cortical and Clonal Contribution of Tbr2-Expressing Progenitors in the Developing Mouse Brain." *Cereb*  
2321 *Cortex* 25(10): 3290-3302.

2322 Villalba, A., M. Götz and V. Borrell (2021). "The regulation of cortical neurogenesis." *Curr Top Dev Biol* 142:  
2323 1-66.

2324 Viti, J., A. Gulacsi and L. Lillien (2003). "Wnt regulation of progenitor maturation in the cortex depends on  
2325 Shh or fibroblast growth factor 2." *J Neurosci* 23(13): 5919-5927.

2326 Voronova, A., S. A. Yuzwa, B. S. Wang, S. Zahr, C. Syal, J. Wang, D. R. Kaplan and F. D. Miller (2017).  
2327 "Migrating Interneurons Secrete Fractalkine to Promote Oligodendrocyte Formation in the Developing  
2328 Mammalian Brain." *Neuron* 94(3): 500-516.e509.

2329 Waclaw, R. R., B. Wang, Z. Pei, L. A. Ehrman and K. Campbell (2009). "Distinct temporal requirements for  
2330 the homeobox gene *Gsx2* in specifying striatal and olfactory bulb neuronal fates." *Neuron* 63(4): 451-465.

2331 Waddington, C.H. (1932). "Experiments on the Development of Chick and Duck Embryos, Cultivated in  
2332 Vitro." *Philos Trans R Soc Lond B Biol Sci* 221: 179-230.

2333 Waddington, C.H. (1934). "Experiments on Embryonic Induction: III. A Note on Inductions by Chick Primitive  
2334 Streak Transplanted to the Rabbit Embryo." *J Exp Biol* 11: 224-227.

2335 Waddington, C.H. (1957). "The Strategy of the Gene." London: George Allen and Unwin.

2336 Walther, C. and P. Gruss (1991). "Pax 6, a murine paired box gene, is expressed in the developing CNS." *Development* 113(4): 1435-1449.

2338 Wang, B., J. E. Long, P. Flandin, R. Pla, R. R. Waclaw, K. Campbell and J. L. Rubenstein (2013). "Loss of *Gsx1*  
2339 and *Gsx2* function rescues distinct phenotypes in *Dlx1/2* mutants." *J Comp Neurol* 521(7): 1561-1584.

2340 Ward, J. H. (1963). "Hierarchical grouping to optimize an objective function." *Journal of the American*  
2341 *Statistical Association*, 58, 236-244.

2342 Wechsler-Reya, R. J. and M. P. Scott (1999). "Control of neuronal precursor proliferation in the cerebellum  
2343 by Sonic Hedgehog." *Neuron* 22(1): 103-114.

2344 Wei, S., H. Du, Z. Li, G. Tao, Z. Xu, X. Song, Z. Shang, Z. Su, H. Chen, Y. Wen, G. Liu, Y. You, Z. Zhang and Z.  
2345 Yang (2019). "Transcription factors Sp8 and Sp9 regulate the development of caudal ganglionic eminence-  
2346 derived cortical interneurons." *J Comp Neurol* 527(17): 2860-2874.

2347 Weisenhorn, D. M., E. W. Prieto and M. R. Celio (1994). "Localization of calretinin in cells of layer I (Cajal-  
2348 Retzius cells) of the developing cortex of the rat." *Brain Res Dev Brain Res* 82(1-2): 293-297.

2349 [Wijgerde, M., J. A. McMahon, M. Rule and A. P. McMahon \(2002\).](#) "A direct requirement for Hedgehog  
2350 signaling for normal specification of all ventral progenitor domains in the presumptive mammalian spinal  
2351 cord." *Genes Dev* 16(22): 2849-2864.

2352 [Winkler, C. C., O. R. Yabut, S. P. Fregoso, H. G. Gomez, B. E. Dwyer, S. J. Pleasure and S. J. Franco \(2018\).](#)  
2353 "The Dorsal Wave of Neocortical Oligodendrogenesis Begins Embryonically and Requires Multiple Sources  
2354 of Sonic Hedgehog." *J Neurosci* 38(23): 5237-5250.

2355 [Wolpert, L. \(1969\).](#) "Positional information and the spatial pattern of cellular differentiation." *J Theor Biol*  
2356 25(1): 1-47.

2357 [Wong, F. K., J. F. Fei, F. Mora-Bermúdez, E. Taverna, C. Haffner, J. Fu, K. Anastassiadis, A. F. Stewart and W.  
2358 B. Huttner \(2015\).](#) "Sustained Pax6 Expression Generates Primate-like Basal Radial Glia in Developing  
2359 Mouse Neocortex." *PLoS Biol* 13(8): e1002217.

2360 [Xie, Q., Y. Yang, J. Huang, J. Ninkovic, T. Walcher, L. Wolf, A. Vitenzon, D. Zheng, M. Götz, D. C. Beebe, J.  
2361 Zavadil and A. Cvekl \(2013\).](#) "Pax6 interactions with chromatin and identification of its novel direct target  
2362 genes in lens and forebrain." *PLoS One* 8(1): e54507.

2363 [Xu, Q., L. Guo, H. Moore, R. R. Waclaw, K. Campbell and S. A. Anderson \(2010\).](#) "Sonic hedgehog signaling  
2364 confers ventral telencephalic progenitors with distinct cortical interneuron fates." *Neuron* 65(3): 328-340.

2365 [Yabut, O. R., G. Fernandez, T. Huynh, K. Yoon and S. J. Pleasure \(2015\).](#) "Suppressor of Fused Is Critical for  
2366 Maintenance of Neuronal Progenitor Identity during Corticogenesis." *Cell Rep* 12(12): 2021-2034.

2367 [Yabut, O. R., H. X. Ng, K. Yoon, J. C. Arela, T. Ngo and S. J. Pleasure \(2020\).](#) "The Neocortical Progenitor  
2368 Specification Program Is Established through Combined Modulation of SHH and FGF Signaling." *J Neurosci*  
2369 40(36): 6872-6887.

2370 [Yabut, O. R. and S. J. Pleasure \(2018\).](#) "Sonic Hedgehog Signaling Rises to the Surface: Emerging Roles in  
2371 Neocortical Development." *Brain Plast* 3(2): 119-128.

2372 [Yang, J. W., W. Kilb, S. Kirischuk, P. Unichenko, M. C. Stüttgen and H. J. Luhmann \(2018\).](#) "Development of  
2373 the whisker-to-barrel cortex system." *Curr Opin Neurobiol* 53: 29-34.

2374 [Yao, J., Y. Liu, J. Husain, R. Lo, A. Palaparti, J. Henderson and S. Stifani \(1998\).](#) "Combinatorial expression  
2375 patterns of individual TLE proteins during cell determination and differentiation suggest non-redundant  
2376 functions for mammalian homologs of *Drosophila* Groucho." *Dev Growth Differ* 40(2): 133-146.

2377 [Young, M. D. and S. Behjati \(2020\).](#) "SoupX removes ambient RNA contamination from droplet-based  
2378 single-cell RNA sequencing data." *Gigascience* 9(12).

2379 [Yun, K., S. Fischman, J. Johnson, M. Hrabe de Angelis, G. Weinmaster and J. L. Rubenstein \(2002\).](#)  
2380 "Modulation of the notch signaling by Mash1 and Dlx1/2 regulates sequential specification and  
2381 differentiation of progenitor cell types in the subcortical telencephalon." *Development* 129(21): 5029-5040.

2382 [Yun, K., S. Potter and J. L. Rubenstein \(2001\).](#) "Gsh2 and Pax6 play complementary roles in dorsoventral  
2383 patterning of the mammalian telencephalon." *Development* 128(2): 193-205.

2384 [Zhang, Y., G. Liu, T. Guo, X. G. Liang, H. Du, L. Yang, A. Bhaduri, X. Li, Z. Xu, Z. Zhang, Z. Li, M. He, J. Tsyporin,  
2385 A. R. Kriegstein, J. L. Rubenstein, Z. Yang and B. Chen \(2020\).](#) "Cortical Neural Stem Cell Lineage Progression  
2386 Is Regulated by Extrinsic Signaling Molecule Sonic Hedgehog." *Cell Rep* 30(13): 4490-4504.e4494.

2387 [Zimmer, C., M. C. Tiveron, R. Bodmer and H. Cremer \(2004\).](#) "Dynamics of Cux2 expression suggests that an  
2388 early pool of SVZ precursors is fated to become upper cortical layer neurons." *Cereb Cortex* 14(12): 1408-  
2389 1420.

2390  
2391

2392  
2393  
2394  
2395  
2396  
2397  
2398  
2399  
2400  
2401  
2402  
2403  
2404  
2405  
2406  
2407  
2408  
2409  
2410  
2411  
2412  
2413  
2414  
2415  
2416  
2417  
2418  
2419  
2420  
2421  
2422  
2423  
2424  
2425  
2426  
2427  
2428  
2429  
2430  
2431  
2432  
2433  
2434  
2435  
2436  
2437

## Supporting Information

### Supplementary Figures

#### Figure S1-S1 Fig. Validation of Pax6 removal and RNAseq data

- (A) Frequently used alleles: *Emx1-Cre<sup>ERT2</sup>* producing tamoxifen (TAM)-inducible Cre recombinase [33](Kessaris et al., 2006); *Pax6<sup>loxP</sup>*, from which paired domain-encoding exons were removed by Cre recombinase (*Pax6<sup>ΔloxP</sup>*), rendering it non-functional [185](Simpson et al., 2009); *RC<sup>EGFP</sup>*, a Cre reporter producing R26R CAG-boosted enhanced green fluorescence protein (EGFP) [37](Miyoshi et al., 2010). Mice with deletions in both copies of *Pax6* were designated conditional knock-outs (*Pax6* cKOs); those with a deletion in just one copy served as controls.
- (B) Quantitative RT-PCR measurements of *Pax6* mRNA levels, normalised to those of *Gapdh*, after tamoxifen administration at E9.5 were used to calculate average ( $\pm$ sem) ratios between levels in *Pax6* cKO and control littermates (n=3 embryos from 3 litters at each age) (Source-Data-Table 1S1 Data).
- (C) Western blots showing Pax6 protein expression in the rostral (R) and caudal (C) cortex of control and *Pax6* cKO littermates at E12.5 and E13.5 after tamoxifen administration at E9.5.
- (D) Quantification of Western blots at E12.5 and E13.5 after tamoxifen administration at E9.5. Pax6 protein levels were measured relative to  $\beta$ -actin levels. Average levels ( $\pm$ sem) were calculated (n=3 independent repeats in each region at each age; in each case, levels in *Pax6* cKOs and controls differed with  $p < 0.01$  in Student's t-tests). (Note that Pax6 protein levels in control rostral cortex were almost double those in caudal control cortex at each age, in agreement with previous observations: [34]Manuel et al., 2007) (Source-Data-Table 1S1 Data).
- (E) Expression of green fluorescent protein (GFP) and Pax6 protein in coronal sections through the cortex of control and *Pax6* cKO embryos at E12.5 and E13.5 after tamoxifen administration at E9.5. GFP was activated by most cortical cells and Pax6 protein was lost from most cortical radial glial progenitors across almost the entire cortex, excluding a narrow ventral pallial domain where *Emx1-Cre<sup>ERT2</sup>* was not expressed. Scale bar: 0.1mm.
- (F) Expression of Pax6 protein in sagittal sections through the cortex of control and *Pax6* cKO embryos at E12.5 and E13.5 after tamoxifen administration at E9.5. Scale bar: 0.1mm.
- (G) Principal component analysis on RNAseq data from control caudal (CC) and control rostral (CR) and *Pax6* cKO caudal (KC) and *Pax6* cKO rostral (KR) cortex at E12.5 and E13.5 showing major clustering based on region and age (raw data are available at the European Nucleotide Archive accession numbers PRJEB5857 and PRJEB6774).
- (H) Significant LFCs with values  $\geq 1$  or  $\leq -1$  obtained from bulk RNAseq on samples of E13.5 rostral cortex plotted against significant LFCs calculated from scRNAseq data (by carrying out differential expression analysis on average gene expression levels obtained from random subsets of rostral E13.5 *Pax6* cKO and control cells). By way of example, genes are named for some datapoints (raw data are available at the European Nucleotide Archive accession numbers PRJEB27937, PRJEB32740, PRJEB5857 and PRJEB6774).
- Figure S2-S2 Fig. Pax6 loss altered gene expression in cortical cells
- (A) The experimental procedure: tamoxifen (TAM) was administered at E9.5; one hemisphere from each E12.5 or E13.5 embryo was used to assess Pax6 mRNA and protein levels; the rostral and caudal halves of the other hemisphere were processed for RNAseq.
- (B) Numbers of genes with significantly upregulated or downregulated expression levels in caudal (C) and rostral (R) *Pax6* cKO cortex (LFC: log fold change).

2438 **(C)** Numbers of significantly upregulated or downregulated genes with a nearby Pax6 binding site (BS) ([raw](#)  
2439 [RNAseq data are available at the European Nucleotide Archive accession numbers PRJEB5857 and](#)  
2440 [PRJEB6774; chromatin immunoprecipitation-sequencing data are from \[38\]](#)).

2441 **(D)** Changes with age in the numbers of significantly upregulated or downregulated genes that showed the  
2442 largest changes in expression levels. We applied a commonly used threshold to include all functionally  
2443 annotated genes (<http://www.ensembl.org/index.html>) that at least doubled or halved their expression  
2444 levels, i.e. with a log<sub>2</sub> fold change (LFC) in expression  $\geq 1$  (for upregulated genes) or  $\leq -1$  (for downregulated  
2445 genes), in at least one of the four combinations of age and region. This produced a subset of 183 genes: 98  
2446 genes were affected at E12.5, 95 remained so and a further 85 were added at E13.5. To gain an initial  
2447 impression of biological processes strongly associated with these genes, we passed them through the  
2448 Database for Annotation, Visualization and Integrated Discovery v6.8 (DAVID v6.8; [66,67]Huang et al.,  
2449 2009a,b) to obtain sets of significantly enriched gene ontology (GO) terms (Table S2S2 Table). Some of the  
2450 GO terms obtained using the upregulated gene set described the development of cell types normally  
2451 generated within the telencephalon but outside the cortex in subpallium (where cerebral cortical  
2452 GABAergic interneurons and, at these ages, oligodendrocytes are made; [9,33,90]Kessaris et al., 2006;  
2453 Miyoshi et al., 2007; Lim et al., 2018). Others described the development of non-telencephalic cell types  
2454 (spinal cord, inner ear, skeletal system and neural crest).

2455 **(E)** Lists of the 183 genes upregulated and downregulated genes which had LFCs  $\geq 1$  or  $\leq -1$  at E12.5 and/or  
2456 E13.5 in at least one of the four combinations of age and region (see D above) arranged according to (i)  
2457 whether the first sign of their upregulation or downregulation (which was defined in this case as an  
2458 adjusted  $p < 0.05$ , irrespective of LFC magnitude) was at E12.5 or E13.5 and (ii) whether they had a nearby  
2459 Pax6 binding site (BS; [38]Sun et al., 2015). We excluded downregulated genes whose expression levels  
2460 were very low, based on (i) our E12.5 and E13.5 control cortical RNAseq data and (ii) expression in sections  
2461 of cortex from normal embryos of similar ages in the following databases: <https://gp3.mpg.de/>;  
2462 <https://developingmouse.brain-map.org/>; <http://www.informatics.jax.org/gxd>. We included all  
2463 upregulated genes for which there was sufficient documented evidence to allow us to reach valid  
2464 conclusions on their normal sites of expression at these ages (Table S3S3 Table contains citations).  
2465 Upregulated genes were separated into those normally expressed by telencephalic cells (Tel) and those  
2466 normally expressed only outside the telencephalon (Extra-tel). Upregulated genes shown in boxes were  
2467 clearly expressed in control cortex, i.e. their counts per million (cpm) were  $> 10$ : most upregulated genes  
2468 could be considered to be ectopically activated since they had little or no expression in our control RNAseq  
2469 data from E12.5 and E13.5 cortex. Genes encoding transcription factors were listed using red font.

2470  
2471 **Figure S3:S3 Fig. Aberrant cell types and ectopic gene expression in E13.5 Pax6 cKO cortex**

2472 [Raw data for \(A-F\) are available at the European Nucleotide Archive accession number PRJEB32740.](#)

2473 **(A)** Violin plots of selected gene expression in each cell type from control and Pax6 cKO E13.5 cortex. RGP,  
2474 radial glial progenitor; aRGP, atypical RGP; IP, intermediate progenitor; DLN, deep layer neuron; CRC, Cajal-  
2475 Retzius cell.

2476 **(B)** Proportions of cells of each type in control and Pax6 cKO E13.5 cortex.

2477 **(C)** The proportions of RGPs and aRGPs in different cell cycle phases in control and Pax6 cKO E13.5 cortex.  
2478 We identified each RGP's and aRGP's cell cycle phase by profiling its expression of known cell cycle phase-  
2479 selective markers [194](Kowalczyk et al., 2015). We found that a relatively higher proportion of aRGPs than  
2480 RGPs were in S phase. This is compatible with previous findings that Pax6 removal causes a shortening of  
2481 G1, G2 and M phases [35,195](Mi et al., 2013 and 2018).

2482 **(D,E)** Violin plots of the expression levels of genes that were significantly differentially expressed between  
2483 RGPs and aRGPs in different cell cycle phases in control and Pax6 cKO E13.5 cortex. The expression levels of  
2484 some of the genes whose expression levels differed between aRGPs and RGPs showed large systematic  
2485 variation with cell cycle phase; examples are shown in D. The aRGPs' elevated expression of genes such as  
2486 *Pclaf*, *Rrm2*, *Lig1* and *Pcna*, whose expression levels increased in S phase, and lowered expression of genes



2487 such as *Ube2c*, whose expression levels increased in G2 and M phases, probably reflected the relative  
2488 increase in the proportions of aRGPs in S phase. However, it was hard to explain all differences between  
2489 aRGPs and RGP in this way. For example, levels of *Fos* and *Meg3*, whose expression levels were elevated in  
2490 aRGPs, and *Neurog2* and *Hes5*, whose expression levels were lowered in aRGPs, showed much less  
2491 variation with cell cycle phase (E).

2492 **(F)** Uniform manifold approximation and projection (UMAP) plots of the scRNAseq data from *Pax6* cKO and  
2493 control cells at E13.5, reproduced from Fig. 1B, showing cell types and  $\log_{10}$  normalized expression of *Fos*.

2494 **(G)** Immunohistochemistry for Fos expression in coronal sections of rostral E13.5 lateral and medial control  
2495 and *Pax6* cKO cortex. Scale bar: 0.05mm.

2496

2497 **Figure S4-S4 Fig. Expression profiles of major cell types in *Pax6* cKO and control cortex at E13.5**

2498 Heat map of gene expression in RGP (radial glial progenitors), aRGPs (atypical RGP), IP (intermediate  
2499 progenitors), DLN (deep layer neurons) and CRC (Cajal-Retzius cells) in E13.5 control and *Pax6* cKO cortex.  
2500 [Raw data are available at the European Nucleotide Archive accession number PRJEB32740.](#)

2501

2502 **Figure S5-S5 Fig. Aberrant cell types and ectopic gene expression in E14.5 *Pax6* cKO cortex**

2503 [Raw data are available at the European Nucleotide Archive accession number PRJEB27937.](#)

2504 **(A)** Violin plots of selected gene expression in each cell type from control and *Pax6* cKO E14.5 cortex. RGP,  
2505 radial glial progenitor; aP, atypical progenitor; eGC-P and eGC-N, proliferating or non-proliferating ectopic  
2506 GABAergic cells; IP, intermediate progenitor; DM-IP and DM-SLN, intermediate progenitor or superficial  
2507 layer neuron in dorsomedial cortex; SLN-L2/3 and SLN-L4, layer 2/3 or layer 4 superficial layer neurons;  
2508 DLN-L5 and DLN-L6, layer 5 or layer 6 deep layer neurons; CRC, Cajal-Retzius cell.

2509 **(B)** Proportions of cells of each type in control and *Pax6* cKO E14.5 cortex.

2510 **(C)** Graphs showing co-expression of markers of normal cortical cells (*Neurog2* and *Eomes*) and normal  
2511 subcortical cells (*Gsx2* and *Dlx1*) in some aPs in E14.5 *Pax6* cKOs.

2512

2513 **Figure S6-S6 Fig. Expression profiles of major cell types in *Pax6* cKO and control cortex at E14.5**

2514 Heat map of gene expression in RGP (radial glial progenitors), aPs (atypical progenitors), eGC-Ps and eGC-  
2515 Ns (proliferating or non-proliferating ectopic GABAergic cells), IP (intermediate progenitors), DM-IPs and  
2516 DM-SLNs (intermediate progenitors or superficial layer neurons in dorsomedial cortex), SLN-L2/3s and SLN-  
2517 L4s (layer 2/3 or layer 4 superficial layer neurons), DLN-L5s and DLN-L6s (layer 5 or layer 6 deep layer  
2518 neurons) and CRCs (Cajal-Retzius cells) in E14.5 control and *Pax6* cKO cortex. Note the increased levels of  
2519 *Pax6* mRNA in *Pax6* cKO cells, which was anticipated because the loss of Pax6 protein would have removed  
2520 the negative feedback constraining the transcription of residual *Pax6* coding sequence (Manuel et al.,  
2521 2007). [Raw data are available at the European Nucleotide Archive accession number PRJEB27937.](#)

2522

2523 **Figure S7-S7 Fig. Integrated scRNAseq data from E14.5 *Pax6* cKO cortex and normal ganglionic eminences**

2524 UMAP plots of scRNAseq data from normal E14.5 ventral telencephalon [86](Mayer et al., 2018) integrated  
2525 with our scRNAseq data from E14.5 *Pax6* cKO cortex ([raw data are available at the European Nucleotide  
2526 Archive accession number PRJEB27937](#)). Abbreviations for cortex in Fig. S5A Fig. Additional  
2527 abbreviations: GE, ganglionic eminence; LGE, lateral ganglionic eminence; CGE, caudal ganglionic eminence;  
2528 MGE, medial ganglionic eminence; VZ, ventricular zone; SVZ, subventricular zone.

2529

2530 **Figure S8-S8 Fig. *Ascl1*, *Neurog2* and *Prdm13* expression in control and *Pax6* cKO cortex**

2531 **(A)** In situ hybridizations for *Ascl1* and *Neurog2* in control and *Pax6* cKO cortex at E13.5 and E14.5. Scale  
2532 bars: 0.1mm.

2533 **(B)** Method for obtaining a surface-view reconstruction of labelling across the cortex from a series of  
2534 equally-spaced coronal sections (s1 to s(n)). Relative intensity of label (I) or labelled cell number (N) were  
2535 measured in areas (a1 to a(n)) with average width (through cortical depth) of 0.1 mm in each section.  
2536 Values were then laid out on a flattened representation of the cortical surface and maps generated by  
2537 interpolation.

2538 **(C)** Quantification showing the similarity in the distributions with depth of the proportions of cells  
2539 expressing *Neurog2* mRNA in control lateral cortex and *Ascl1* mRNA in *Pax6* cKO lateral cortex at E13.5 and  
2540 E14.5. Data were obtained using 25 $\mu$ m  $\times$  100 $\mu$ m bins, as shown, from the lateral cortex in centrally located  
2541 coronal sections through the brains of 4 *Pax6* cKOs and 4 controls at E13.5 and 3 *Pax6* cKOs and 3 controls  
2542 at E14.5. Data-points are for individual animals and shaded areas show the range of values with depth  
2543 ([Source-Data-Table 24S2 Data](#)).

2544 **(D)** In situ hybridization for *Prdm13* in rostral and caudal *Pax6* cKO cortex at E16.5 after tamoxifen  
2545 administration at E9.5. Scale bar: 0.1mm.

2546

2547 **Figure S9:S9 Fig. Pax6 loss induced ectopic gene expression in distinct spatiotemporal patterns**

2548 **(A)** Immunoreactivity for *Gsx2* in control and *Pax6* cKO cortex between E12.5 and E16.5 following  
2549 tamoxifen at E8.5, E9.5, E10.5 or E13.5 and in the cortex of E13.5 constitutive *Pax6*<sup>-/-</sup> embryos. Scale bar:  
2550 0.1mm.

2551 **(B,C)** In situ hybridizations for *Dlx1* and *Gad1* in control and *Pax6* cKO cortex at E12.5 and E14.5 following  
2552 tamoxifen at E9.5. Scale bars: 0.1mm.

2553 **(D)** In situ hybridizations for *Gad1* and immunoreactivity for GFP in control and *Pax6* cKO cortex at E14.5  
2554 following tamoxifen at E9.5, showing enlargement of boxed area with and without *Gad1* staining. Red  
2555 arrows in *Pax6* cKO cortex: examples of *Gad1*<sup>+</sup> cells that were GFP-negative. Scale bars: 0.1mm and  
2556 0.01mm.

2557 **(E)** Fluorescence and colorimetric immunoreactivity for *Ascl1* and *Gsx2* and in situ hybridizations for *Dlx1*  
2558 and *Gad1* in *Pax6* cKO lateral cortex at E14.5 following tamoxifen at E9.5. Scale bars: 0.1mm.

2559 **(F)** Summary of gene expression changes in (F) with time following *Pax6* deletion.

2560 **(G)** Fluorescence and colorimetric immunoreactivity for *Gsx2* and *Eomes* and in situ hybridizations for *Dlx1*  
2561 and *Gad1* in *Pax6* cKO cortex at E13.5 and E14.5 following tamoxifen at E9.5. Scale bar: 0.01mm.

2562 **(H,I)** Colorimetric and fluorescence immunoreactivity for *Olig2* and *Ascl1* in control and *Pax6* cKO cortex  
2563 between E13.5 and E16.5 following tamoxifen at E9.5, E10.5 or E13.5. Scale bars: 0.1mm.

2564

2565 **Figure S10:S10 Fig. Pax6 deletion and Olig2 expression in Pax6 cKO cortex**

2566 **(A)** Expression of *Pax6* protein in coronal sections through the cortex of control and *Pax6* cKO embryos at  
2567 E13.5 after tamoxifen administration at E10.5 and at E16.5 after tamoxifen administration at E13.5. Scale  
2568 bar: 0.1mm.

2569 **(B)** Expression of *Pax6* protein and GFP in sections through the *Pax6* cKO cortex at E16.5 after tamoxifen  
2570 administration at E13.5. The vast majority of cortical RGP were *Pax6*-negative. Many of the few remaining  
2571 *Pax6*<sup>+</sup> cells were GFP-negative (examples marked with white dots). Scale bar: 0.01mm.

2572 **(C)** UMAP plots from *Pax6* cKO cortex at E14.5 showing relative expression and co-expression levels of  
2573 *Olig2*, *Gsx2*, *Dlx1* and *Gad1* in each cell (on a 0-10 scale, 10 was the highest expression level of the gene in  
2574 question). [Raw data are available at the European Nucleotide Archive accession number PRJEB27937.](#)

2575

2576 **Figure S11:S11 Fig. Analyses of eGC fates**

2577 **(A)** Colorimetric immunoreactivity for Gsx2 and in situ hybridization for *Gad1* in E14.5 *Pax6* cKO lateral  
2578 cortex after tamoxifen<sup>E9.5</sup>. Scale bar: 0.1mm.

2579 **(B)** Fluorescence immunoreactivity for Gsx2 and GFP, the latter marking Gsx2-lineage cells, in E14.5 control  
2580 and *Pax6*<sup>-/-</sup> telencephalon. Scale bar: 0.1mm.

2581 **(C,D)** Fluorescence immunoreactivity for GFP+ (*Gsx2*-lineage) and in situ hybridization for *Gad1*+ cells in  
2582 E16.5 control and *Pax6*<sup>-/-</sup> lateral cortex. Scale bars: 0.1mm and 0.01mm.

2583 **(E)** Three *Gad1*+ cells in the CP of an E18.5 *Pax6* cKO (tamoxifen<sup>E9.5</sup>) carrying the *RCE*<sup>EGFP</sup> Cre-reporter. One  
2584 was *Emx1*-lineage (GFP+). Scale bar: 0.01mm.

2585 **(F)** Experimental design for analysis of the effects of Pax6 deletion on cortical cell numbers (Fig. 4H). The  
2586 *Emx1-Cre*<sup>ERT2</sup> allele with tamoxifen<sup>E9.5</sup> was used to delete *Pax6*; embryos carried a GFP reporter of Cre  
2587 activity; embryos were collected at E18.5; regularly-spaced coronal sections were double-stained for GFP  
2588 protein and *Gad1* mRNA. We measured the surface area of the cortical plate (CP) of the lateral cortex and  
2589 the surface area of the sub-CP masses of one hemisphere in each section and interpolated to estimate the  
2590 volumes of these structures in each embryo. We used random sampling (e.g. white boxes) to measure the  
2591 average densities of cells in each region. We then calculated their total numbers in each region in each  
2592 embryo. Data from 4 littermate pairs from separate mothers were used to produce Fig. 4H.

2593 **(G)** Fluorescence immunoreactivity for GFP (*Emx1*-lineage) and in situ hybridization for *Gad1*+ cells in P34  
2594 control and *Pax6* cKO cortex after tamoxifen at E9.5. High magnification images: same region of CP with  
2595 and without *Gad1* staining. Scale bar: 1mm and 0.1mm.

2596 **(H)** Immunoreactivity for Caspase-3 in CP and in sub-CP masses in *Pax6* cKO cortex at E16.5 and at P10 after  
2597 tamoxifen at E9.5. Scale bar: 0.1mm.

2598

2599 **Figure S12:S12 Fig.: Comparing the effects of losing Pax6 alone versus Pax6 and ectopic Gsx2**

2600 **(A)** Alleles used to delete conditionally *Gsx2*: *Emx1-Cre*<sup>ERT2</sup> producing tamoxifen (TAM)-inducible Cre  
2601 recombinase [33](Kessarlis et al., 2006); *Gsx2*<sup>loxP</sup> [47](Waclaw et al., 2009); *RCE*<sup>EGFP</sup> [37](Miyoshi et al., 2010).

2602 **(B,C)** Immunoreactivity for *Ascl1* and in situ hybridization for *Neurog2* in *Pax6* cKO and *Pax6 Gsx2* dcKO  
2603 cortex at E13.5 and E14.5. Scale bar: 0.1mm.

2604 **(D)** In situ hybridization for *Gsx1* in control, *Pax6* cKO and *Pax6 Gsx2* dcKO cortex at E13.5. Scale bar:  
2605 0.1mm.

2606 **(E)** Principal component analysis on RNAseq data from *Pax6* cKO (n=5 embryos) and *Pax6 Gsx2* dcKO (n=5  
2607 embryos) cortex at E13.5. Data were from the rostral half of the cortex, where the proportion of cells  
2608 activating *Gsx2* after *Pax6* deletion was highest. [Raw data are available at the European Nucleotide Archive](#)  
2609 [accession number PRJEB21105.](#)

2610 **(F)** A list of all genes that were significantly downregulated or upregulated (adjusted p<0.05) in *Pax6 Gsx2*  
2611 dcKO cortex compared to *Pax6* cKO cortex and their log<sub>2</sub> fold changes (LFCs) in *Pax6* cKO compared to  
2612 control cortex (n.s., not significant). [Raw data are available at the European Nucleotide Archive accession](#)  
2613 [numbers PRJEB21105 and PRJEB5857.](#)

2614

2615 **Figure S13:S13 Fig. Widespread loss of gene expression in Pax6 cKOs**

2616 **(A)** Tamoxifen (TAM) was administered at E9.5 to generate control and *Pax6* cKO embryos; brains were  
2617 sectioned sagittally at E13.5.

2618 **(B)** In situ hybridizations for *Pde1b*, *Rlbp1*, *Igsf11*, *Heg1* and *Neurod4* in E13.5 control and *Pax6* cKO cortex.  
2619 Scale bar: 0.1mm.

2620

2621 **Figure S14: S14 Fig. Cortical plate development from Pax6 cKO RGP**

2622 **(A)** The experimental procedure for (B): tamoxifen (TAM) was administered at E9.5 to generate control and  
2623 Pax6 cKO embryos; 5-Bromo-2'-deoxyuridine (BrdU) was injected on either E13.5 or E16.5; brains were  
2624 sectioned coronally and analysed at P10.

2625 **(B)** BrdU-labelled cells in P10 lateral cortical plate; experimental procedure in (A). Scale bar: 0.1mm.

2626 **(C)** Immunoreactivity for Slc17a7 (formerly Vglut1) in E18.5 control and Pax6 cKO cortex after tamoxifen at  
2627 E9.5. Scale bar: 0.1mm.

2628 **(D)** The experimental procedure for (E-I): slices from P5-13 *Emx1-Cre*; *RCE<sup>EGFP</sup>*; *Pax6<sup>loxP/+</sup>* (control) or  
2629 *Pax6<sup>loxP/loxP</sup>* (Pax6 cKO) mice were used for electrophysiology.

2630 **(E)** GFP+ cells in layers 2/3 and 5 of somatosensory cortex area 1 (S1) were targeted for whole cell current  
2631 clamp recordings (electrodes are visible in inset in upper panel and targeting a GFP+ cell in lower panel).

2632 **(F)** Examples of membrane voltage responses to progressive current injections for control and Pax6cKO  
2633 cortex (500ms square steps; hyperpolarizing step: -25 pA; depolarizing steps: rheobase and double  
2634 rheobase).

2635 **(G)** Unsupervised hierarchical clustering analysis for S1 layer 5. Features used for clustering are listed in  
2636 [Table S5S5 Table](#). Purple tones represent older pups (P8-P10). Green tones represent younger pups (P5-P7).  
2637 Genotype bar indicates control cells (grey; n=54) and Pax6cKO cells (red; n=55). Cells from both genotypes  
2638 were spread across the clusters with no segregation of Pax6cKO cells. Silhouette coefficient analysis  
2639 suggested the optimal number of clusters was 2 (silhouette coefficient =0.26, k=2), which separated cells  
2640 mainly by age ([Sheet C in Source Data Table 54C55C Data](#)).

2641 **(H)** Unsupervised hierarchical clustering analysis for S1 layers 2/3. Features used for clustering are listed in  
2642 [Table S5S5 Table](#). Silhouette coefficient analysis suggested the optimal number of clusters was 2 (silhouette  
2643 coefficient = 0.44, k=2). Clustering split the cells into two main branches, with one containing three cells all  
2644 from Pax6cKO mice, but this separation might have occurred by chance (Barnard unconditional two-tailed  
2645 test, p=0.09) ([Source Data Table 54C55C Sheet C in S5 Data55C Data](#)).

2646 **(I)** S1 layer 2/3 GFP+ fast spiking cell; double rheobase current injection response.

2647

2648 **Figure S15: S15 Fig. Expression and effects of Shh on eGC production**

2649 **(A)** Flattened surface views of the cortex showing the densities of *Gad1+* cells at E13.5 and E14.5 in  
2650 controls: *Gad1+* cells spread in increasing numbers across the cortex from lateral to medial with a similar  
2651 spatiotemporal pattern to the spread of *Gsx2* and *Dlx1* activation after tamoxifen at E9.5 (maps for *Gsx2*  
2652 and *Dlx1* reproduced from Fig- 3H).

2653 **(B)** Validation of the Shh antibody: comparison of staining patterns, in both neural and non-neural tissues  
2654 [\[196\]\(Bitgood and McMahon, 1995\)](#), with in situ hybridization patterns from the Allen Brain Atlas in E11.5  
2655 and E13.5 controls and lack of staining in E13.5 *Shh<sup>-/-</sup>* mutants (kindly provided by Laura Lettice and Bob Hill,  
2656 Edinburgh University). Scale bar: 0.1mm.

2657 **(C)** Immunoreactivity for Shh in control telencephalon at E14.5 and in Pax6 cKO telencephalon after  
2658 tamoxifen (TAM) at E9.5 at E14.5 and after 2 days in vitro (DIV) from E13.5 (Fig. 6A). Scale bars: 0.1mm and  
2659 0.01mm.

2660 **(D)** Following the experimental procedure reproduced from Fig- 6K: constructs expressing *Smo* shRNA +  
2661 GFP or scrambled shRNA + GFP were electroporated into the cortex of E14.5 Pax6 cKO embryos made using  
2662 *Emx1-Cre*; electroporated cells were analysed at E15.5. Blind to *Gsx2* expression, we identified 80-100 GFP+  
2663 cells and a random selection of 80-100 intermingled GFP- cells in each of 3 embryos from 3 litters given  
2664 *Smo* shRNA and each of 4 embryos from 3 litters given scrambled shRNA. The intensity of *Gsx2*  
2665 immunoreactivity was then measured in all of these cells and frequency distributions of intensities in  
2666 electroporated versus non-electroporated cells were compared in brains that received *Smo* shRNA and in  
2667 brains that received scrambled shRNA (results in Fig- 6M).

2668

2669 **Figure S16:S16 Fig. Foxg1 deletion and co-deletion with Pax6**

2670 **(A)** Deletion of *Foxg1*, here with *Emx1-Cre<sup>ERT2</sup>* and tamoxifen (TAM), removes its coding region  
2671 [\[184\]\(Miyoshi and Fishell, 2012\)](#) and activates the Cre reporter.

2672 **(B)** Tamoxifen (TAM) was administered at E9.5 to generate *Pax6* cKOs in which both, one or neither *Foxg1*  
2673 allele(s) were also deleted; brains were analysed at E13.5 and E14.5. The *Pax6<sup>loxP</sup>* allele was shown in [Fig.](#)  
2674 [S1A Fig.](#)

2675 **(C)** In situ hybridizations for *Foxg1* and immunohistochemistry for Foxg1 and Pax6 following deletion of  
2676 both, one or neither *Foxg1* allele(s) at E13.5 and E14.5. Arrows: a few cells remained undeleted and formed  
2677 small clones expressing both Foxg1 and Pax6. Scale bars: 0.1mm.

2678 **(D)** Immunoreactivity for *Ascl1* in E14.5 cortex from *Pax6* cKO embryos in which neither, one or both *Foxg1*  
2679 allele(s) were deleted by tamoxifen at E9.5. Scale bars: 0.1mm.

2680 **(E)** Immunoreactivity for *Eomes* in E16.5 lateral cortex from control embryos and *Pax6 Foxg1* double KOs.  
2681 Scale bar: 0.1mm.

2682 **(F)** Proportions of cells in the ventricular and subventricular zones of E16.5 lateral cortex expressing *Eomes*  
2683 in control embryos and embryos of the three genotypes in (B) (averages  $\pm$  sd of n=3; *Pax6* single cKO  
2684 average was significantly lower than all others,  $p < 0.05$  in all comparisons; Student's t-tests) ([Sheet D in](#)  
2685 [Source Data Table 76DS7D Data](#)).

2686 **(G)** Results of experiment in Fig- 7F: co-expression of *Eomes* and mCherry in a coronal section. Scale bar:  
2687 0.1mm.

2688

2689 **Figure S17:S17 Fig. Quantification method for dissociated cultures**

2690 Method for quantification of the effects of SAG on numbers of GFP+ cells expressing various markers: cells  
2691 were cultured on coverslips and, after fixation and reaction, counting grids were used to sample 5 randomly  
2692 selected areas from each coverslip. Several independent biological repeats were used for each condition  
2693 (i.e. each concentration of SAG or vehicle alone, on *Pax6* cKO or control cells) (Fig- 8).

2694

2695 **Figure S18:S18 Fig. Phospho-Smad1/5/9 expression and Bmp4 effects on Olig2 expression in control and**  
2696 **Pax6 cKO cortex**

2697 **(A)** Immunoreactivity for phospho-Smad1/5/9 in E14.5 control and *Pax6* cKO cortex after tamoxifen<sup>E9.5</sup>.  
2698 Scale bar: 0.1mm.

2699 **(B)** Concentration-response measured using qRT-PCR: *Olig2* levels (averages  $\pm$  sem; values are relative to  
2700 the average level in control cortex treated with 0 Bmp4) in control and *Pax6* cKO slices with increasing  
2701 concentrations of Bmp4 (n=3 independent cultures at each concentration). Two-way ANOVA showed  
2702 significant effects of genotype on *Olig2* ( $p < 0.005$ ), but no significant effect of Bmp4 concentration and no  
2703 significant interaction effect. Differences between genotypes at each Bmp4 concentration were tested with  
2704 Bonferroni's method for comparison of means (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.005$ ) ([Source Data Table](#)  
2705 [98S9 Data](#)).

2706 **Supplementary Tables**

2707

2708 [Table S1:S1 Table](#). Results of bulk RNAseq: log<sub>2</sub> fold changes of genes that were significantly differentially  
2709 expressed between control and *Pax6* cKO cortex (adjusted p, or padj, <0.05) rostrally and caudally at E12.5  
2710 and E13.5.

2711

2712 [Table S2:S2 Table](#). Significantly enriched gene ontology (GO) terms obtained by passing through DAVID v6.8  
2713 all functionally annotated genes with a LFC in expression ≥ 1 (for upregulated genes) or ≤ -1 (for  
2714 downregulated genes) in at least one of the four combinations of age and region studied.

2715

2716 [Table S3:S3 Table](#). Citations providing evidence on the normal sites of expression of genes that were  
2717 upregulated in *Pax6* cKO RNAseq datasets.

2718

2719 [Table S4:S4 Table](#). Genes whose expression levels were the most different between RGP and aRGP  
2720 (average LFCs >0.3 or <-0.3) and GO terms obtained by passing this list through DAVID.

2721

2722 [Table S5:S5 Table](#). Intrinsic properties of primary somatosensory cortex (S1) layer 5 cells at P5-7 and P8-  
2723 P10 and layer 2/3 cells at P10-13. Values are means ± 95% confidence intervals.

2724

2725 [Source Data Tables 1-98:S1 Data](#), [Data referred to in S1 Fig.](#)

Formatted: Font: Not Bold

2726

2727 [S2 Data](#), [Data referred to in S8 Fig.](#)

Formatted: Font: Not Bold

2728

2729 [S3 Data](#), [Data referred to in text.](#)

Formatted: Font: Not Bold

2730

2731 [S4 Data](#), [Data referred to in Fig 4.](#)

Formatted: Font: Not Bold

2732

2733 [S5 Data](#), [Data referred to in Figs 4 and S14 Fig.](#)

Formatted: Font: Not Bold

2734

Formatted: Font: Not Bold

2735 [S6 Data](#), [Data referred to in Fig 6.](#)

Formatted: Font: Not Bold

2736

2737 [S7 Data](#), [Data referred to in Figs 6, and 7, and S16 Fig and text.](#)

Formatted: Font: Not Bold

2738

Formatted: Font: Not Bold

2739 [S8 Data](#), [Data referred to in Fig 8.](#)

Formatted: Font: Not Bold

2740

Formatted: Font: Not Bold

2741 [S9 Data](#). [Data referred to in Figs 9 and S18 Fig, the text and Figure legends.](#)

2742 **Western blot raw images**

2743

2744 **S1 Raw Images:** Western blots shown in [Fig-S1S1 Fig.](#)

